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Chapter 1 
Introduction
1,1 The history of nucleic acids and nucleoside analogues
The disovery of nitrogen containing heterocyclic compounds featured in the early 
development of "organic" chemistry which concentrated on the study of materials isolated 
from living sources. Uric acid (1), a purine derivative, was one of those early discoveries, 
having been isolated from gall-stones and urine by Scheelel in 1776 but the elucidation of 
the correct structure of this purine did not occur for a further 100 years.
HN
HH
i
3 H 9  j
Uric Acid (1) Purine numbering (2) I
Alloxan (3), the first pyrimidine, was isolated in 1818 by Brugnatelli^ via the 
oxidation of uric acid with nitric acid.
O
O ^ N  O  ^  N  4
H 3
Alloxan (3) Pyrimidine numbering (4)
Of the five conunon nucleoside bases, the most common purines, adenine (5) and 
guanine (6), have been known since 1885 and 1884 respectively3, although other bases 
have been isolated more recently from RNA including 2-methyl-6-aminopurine, 6-
methylaminopurine, 6-(N,N-dimethylamino)purine, 6-hydroxy-2-methylaminopurine and 
l-methylguanine4. The three common members of the pyrimidine group comprise uracil 
(7), thymine (8), and cytosine (9). Another minor pyrimidine component is 5- 
methylcytosine^.
Adenine (5)
O
HN N
HoN H 
Guanine (6)
OA3HNj II
O '^ N ,
H
Uracil (7)
a ^ N '
H
Thymine (8) Cytosine (9)
Although certain purines and pyrimidines had been isolated from natural sources at 
earlier dates and the first nucleoside, inosinic acid, was discovered by Liebig in 1847^, 
nucleic acid research really began with Miescher's^ isolation of a material with a high 
phosphorus content which he termed nuclein. The term nucleic acid was coined by 
Altmann^ who continued Miescher's work after the death of the latter. By 1914 the work of 
Levene^ had determined all the main constituent bases of the nucleic acids as well as the 
sugar D-ribose. The existence of two distinct types of nucleic acid had also become 
apparent with Levene and Bass^O isolating 2-deoxy-D-ribose at a later date. The first 
nucleosides to be synthesised were the glucose analogues of the natural purine and 
pyrimidine nucleosides by Hilbert and Johnson but Todd and co-workers 12 in 
Cambridge synthesised the first natural nucleosides using a similai' synthesis and continued 
with these rigorous syntheses and proofs of structure of further nucleosides and 
nucleotides. Thus by the 1940s all the major components of the nucleic acids were known.
the P-configuration of nucleosides and the 3',5'-phosphodiester linkage had both been 
proposed but further progress did not occur until the introduction of more sensitive 
chromatographic techniques such as paper chromatography, paper electrophoresis and ion- 
exchange chromatography which allowed great improvment in the separation and 
purification of nucleosides, nucleotides and cellulai' components.
The careful analytical work undertaken by Chargaff^^ determined the base-pair ratio 
of adenine:thymine and guanine:cytosine and with the demonstration of the 3',5'- 
phosphodiester linkage by Brown and Todd^^, the way was left open for the elucidation of 
the double helical structure of DNA by Watson and C r i c k i n  1953. Allied with the 
discovery in 1944 by Avery, MacLeod and M cC arthy that the genetic structure of cells 
was connected to DNA, the way in which genetic information was stored and inherited 
could now be fully understood and its importance fully appreciated.
Nucleic acids may be broken down to their building blocks by a series of 
successive hydrolyses to yield eventually the bases and sugars. This information is 
summarised in figure 1.
Figure 1
Nucleic acids
Nucleotides
Nucleosides
Ribose orPurines and 
pyrimidines 2-deoxyribose
The term nucleoside, originally devised by Levene and J a c o b  and restricted to the
purine and pyrimidine A-glycosides of ribose and 2-deoxyribose, is now more generally 
applied to other heterocyclic glycosides, including the 5,6-dimethylbenzimidazole riboside 
of vitamin B12 and all other carbohydrate derivatives of iV-heterocyclic compounds 
irrespective of attachment through nitrogen, carbon or oxygen. A nucleoside (in terms of 
DNA or RNA) is normally a p-glycoside consisting of a base (purine or pyrimidine) 
bonded via an A-glycosyl linkage to a sugai' (ribose or 2-deoxyribose). The bond is formed 
between N-9 of a purine or N-1 of a pyrimidine to C-1' of either of the aforementioned 
sugars.
The term nucleotide was also devised by L e v e n e  and is the phosphate monoester 
of the nucleoside, formally derived by the reaction of the 5'-hydroxyl of the sugar and 
phosphoric acid; the phosphate monoesters may also be formed on any of the other 
hydroxyl groups. Cyclic phosphates may be formed between any two of the hydroxyl 
groups; di- and tri-phosphates on the 5'-hydroxyl also exist in the cellular environment.
The biosynthesis of nucleic acids involves polymerisation of nucleoside 
triphosphates, with the concomitant release of pyrophosphate. The 5'-hydroxyl of one 
nucleotide is linked with the free 3'-hydroxyl of another giving an alternating sugar- 
phosphate backbone with a 3',5'-phosphodiester linkage. The pyrophosphate combines 
with another nucleotide to maintain the cellular energy level. In the case of DNA, 
complementary bases pair up through intermolecular hydrogen bonding to give 
complementary strands where adenine bonds to thymine and guanine bonds to cytosine 
resulting in the formation of a double helix. In RNA uracil replaces thymine, and bonds to 
adenine if a double helix is present. In the cellular environment these processes are aided by 
enzymes, coenzymes and very many other essential components.
1.2 Some early antiviral drugs
Some antiviral drugs (nucleoside analogues) work by mimicking the natural 
nucleoside and are incorporated into the biochemical pathways of the virally infected cell, 
disrupting the normal processes and hence resulting in cell death and the prevention of
proliferation of the virus. For the nucleoside analogue to be accepted in place of a natural 
nucleoside it must have a very similar structure to the usual substrate: hence antiviral 
chemotherapy is an extremely new science resulting from recent advances in the 
understanding of the structures of DNA and RNA.
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Natural nucleosides and unnatural analogues have been studied widely in a search 
for antivhal, fungicidal and anticancer agents. Anticancer activity is displayed by 5-fluoro- 
2'-deoxyuridine (14)^^ and both 1 -|3-D-arabinofuranosylcytosine (Ara-C, 12) and 9-p-D- 
arabinofuranosyladenosine (Ara-A, Vidarabine, 13) also posses antiviral activity as well as 
anticancer ac t i v i t y b y  interfering with nucleic acid biosynthesis. These display little 
selectivity between infected and host cell, the lack of selectivity being the root of associated 
side effects. Vidarabine (13) is phosphorylated by both cellular and viral thymidine kinases 
but its "selectivity" comes at the DNA polymerase level where the virally induced 
polymerase is 6-12 times more sensitive to vidarabine triphosphate. Before the discovery of
acyclovir (see page 9), vidarabine was the principal treatment for herpes simplex and 
varicella zoster viral infections.
1.3 HIV, AIDS and AZT
With the discovery of the HIV virus and AIDS as a serious illness with the potential 
to infect the population at large there has been an explosion of research into antiviral 
nucleoside analogues. The finding that the dideoxy nucleoside, AZT (3'-azido-3'- 
deoxythymidine, 17)^1 was a potential therapeutic agent for the treatment of AIDS 
(although initially developed as an anticancer therapy) and that ddl (2' ,3 '-dideoxyinosine, 
16)^2 and ddC (2',3'-dideoxycytidine, 15)^2 were the only other FDA-licensed drugs for 
this purpose has prompted further nucleoside analogue research. Each of the 
aforementioned drugs has a very similar mode of action. Each being phosphorylated by 
host cell enzymes, their triphosphates inhibit HTV reverse transcriptase (HIV RT) due to the 
absence of a 3'-hydroxyl for chain elongation hence stopping DNA polymerisation. HIV 
RT is 100 times more sensitive to AZT triphosphate (AZTTP) than DNA polymerase 
affording a high level of selectivity. Ddl is converted intracellularly to dideoxyadenosine 
triphosphate, its active form, and so is suitable for those unresponsive to AZT therapy. 
DdC, on the other hand, is used in conjunction with AZT. In summary, AZT, ddl and ddC 
are prodrugs and are sequentially phosphorylated by thymidine kinase to the 5'- 
triphosphate which is then incorporated into the growing viral DNA chain and acts as a 
chain terminator, there being no 3'-hydroxyl group in any of these. Unfortunately, several 
side effects are associated with long term administration of the drugs and resistance has 
also been known to develop in the virus^^. Trials have addressed the use of lower doses of 
AZT to lessen toxicity: these have proved promising with no difference being observed in 
the progression of opportunistic infections24.
N N
ddC (15) ddl (16) AZT (17)
1.4 The herpes viruses and early anti-herpetic agents
Antiviral chemotherapy continues to be a very active research area with the major 
target being AIDS. However a recent change of direction away from nucleoside analogues 
towards protease inhibitors and non-nucleoside reverse transcriptase inhibitors has 
occurred. The mainstay of nucleoside analogue research -  still the second largest area of 
antiviral research -  is thus directed towards the herpes group of viruses.
The group of human herpes viruses may be divided into three different subfamilies 
based upon different viral characteristics, although the entire group have the ability, once 
initial infection has subsided, to remain latent and recur at any time on production of the 
correct stimulus.
The first subfamily includes herpes simplex virus types 1 and 2 (HSVl and HSV2) 
and varicella zoster virus (VZV). In general terms, these affect the skin and the latent 
infection resides in the nervous system. HSV1 was the first human virus to be recognised. 
Among other infections, HSVl is the cause of cold sores and HSV2 the cause of genital 
herpes but each is also responsible for conditions such as meningitis and encephalitis. The 
divisions between the infection are not rigid, as HSV2 may cause cold sores and HSVl 
genital herpes. VZV manifests itself as chickenpox (varicella) and with recurrence of the 
latent infection in later life causes shingles (herpes zoster).
The second subfamily includes human herpes viruses 6 and 7 (HHV6 and HHV7)
which were both isolated recently from the blood of AIDS patients where the latent 
infection resides in particular types of blood cells. The third member of this subfamily is 
human cytomegalovirus (HCMV), which is present in 2-5% of newborn babies and up to 
50% of adults in the developed world, the infection is usually asymptomatic. Reactivation 
of the latent phase is brought about by immunosuppression (artificial or through HIV 
infection) and is responsible for retinitis, pneumonia and other opportunistic infections.
The final subfamily has only one member in Epstein Barr virus (EBV), the cause of 
glandular fever, for which there is no effective treatment apart from preferred exposure in 
early life when the infection is less severe. The herpes group of viruses is only one of a 
number of viral infections which cause serious conditions in the human and of particular' 
concern are the effects these have on the immunocompromised.
Viral infections are very important economically in being the cause of the most days 
of absenteeism among the working population. As a virus is so small and simple in 
comparison to a bacterium, the possible points of attack for a therapeutic agent, where a 
difference in biochemistry may be pinpointed, are very few; the problems of producing a 
non-toxic, effective antiviral agent which is not harmful to the host are considerable. The 
common cold and influenza present little problem as recovery is almost always guaranteed, 
however many of the opportunistic viral infections which affect the immunosuppressed 
require extensive and effective treatment. The aim of antiviral chemotherapy is to suppress
viral replication in infected cells with no or minimal damage to uninfected host cells. |
!
Selective inhibition of viral replication depends upon blocking one or more virus-specific |
!metabolic steps in infected cells. |
iOf the more serious viral infections of the herpes group, ocular herpes keratitis and j
herpes virus encephalitis have proved amenable to antiviral chemotherapy. Ribavirin I
(Virazole, 18)25, ^ guanosine analogue in which the imidazole is replaced by a 1,2,4- |
triazole and the pyrimidine ring is not closed, was marketed by ICN Pharmaceuticals in j
some South American countries as an antiviral agent for treatment of these infections; it has 
multiple sites of action inhibiting many important viral processes and is also effective it
against Lassa fever. j
o
HoN
HO—1
HOHO
Ribavirin 
(Virazole) 
ION Pharmaceuticals 
(18)
Much effort has been expended in the search for effective antivirals with many other 
nucleoside analogues incorporating purine or pyrimidine bases and a variety of sugars 
showing activity against viruses. Some of the clinically useful compounds have included; 
5-iodo-2-deoxyuridine (Idoxuridine, 20)^^, the first anti-HSV drug approved for human 
use, a mimic of thymidine which inhibits the biosynthesis of the latter and causes genome 
misreading and mutation resulting in virus inactivation; 9-p-D-arabinofuranosyladenine 
(Vidarabine, Ara-A, 13, see pg. 5)^ ®> and some non-nucleoside antivirals including 
1-aminoadamantane hydrochloride^^ (Amantadine, 19) which has activity against influenza 
A virus.
NH3 C1
Æ : 7
1 -Aminoadamantane 
hydrochloride (19)
O
HN
O ^ N '
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5-!odo-2'-deoxyuridine 
Idoxuridine (20)
1.5 Acyclovir
Most significant progress was made with the drug acyclovir (Zovirax, 21, page
10
11)^9 (formerly produced by Wellcome, now GlaxoWellcome) which was regarded as the 
prototype of a totally new class of compounds with excellent and selective antiviral activity. 
This compound confirmed previous predictions that an intact sugar was not necessary for a 
nucleoside to bind to relevant enzymes^^. Acyclovir has good activity against HSV1 and 
HSV2 with good selectivity over the host cell and virtually no cytotoxicity at therapeutic 
levels. Preliminary studies had also shown activity against VZV, but the activity is much 
lower and requires intravenous administration to achieve high plasma levels for 
effectiveness. Acyclovir has poor activity against HCMV (which does not code a thymidine 
kinase) and no activity against a range of RNA viruses^l or HSV strains deficient in the 
ability to encode a thymidine kinase or DNA polymerase^^.
Table 1.1 Relative potencies of selected HSVl treatments^ ^
Compound IDsn tfiM') Potency relative to Idoxuridine
Vidarabine 16 6
Idoxuridine 1 100
Acyclovir 0.1 1000
The selectivity and low cytotoxicity may be attributed to the specificity of acyclovir 
towards virally-induced enzymes over host cell enzymes. Acyclovir is converted into its 
monophosphate by virally specified thymidine kinase 30-120 times faster than by host cell 
thymidine kinase and subsequently to di- and triphosphates by cellular enzymes. 
Incorporation into the growing DNA chain by HSV DNA polymerase thus allows 
competitive inhibition of the natural nucleosides^^ at the active site and action as a chain 
terminator once incorporated^^ due to the absence of the lower sugar portion.
Since its inception, acyclovir has been a market leader and the benchmark by which 
all competitors are measured. First marketed as an injectible solution in 1982 (for the 
treatment of HSV2) and later accepted by the FDA in oral dosage form, it is now available 
over the counter as a topical treatment for recurrent cold sores (HSVl) and is regularly
11
prescribed for the treatment of shingles (VZV).
Despite being an excellent therapy, acyclovir has very poor bioavailability. Attempts 
to improve GI (gastrointestinal) absorption by oral administration of a prodrug, namely 6- 
d eo x y a cy c lo v ir^ ^  (Desciclovir), met with considerable success in vivo, oxidation occurring 
via xanthine oxidase to the active acyclovir. However further work has been limited and 
furthermore the low bioavailability has been proposed to be a factor in the low cytotoxicity.
Acyclovir (21) Desciclovir (22)
1.6 Commercial competitors of acyclovir
Although acyclovir has been extensively pursued for its clinical efficacy, it has also 
been responsible for increased activity in the search for selective antiviral nucleoside 
analogues in what is an expanding and very profitable market and has lead to competitor 
companies discovering among others ganciclovir (Syntex/Merck), 9-[(l,3-dihydroxy-2- 
propoxy)methyl]guanine, DHPG, 2'-nor-2'-deoxyguanosine, 2'NDG, BIOLF-62 or 
BW759U (23), which more closely resembles the natural deoxynucleoside and whose 
activity has been reported independently by several groups '^^. Like acyclovir, ganciclovir 
(23) is selective for the virally infected cells yielding the monophosphate which is further 
phosphorylated by host cell kinases and accepted as a substrate by the viral DNA 
polymerase affording another level of selectivity over the host. Ganciclovir is a broadly 
active antiherpetic agent which is substantially devoid of toxicity, more water soluble and 
bioavailable than acyclovir but is similarly active against HSVl, HSV2 and VZV. In 
addition, ganciclovir is more potent against HCMV and Epstein Barr virus well below 
cytotoxic levels, is superior in vivo^^ and is active against acyclovir resistant strains of
12
H S V l w h i c h  do not possess a virally specified thymidine kinase but have a DNA 
polymerase suggesting a different mode of action^^. The activity against HCMV bears great 
interest for the treatment of severe cytomegalovirus infections (including pneumonia, 
chorioretinitis and organ damage) in immunosuppressed (recipients of organ and bone 
marrow transplants) and immunocompromised (AIDS) patients. Although there is no 
HCMV encoded thymidine kinase sufficient selectivity is presumably attained at the virally 
encoded DNA polymerase leveP^ (phosphorylation still occurring to a greater degree in 
infected cells).
O
HN
HO
OH
Ganciclovir (23)
However, ganciclovir has been cited as having adverse effects (bone marrow 
toxicity) in humans and an im als^ S . In bone marrow transplant patients, maintenance 
therapy is required until the immune system has recovered sufficiently whereas in AIDS 
patients, indefinite maintenance may be required to prevent disease progression as the latent 
infection is not eradicated. This results in adverse haematological effects which although 
reversible, may require the cessation of t h e r a p y ^  ^ and hence the risk of further 
opportunistic infection.
In parallel with the research being cairied out to produce acyclovir and ganciclovir, 
a group at SmithKline Beecham was looking at the potential of an anti-heipes therapy in the 
carba-analogue of ganciclovir, BRL39123 or 9-[4-hydroxy-3-(hydroxymethyl)butyl] 
guanine (24). This was first reported in 1972"^ ® and had notable antiviral properties'^k 
BRL39123 had similar in vitro activity against HSVl and HSV2 but like acyclovir was
13
inactive with mutant HSV strains encoding no thymidine kinase: polyphosphorylated 
metabolites were proposed to be competitive inhibitors of deoxyguanosine triphosphate at 
the viral DNA polymerase leveH^ indicating an acyclovir-like mode of action and chain 
termination of the growing DNA chain.
O
OH
BRL 39123 
9-[4-Hydroxy-3-
HN
OH
BRL 45148 
9-[3-Hydroxy-2-
(hydroxymethyl)butyl] (hydroxymethyl)propoxy] 
guanine (24) guanine (25)
HN
Hg
HO
BRL 44385  
9- (3-hyd roxyp ropoxy) 
guanine (26)
Later work by the same group produced some interesting analogues with good 
activity. In BRL45148 (25) the -CH2- at the 1' position of the acyclic moiety had been 
replaced by an oxygen atom to give an N-O linkage to the guanine base and in BRL44385 
(26) one of the 3* hydroxymethyl groups has also been removed. Little had been reported 
on the stability of these N-O bonds; however, studies have proved them to be stable under 
a vaiiety of conditions'^. Poor bioavailability was also a problem here and prodrugs in the 
form of 6-deoxy and ester congeners (27) and (28) were synthesised and investigated for 
GI absorption and conversion into the active drug. These have provided in varying 
degrees, substantially higher concentrations of the active compound in the blood than are 
obtainable by direct oral administration of the active agent itself 43,44^
R C (0)0—I
R C (0)0 R=alkyl or aryl
(27)
HgN N N
RC(0)0
R C (0)0
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Table 1.2 Comparison of the in vitro activity of Acyclovir and SB
compounds42, 43
Compound 
Acyclovir 
BRL 39123 
BRL 45148 
BRL 44385
ICsoIMM)
HSVl HSV2
6.7 2.5
6.4 6.4
2.1 0.71
5.9 5.9
VZV
20
4.4
11
Many other modifications to the base'^^ and acyclic side chain'^^ at positions C-1', 
C-2' and C-3' have also been investigated producing a comprehensive sti’ucture-activity 
relationship of these acyclonucleosides. This research has resulted in the introduction of the 
new antiviral drug, Famvir by Smith-Kline Beecham. Around the same time Glaxo­
Wellcome received FDA approval for and introduced its successor to acyclovir, 
Valacyclovir (the patent of acyclovir having almost expired) as a treatment for HSV and 
herpes zoster (shingles). Valacyclovir (Valtrex, 30) is the L-valyl ester prodmg of acyclovir 
providing improved bioavailability via involvement of a stereospecific transport process 
and hence requiring a less frequent dosing schedule^^.
AcO
AcO Famvir (29)
HN
Ha
N
N
SmithKline Beecham
O'
NH(
O
Valacyclovir (30) 
(Valtrex)
CH3 
CH3
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1.7 Benzimidazoles and benzimidazole N -oxides of biological interest
Rigorous research into benzimidazoles and benzimidazole V-oxides has also been 
undertaken during this explosion of intensive nucleoside research producing an array of 
compounds with interesting biological activities. This was stimulated, in part at least, by 
the discovery of a benzimidazole riboside, 5,6-dimethyl-l-(a-D-ribofuranosyl) 
benzimidazole, as an integral part of the structure of vitamin B 12 through the elucidation of 
its structure by X-ray crystallography"^^. Vitamin B12 contains a highly substituted and 
reduced corrin ring and an unusual nucleoside monophosphate which has an a-glycosidic 
bond (in contrast to the P-glycosidic bond of the nucleic acids, page 2). The discovery of a 
benzimidazole as part of a natural biological system, if taken together with the structural 
similarities benzimidazoles bear to the natural purines, may be responsible for the increase 
in interest in the chemistry associated with this area.
A certain amount of commercial success has arisen from biologically active 
benzimidazoles such as compound (31), a non-steroidal anti-inflammatoiy for the treatment 
of chronic inflammatory disease^^.
H
1 “[3-(4-Methyl-1 -piperazinyl)propyl] 
-2-(3,4-dichlorobenzamiclo)- 
benzimidazoie (31)
Although many other similar compounds have been developed, the most important 
commercial benzimidazole is the fungicide BenomyP® (methyl l-(butylcarbamoyl) 
benzimidazol-2-ylcarbamate, 32). It was introduced in 1967 by Du Pont and used in the 
treatment of a wide range of fungi and mites but its use has recently declined owing to the 
development of resistance in pathogenic fungi. Other such active agents include the
16
anthelmintic and fungicide Thiabendazole (33)^0  ^the analgesic Bezitramide (34)50 and the 
anticancer agent Imet 3393 (35)50.
NHCOgMe
Benomy! 
CONH-Bu" (Du Pont) 
(32)
Thiabendazole 
(Merck) (33)
C O Et
(C1CH2)2N
CH2CH2C(CN)Ph2 
Bezitramide 
(Janssen) (34)
 ^ (CH2)3C02H
Imet 3393  
(35)
1.8 Benzimidazole ribonucleosides
More importantly, in the 1950s, Tamm and co-workers reported the activity of a 
benzimidazole riboside [(5,6-dichloro-l-p-D-ribofuranosyl)benzimidazole, DRB (36)] 
against a number of RNA and DNA vimses. However the antiviral activity was poorly 
separated from cytotoxicity, affecting multiple cellular processes and hence having no 
utility as an antiviral agent5l but with possible implications as an anticancer agent.
H O - - P - <
6  OH
HO
HO HO
DRB (36)
Foscarnet 
Phosphonoformic 
acid (37)
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In an effort to find possible anticancer agents modifications to both the benzene ring 
and the sugar moiety of DRB were investigated by Townsend, et in the 1960s. These 
modifications resulted in a decrease in anticancer activity relative to DRB (36) itself. 
However introduction of a halogen at the 2-position produced compounds which although 
of little anticancer activity possessed low cytotoxicity and surprisingly were found to inhibit 
HCMV replication.
These trihalogenobenzimidazole ribonucleosides, TCRB (38) and BDCRB (39) 
possess good activity against HCMV at a low cytotoxicity and act by a unique mechanism 
in the inhibition of the DNA processing^C urrent therapies for HCMV, including 
ganciclovir (previously mentioned) and foscarnet (37), suffer from the twin drawbacks of 
low potency and significant adverse side effects. Foscarnet^"  ^resembles pyrophosphate and 
occupies its position in the nucleotide binding site of DNA polymerase to prevent its 
binding. It is active against all heipesvirus DNA polymerases and HIV RT but has side 
effects associated with the chelation of divalent metal ions such as calcium.
01
^ — 01
01
H O -i HO-n
HO HO
TORB (38)
">— Br
HO HO
BDORB (39)
Investigation of further substituents at the 2 position and on the benzene ring have 
provided no better activity than that of TCRB and BDCRB^f^3,54 (gee table overleaf).
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Table 1.3 Activity and toxicity of benzimidazole ribosides and established 
treatments against human cytomegalovirus^ 1 53
Compound IC50 (pM) Toxicity (pM)
DRB 42 24
TCRB 2.9 238
BDCRB 0.7 118
DHPG 7.4 >100
acyclovir 86 >100
foscarnet 39 >100
Other work by Townsend et al. has focussed on the activity of benzimidazoles as 
antifilarials^S, antineoplastics and anti-HIV agents^^. The latter, non-nucleosidic inhibitors 
of reverse transcriptase, targetting an allosteric site are only active against HIVl (not HIV2) 
and are analogues of the thoroughly investigated TIBO^^ tricyclic system (40) but with a 
scission of the diazepine ring to give 2-mercaptobenzimidazole derivatives (41).
TIBO Analogue Ri=H, CH3
(R82150) (40) R2 =alkyl, aryl
(41)
In an effort to produce compounds similar to the TIBO analogues (40) and those 
prepared by Townsend et al. (41), Gardiner and co-workers at UMIST^^ discovered a
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cascade of reactions which produced 2-substituted benzimidazole N-oxides which are also 
alkylated on the oxygen without further reaction (44). Alkylation of substituted o- 
nitroanilines (42) with alkyl, aryl and allyl halides using sodium hydride as the base was 
shown not to stop at either the A-substituted-o-nitroaniline (43) or the subsequent 2- 
substituted benzimidazole A-oxide (see page 22) but proceed directly to the 0 -substituted 
benzimidazole to furnish a final stmcture (44) and return only a small amount of unreacted 
starting material.
r"
N o : &  " C X n o . *'2 ^  (NW2
(42) (43) (44)
R O
When alkyl halides are reacted with o-nitroanilines possessing a variety of 
substituents on the benzene ring, the A-alkoxyheteroaromatic compounds produced (45) 
have similar characteristics to many active biological species and were found to possess 
moderate activity (|iM range) against HIV RT^^. Similar products may be formally derived 
via the alkylation of functionalised benzimidazole V-oxides.
R O
2-substituted-1 -propoxy 
benzimidazoles (45)
Reference has previously been made to the biological activity of 9-alkoxypurines 
(see page 13); some purine iV-oxides have biological activity in their own right. The
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HN
Hg H
Purine A/-oxides 
O.
NH(
k X }
(46)
N 
(47) O&
HO OH NHMe
A^-oxides of both guanine and a substituted adenine have been found to possess biological 
properties: the 7-oxide of guanine (46) has been reported to have antimicrobial, antiviral 
and anti tumour a c t i v i t y  and the 1-oxide of the adenine (47) has been reported as a 
hypocholesteremic^l.
1.9 Benzimidazole iV-oxides
Several benzimidazole 7/-oxides have also been found to have a variety of 
commercially exploitable biological actions including herbicides (48)^^, nematocides (49)^^ 
and anthelmintics (50)^^.
A/-oxides with biological activity
The correct structure for the benzimidazole A -^oxide (52) was only assigned in 
1951^5, previously the oxbenzimidazoles (as they were called) had been assigned a tricyclic 
structure (51). They were first discovered, apparently independently, by both von 
Niementowski in 1887^^ and Bankiewicz in 1888^^. After discovery, their chemistry 
suffered almost complete neglect until the early 1950s when heterocyclic A-oxides became
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a very active area of research.
Unlike other heterocyclic N-oxides the benzimidazoles cannot be oxidised to the 
iV-oxide either by directes or indirect^^ methods and their syntheses are dominated by 
routes leading to the final formation of the C(2)-N(3) bond in a cyclisation reaction. 
However, they can be reduced, like other heterocyclic A -^oxides, by a vaiiety of conditions 
to the parent heterocycle.
?  ^N R
N+I
O"
R'
Oxbenzimidazole (51) Benzimidazole N-oxide (52)
The cyclisations fall into three basic types (1,2,3 below):
Type 1 involves the condensation of a hydroxylamine (54), resulting from the 
partial reduction of an o-nitroanilide (53), with an acidic carbonyl. Initially the A^-oxides 
were by-products of the total reduction of the o-nitroanilide but careful manipulation of the 
reductive conditions'^ can lead to significant yields of the benzimidazole N-oxides (55).
lyaeXl);.
NRCOR'
I I
NOg (53)
NRCOR
NHOH
NR
^  r 2— r-
N+
(55) 6 -
The second type of cyclisation involves the interaction of an azomethine carbon 
with an o-nitroso group (57); the simplest of this type of reaction being the acid catalysed 
condensation of an o-nitrosoaniline (56) with an aldehyde (benzaldehyde)^M however the
o-nitrosoanilines are very difficult to prepare and are themselves an unstable species.
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Type (2):
R"
(56)
NH,
NO
R'CHO R"
(57)
N=CHR'
NO
I ^ R '
(55) o
Finally, o-substituted nitroarenes (58) may be cyclised to benzimidazole A^-oxides 
(type 3, 55) with the condensation of the nitro group and a nucleophilic centre in the ortho 
substituent (59)^^. The ortho substituent must be alkyl- or aryl-amino, and the reactive 
centre activated by an electron accepting group such as nitrile, ester, ketone or amide 
resulting in a 2-substituent in the final product. These cyclisations may be acid, base or 
thermally induced. With the aforementioned activating groups the cyclisation occurs under 
extremely mild conditions; weaker electron acceptors (e.g. R'=aryl in the scheme below) 
require more extreme conditions.
Iype_.(,3};.
R"
NHCHgR'
NOc
(58)
R"
(59) HO O' (55) O'
1.10 A general synthetic route to benzimidazole A-oxides
During the past 20 years, this research group in St. Andrews has been investigating 
the synthesis of benzimidazole N-oxides and more recently working towards the 
production of a general synthetic route for the introduction of functionality to the 
carbocyclic ring; thus enabling the synthesis of benzimidazole A^-oxides which are 
structurally similar to the natural purines, adenine and guanine.
The reported^^ synthetic route is based upon the o b s e r v a t i o n ^ ^  that benzimidazole-
2-cai'boxylic acid A -^oxides undergo facile decarboxylation when heated in solvents even at
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relatively low temperatures (~80“C). Cyanométhylation^^ of a suitable o-nitroaniline (60) 
and subsequent cyclisation affords the 2-cyanobenzimidazole 3-oxide (62a). Hydrolysis in 
concentrated hydrochloric acid yields the hydrochloride salt of the N-oxide (65), formally 
derived through the hydrolysis of the nitrile to the carboxylic acid and spontaneous 
decarboxylation upon heating. The free //-oxide is obtained by a simple work-up procedure 
involving aqueous ammonia^^. The cyanométhylation step is simply modified by varying 
the quantity of Lewis acid according to the basicity/nucleophilicity of the amine: the less 
basic/nucleophilic amines requiring a greater amount of Lewis acid.
In certain cases //-o-nitrophenylglycine esters (64) may conveniently replace the 
//-cyanomethyl-o-nitroanilines (61). The reaction of a halogenonitrobenzene (63) with a 
glycine alkyl ester affords a nitrophenylglycine ester (64) which will cyclise like the 
corresponding nitriles under mild, basic conditions to produce a benzimidazole //-oxide 
carrying an ester group at C-2 (62b). This method removes the need to use potassium 
cyanide, but is applicable only when the starting halogeno compound is available.
NHg (CHgOln. J1Q.N...
ZnClg 
NOg AcOH
R"
NHCHgCN
8ase^ p 2
H2NCH2CO2R
(62a) Q-
Y=CN
NHCHgCOgR 
NOg
-BâS^ r 2. NHI Y
N+
(62b)
Y=COgR
(62a/b) 0 “
hYa,
COgR
24
1-Unsubstituted benzimidazole 3-oxides are tautomeric with iV-hydroxy- 
benzimidazoles, the position of the equilibrium having been studied extensively for certain 
derivatives. In these cases the N-oxide predominates in aqueous solution. In other solvent 
systems as the hydrogen bonding power (polarity) of the solvent decreases, so the 
proportion of //-hydroxy tautomer increases^^. In the remainder of this thesis, however, 
these compounds are all referred to, for convenience, as benzimidazole 3-oxides.
Benzimidazole 3-oxides are weakly basic^^ and the 1-unsubstituted benzimidazole 
3-oxides are also weakly acidic, requiring only mild bases to effect deprotonation. 
Alkylation of the //-oxide species (in the majority of cases studied so far) in the presence of 
a base and an alkyl halide leads to the formation of 1-alkoxybenzimidazoIes. The 
benzimidazole is thus attached to a side chain77,78,79 via a N-O-C linkage.
1.11 Aims
The aim of this research is to exploit the already established general synthetic route 
to benzimidazole 3-oxides to produce novel guanine analogues in which an acyclovir-like 
appendage is attached to the base via alkylation of the //-oxides on the oxygen atom.
Initial routes will investigate the production of a 5-nitrobenzimidazoIe 3-oxide with 
the express purpose of later reduction to furnish the amino group and consequent guanine 
analogue while leaving the N-O-C linkage intact. Possibilities for expansion of the 
synthetic route to produce nucleoside analogues possessing functionality at C-2, as 
proposed to be required for the maintenance of activity in the Townsend series of 
benzimidazole ribonucleosides will be explored as well as the production of similar
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benzimidazole ribonucleosides will be explored as well as the production of similar 
polyhalogenated nucleoside analogues.
The biological target is initially postulated to be the herpes group of viruses for 
which HSVl testing will be carried out in-house. More importantly, HCMV is also a target 
and as has been previously outlined, a potent, effective and non-toxic therapy for the 
treatment of its manifestations in the immunosuppressed/compromised has not yet been 
discovered. Testing for such activity and against a more expansive panel of viruses will be 
undertaken outwith the university.
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Chapter 2 
AT-Alkoxvbenzimidazoles related to guanosine
2.1 Introduction
This research group in St. Andrews has provided, over the years, a general 
synthetic route to benzimidazole A-oxides with a variety of substituents on the carbocyclic 
ring; these benzimidazole oxides are unsubstituted at the other nitrogen and may also be 
unsubstituted at C-2. Benzimidazole iV-oxides may be synthesised with functionality 
similar to the natural purines; compounds with substituents such as 5- and 6-amino groups 
could be regarded as guanosine analogues [cf. (79), (81) and (82)] and those with the 4- or 
7-amino substituent as adenosine analogues [cf. (80), (83) and (84)]. Benzimidazole 
//-oxides with amino functionality on the benzene ring may be synthesised through the 
reduction of a nitrobenzimidazole A-oxide. A suitable point in the synthesis of the 
benzimidazole oxide would need to be chosen for the reductive step. Alternatively, the 
amino groups may be protected at the beginning of the synthetic route, the exocyclic 
nitrogen at the correct oxidation level, and deprotected after the formation of the required 
benzimidazole A -^oxide. Reaction of the benzimidazole A-oxide with a suitable acyclic 
halide or sugar derivative may then lead to nucleoside analogues in which the attachment to 
the benzimidazole (base) is via an N-C (natural) or an N-O-C (unnatural) linkage; both are 
theoretically possible.
HgN
}  <1 }
Sugar Sugar
Guanosine (79) Adenosine (80)
The excellent activity of maiket-leading antiviral compounds such as acyclovir (21) 
and famvir (29), coupled with their structural similarity to the natural nucleosides makes the
HN
Hg
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study of benzimidazole nucleoside analogues particularly important due to their structural
similarities to both the natural substrates and the commercially successful antiviral agents. 
^  HgN
HoN
6  (81) (83)
possible . 
G uan osine^  
equivalents
Sugar'
O
// N
Suga
(82)
Sugar J
possible  
V  Adenosine 
equivaients
The most straightforward synthetic route leading to benzimidazole N-oxides is via 
the cyclisation of ^ -(activated alkyl)-o-nitroanilines with the subsequent removal of the 
functionality at C-2, if desired, by hydrolysis/decarboxylation in concentrated mineral acid.
The initial aim was to find a route to a guanosine analogue. It was decided, in view 
of previous work^S, to proceed via a nitrobenzimidazole oxide and reduce the nitro group 
to the required amino functionality in the latter stages of the synthesis. The proposed route 
would involve reaction of a halogenonitrobenzene (85) and a glycine alkyl ester (ethyl or 
methyl) with subsequent cyclisation of the nitrophenylglycine ester (86) to the 
benzimidazole A^-oxide with the ester functionality at C-2 (87). A choice of routes in the 
synthesis was then available; either alkylation or hydroxyalkylation first, giving (89), 
followed by the hydrolysis/decarboxylation, or the alternative process of 
hydrolysis/decarboxylation to (88) prior to (hydroxy)alkylation giving (90). The choice of 
two routes could prove to be a valuable tool in the synthetic route by providing more 
flexibility. Little was known prior to this investigation concerning the stability of the 
N-O-C linkage (89)^8,79 under the hydrolytic conditions required to remove the 
functionality from C-2, or indeed under any reaction conditions (see scheme 2.1 overleaf: 
boxed structures (89), (90) and (91) are of potential biological interest).
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Scheme 2.1
Proposed synthetic route
NH2CH2CO2R
NHCHgCOgR 
NOg
B ase
NOg (86)
B ase R=Et or R=Me
NH
I ^ C O g R  (87) 
N+
1
OR' (90)
Reduction
’
y \
OR' (91)
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2.2 Synthesis of 5-nitrobenzimidazole 3-oxide
As stated in the literature^^, 2,4-dinitrophenylglycine ethyl (86a) and methyl (86b) 
esters were synthesised from l-chloro-2,4-dinitrobenzene (85) and the relevant glycine 
alkyl ester hydrochlorides. Only mild conditions are required due to the electrophilicity of 
the carbon atom which is both ortho and para to the nitro groups. [In the case of ring 
substituents which are electron-donating, either a more labile halogen atom (fluorine) or a 
more nucleophilic nitrogen atom, or both, are required. ]
Cl NHCHgCOgR
NOg
NH2CH2C0 2 R
NaHCOa
I EtOH
NOg 
(85)? NO, g g g
The cyclisation step was r e p o r t e d ^ ^  to be effected under extremely mild conditions 
(piperidine in ethanol): however, this procedure could not be repeated. Numerous attempts 
involving the varying of reaction times and the use of freshly purified and different batches 
of piperidine, still only yielded trace amounts of product and returned much of the starting 
material unchanged. When anhydrous potassium carbonate was used in place of piperidine, 
the desired product (87a/b) was obtained in a cleaner reaction and with a reasonable yield; 
both the ethyl (86a) and methyl (86b) esters cyclised equally well. It is suggested that the 
piperidine used by previous workers was of poor quality and contained sufficient water that 
its attempted drying over potassium hydroxide resulted in the partial dissolution of some of 
the hydroxide, which in turn had acted as the base in the previous cyclisations.
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, NHCHgCOgR 
NOg
NOg
(86a) R=Et 
(86b) R=Me
KgCOa
EtOH
OoN
I ^— COgRrOr
(87a) R=Et 
(87b) R=Me
The cyclisation is most simply formulated by the base (potassium carbonate) 
abstracting a proton from the active methylene group of (92). The intermediate caibanion 
(93) (stabilised by the ester group) attacks at the electrophilic centre of the nitro group in an 
intramolecular aldol-type reaction giving (95), after which a molecule of water is eliminated 
to furnish the A -^oxide (87a) with the ester functionality at C-2.
OoN
H
N~ O 
(92) o "
Base  
H H OEt
"  !fN n -O E t
B a se
OoN
OoN
H 
N 
^— COgEt
r0 “ (87 a)
OEt
H-Base
N = 0OoN
(94) o
OEt
:'-0 -
Having synthesised both the ethyl (87a) and methyl (87b) 5-nitrobenzimidazole-
2-carboxylate 3-oxides, a possible branch point in the synthesis had been reached. The next
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step could either be alkylation on the oxygen atom (N-1 was also theoretically possible) or 
hydrolysis/decarboxylation of the ester (see scheme 2.1, page 28). Hydrolysis/ 
decarboxylation will be dealt with in the first instance. It has been reported^^ that 
benzimidazole-2-carboxylic acids (96) undergo facile decarboxylation when heated in 
solvent at moderate temperatures to yield the benzimidazole oxide unfunctionalised at C-2. 
This had provided the ideology for the removal of either nitrile or ester under the perfected 
hydrolytic conditions.
V“ COpR
H
^ 1_  R=HO"
Heating of the alkyl 5-nitrobenzimidazole-2-carboxylate 3-oxides (87a) or (87b) in 
concentiated hydrochloric acid yields the A/-oxide (88a) as its hydrochloride salt which 
crystallises out of the reaction mixture upon cooling. Such hydrochloride salts have 
characteristic ^H nmr spectra in which H-2 has a shift of approximately ô 9.5-10. The free 
//-oxide (88) is reached through a simple work-up in aqueous ammonia, the product 
crystallising out of solution on paitial concentration under reduced pressure.
The hydrolysis/decarboxylation reactions of (87a/b) to produce the iV-oxide (88) 
were also attempted in a basic medium in order to introduce further flexibility to the 
synthetic route. The esters were stirred in an aqueous sodium hydroxide medium for 2 
hours and the precipitates collected. In the case of the ethyl ester (87a) the product was 
isolated in good yield but in the case of the methyl ester (87b), a mixture of the //-oxide
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(88) and its hydrochloride salt (88a) was isolated. The reaction was pursued no further in 
view of the success of the acidic hydrolysis route.
OoN
(87a) R=Et 
(87b) R=Me
H
I CO2R
N+I
O"
HCI or 
NaOH,
OoN
OoN
H
I %N+ (88a)
OH.cr
NH3/H2O
H
I 
N^+I
O"
(88)
2.3 O-Alkylation of the benzimidazole oxide
The 5-nitrobenzimidazole 3-oxide (88) was then available via acidic or basic 
hydrolysis for the attempted alkylation upon the oxygen atom to provide the desired N-O-C 
linkage. Benzimidazole A^-oxides (97) were known^^’^  ^ to undergo O- rather than 
77-alkylation with an alkyl halide in the presence of a base to give, e.g. (98).
H 
N
I
N+ 
(97) 6-
Mel
NaOH
N
I N
(98)
CH3O
Initial attempts at alkylation were centred upon a simple model system using ethyl 
iodide. This had been used in earlier work by Moody^ 1 to afford 1 -ethoxy-2-cyano-6- 
acetamidobenzimidazole (100) from the coiTesponding A -^oxide (99) using triethylamine as 
the base. Removal of the acetyl protective group gives the amine (101) as its hydrochloride
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with the nitrile still intact. Attempts by Moody to react both benzimidazole A-oxide and
ethyl 5-nitrobenzimidazole-2-carboxylate 3-oxide with a-acetobromoglucose (2,3,4,6-
tetra-O-acetyl-a-D-glucopyranosyl bromide) proved partially successful, in that the
products were detected spectroscopically but proved impossible to isolate in a pure form.
H
AcNH
I v~~CN
(99) O"
Bl.
EtOH
AcNH
1 / — CN
cr
(100)
N
O (101)
The use of more complex acyclic alkylating agents by McFarlane^^ had also 
produced little success. Attempted reaction of 5-methylbenzimidazole 3-oxide with both 2- 
bromoethanol and 3-bromopropan-l-ol returned only unreacted starting material. Limited 
success was met in the reaction with this benzimidazole oxide with ethylene caibonate, but 
on attempted purification a resinous material was produced which had lost the H-2 
resonance in the nmr. A molecular ion of M+ =236 in the mass spectrum led to the 
proposal of structure (102) for the product through the mechanism shown overleaf, 
unfavourable side reactions having resulted in the loss of the desired N-O-C linkage and the 
attachment of the side chain at C-2. Failure was also met in attempts at the reaction with 
a-acetobromoglucose the product proving impossible to isolate in pure form.
Following literature methods^h^l the A^-oxide (88) was dissolved in DMF and 
addition of a solution of sodium ethoxide followed by ethyl iodide furnished 1 -ethoxy-6- 
nitrobenzimidazole (90) but in low yield. [Ethanol was initially used as the solvent but 
precipitation occurred on addition of the base and the reaction proceeded no further. The 
isolated product seemed to be the sodium salt of unchanged starting material which had
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proved insoluble in the original ethanol solvent, hence the dipolar aprotic solvent was 
required to maintain the reactive species in solution.] Slight improvement in the yield was 
accomplished by adding the sodium ethoxide to a solution of the N-oxide in ethanol to 
create the anion, followed by removal of the solvent through evaporation then dissolution 
of the resultant solid in DMF before addition of the alkylating agent (ethyl iodide).
CH
HO
CH.
O
(102) HO— (^ ^ 2)2
O
OoN
(88)
H
I
N+
I
O'
B ase CH
O
H
II N (CH2)2 CH.
i)NaOEt, EtOH
ii)Etl, DMF
O2N
(90)
:0
Hf
(CH2)2
. 0
(CHz)2
a ( ^ ^ 2)2o .
(CH2)2
O
O
In further attempts to improve the alkylation yield, the addition of a two-fold excess 
of base resulted in the isolation of an unexpected product which could be explained by a 
rather interesting rearrangement^® (see mechanism below). Alkylation initially occurs, as 
normal, at the more nucleophilic oxygen site following the addition of the first equivalent of 
base and the ethyl iodide; however upon addition of a second equivalent of base which 
attacks nucleophilically at C-2 and results in the subsequent elimination of the ethoxy group
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from N-1 giving the final product, 2-methoxy-5-nitrobenzimidazole (103), which was 
characterised by nmr.
OoN
H "Base
I0“
Base=Na OMe
OoN
OoN OoN
r-Ef
H
N OMeOoN
Base H
j f V V o M e
(103)
Although the addition of a two-fold excess of base resulted in elimination of the 
alkoxy group, one equivalent of base did not result in full deprotonation, inasmuch as 
peaks representing starting material were still present in the aromatic region of the nmr 
spectrum of the final product. Addition of a slight excess of alkylating agent and base (each 
1.1 equivalent) did little to improve the yield, with unreacted starting material still present 
in the final product, hence the reaction still not going to completion. The umeacted staiting
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material was removed by washing the organic phase of the reaction mixture with aqueous 
sodium hydroxide, via the formation of the water-soluble sodium salt of the benzimidazole 
N-oxide and its removal in the aqueous layer. This produced a product free from starting 
material according to the iH nmr spectrum.
With the slightly improved alkylation conditions providing the desired product in 
reasonable yields, alkylation of both esters (87a) and (87b) was next undertaken (see 
scheme 2.1, page 28). Although no heating was applied to the reaction, it was debatable if 
the ester would withstand the reaction conditions. In the case of the ethyl ester (87a) the 
expected product (89a) was isolated in a reaction with sodium ethoxide and ethyl iodide in 
DMF; with the methyl ester, using sodium ethoxide as the base, exchange occurred 
between the ester and the ethoxide anion and this resulted in a mixture of ethyl and methyl 
esters. The use of sodium methoxide as the base in the presence of the methyl ester, 
prevented any such exchange.
H
V -C O jR  NaOR,ROH ^
0,N
> - COoR
(87a) R=Et °     (89a) R=Et
(87b) R=Me O (89b) R=Me
With the alkylation in the presence of the ester groups having proved successful, 
hydrolysis/decarboxylation remained the only stage left to complete all the alternative routes 
prior to the final reductive stage. As no difference in the reactivity of the esters had been 
found so far, the acid and base hydrolyses were carried out only on the ethyl ester (89a). 
Acid hydrolysis of (89a) yielded a high-melting solid with the correct nmi* but with an 
M+ at m/z 208 which corresponded to the hydrochloride of the desired product. Basic 
hydrolysis of the ester (89a) in sodium hydroxide solution (on addition of the hydroxide to 
the reactant, the characteristic deep red colour of the anion in solution was immediately 
visible) furnished the desired free A -^oxide (90) after heating at 50“C for 2 hours.
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I y—CO2R
0 ,N "  'N  0 ,N
(89a) R=Et (90)
Attempts were then made to effect hydroxyalkylation of 5-nitrobenzimidazole
3-oxide with the inexpensive and commercially available 3-bromopropan-l-ol while 
maintaining the previously used reaction conditions This would furnish a benzimidazole 
with a more complex acyclic side chain; equivalent in length to that of acyclovir (21) (see 
chapter 1, pH ) but possessing the N-O-C linkage between the base and side chain similar 
to that of BRL 44385 (26) (see chapter 1, pl3).
X—!— II y -R  = >
N 
H O -i I 
1 ^ 0
I /V~R +  HO
HO Br
The hydroxyalkylation with 3-bromopropan-l-ol was initially attempted with the 
hydroxyl group protected as its 2-tetrahydropyranyl ether in order to avoid any unwanted 
side reactions of the hydroxyl group involving C-2, further alkylating agent, the nitro 
group or the amino group subsequent to reduction of the nitro group. Protection of the 
hydroxyl group as its tetrahydropyranyl ether was chosen due to its stability under a vaiiety 
of conditions, including catalytic reduction, the ease of handling of dihydropyran and the 
mildness and efficiency of the conditions required to introduce the ether and furthermore to 
regenerate the alcohol^^ at the appropriate stage.
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The 2-tetrahydropyranyl ether (THP ether) of 3-bromopropan-l-ol was furnished 
using pyridinium p-toluenesulphonate (PPTS) as the catalyst in a method developed by 
Grieco et alM . The THP ether (105) then replaced ethyl iodide in the alkylation of 
5-nitrobenzimidazole 3-oxide (88) and furnished the desired product (106) although not 
using the established protocol but on the later discovery of potassium carbonate as a more 
suitable base. Regeneration of the alcohol (107) required slightly elevated temperatures 
relative to the literature procedure^^ and returned the unprotected product in a crude form 
which unfortunately could not be isolated by distillation under high vacuum or by 
crystallisation, and resulted only in the production of carbonaceous material due to thermal 
instability.
n
DoN
(104)
H
PPTS
DCM
i)base, EtOH PPTS
OpNOpN
(88) 0 “
HO
(106) (107)
■n '
O
In view of the final stage of the synthetic route being reduction of the nitro 
functionality to an amino group, a benzyl protecting group for the halogenopropanol (104)
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was investigated in order that hydrogenoiysis of the benzyl group might occur in parallel 
with the reduction of the nitro group, so disposing of the need for a separate deprotection 
step. Two possible methods for the synthesis of l-(benzyloxy)-3-bromopropane (108) 
were investigated. The first benzylation was developed from the method of Michelson and 
Todd^5, originally used in the protection of sugars, however the yield was very poor and 
returned only enough of the product (108) for characterisation. The second method^^ 
proved a little more successful and involved a slightly different approach, the bromination 
of l-(benzyloxy)-3-propanol (109) with A^-bromosuccinimide and triphenylphosphine to 
provide the desired product (108) in more appreciable quantity. The reaction of the
3-bromo- 1-benzyloxypropane (108) with 5-nitrobenzimidazole 3-oxide (88) gave the 
desired product (110) although in a very poor yield. Again the product (110) proved very 
difficult to purify and was not isolated in its pure form.
Br' ^  OH 
(104)
OoN (88) o-
BnCI
KOH
toluene  
1,4-dioxan
PPh3,
NBS
l)NaOEt, EtOH 
ii)BnO(CH2)3B* 
DMF
Br' ^  OBn (106)
BnO' 'B r  
(108)
(110)
As this type of O-alkylation had been partially successful the reaction between 5- 
nitrobenzimidazole 3-oxide (88) and unprotected 3-bromo-1-propanol (104) was then 
attempted. When the reaction was carried out the tic was seen to be more complex than 
those previously observed, but the major and only isolated product was the desired 
l-(3-hydroxypropoxy)-6-nitrobenzimldazole (107), free from contaminants and judged to 
be pure spectroscopically. The good yield obtained implied that the reaction was 
substantially free of side reactions.
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OoN
(88)
H
I ^r 
0 “
i)NaOEt, EtOH
ii)HO(CH2)3B7 
DMF ^2OoN
I  %N
(107)
In the reaction of the unprotected 3-bromopropan-l-ol (104) with ethyl 
5-nitrobenzimidazole-2-carboxylate 3-oxide (87a), the possibility of unfavourable side 
reactions involving the hydroxyl group still existed. A further alteration to the reaction 
procedure was introduced in this reaction: potassium carbonate was used as the base 
instead of sodium ethoxide in an effort to improve the yield. This was a great success: 
potassium carbonate proved to be a far superior base, furnished the product (111) in a 
greater yield from a cleaner reaction, and disposed of the need to deprotonate the 
benzimidazole A-oxide in a separate step.
H
OoN
j ^ V c O g E t
(87a) O"
i)K2C03
ii)HO(CH2 )3 Br
DMF OoN
I y -C O g E t  
N
I (1 1 1 )
The (hydroxy)alkylation (using ethyl iodide and both 3-bromopropan-l-ol and its 
hydroxy-protected counterparts) was successful for both 5-nitrohenzimidazole 3-oxide (88) 
and its 2-carboxylate esters (87a/b). The only remaining step was the reduction of the nitro 
group to an amino group to produce the desired guanine functionality and hence a 
nucleoside analogue.
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2.4 Attempted reductions of the nitro functionality
The first attempt at reduction of the nitro group was carried out on l-ethoxy-6- 
nitrobenzimidazole (90), a model system, before the more complex hydroxypropoxy 
systems. 5-Aminobenzimidazole 3-oxide (112) had been produced previously^? by 
catalytic hydrogenation. The synthesis however involved the catalytic hydrogenation of the 
ester (87a), followed by hydrolysis/decarboxylation, due to the insolubility of the nitro 
compound (88) in typical hydrogenation solvents. The final product (112), reached via acid 
hydrolysis, was isolated as the dihydrochloride. Work by the a u t h o r h a d  previously 
resulted in the spectroscopic detection, but not isolation, of 6-amino-1- 
ethoxybenzimidazole (113), but time constraints had prevented further investigation and the 
reaction was only attempted once. The reducing agent used was sodium dithionite^^ and 
although the reduction had been successful (by nmr/mass spectrum), the yield had been 
very poor.
OpN
OpN
HN i) H2(g),
^ C O , R
(90)
O
O- (87a)
N Na2S20^
N
H^N
H 
N
I ;>
(112)OH 2C|-
H,N (113)
O
Catalytic hydrogenation was the first method employed in the attempted reduction 
of the nitro group of compound (90); using 5% palladium on carbon as the catalyst, as in 
the previous®? successful reduction of (87a). The product (113), isolated in low yield, was 
purified on a column of silica and had the correct iH nmr, but proved unstable in air, the 
light coloured product darkening over a few days. With this knowledge, the catalytic 
hydrogenation was reattempted but the final solution treated with hydrogen chloride gas to
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prompt the crystallisation of hydrochloride or dihydrochloride salt of 6-amino-1- 
ethoxybenzimidazole (113). This protocol led to the formation of a white precipitate which 
was collected. A second crop of crystals was also isolated from the supernatant liquid. 
Spectroscopic analysis of the two products showed that the first product was 
5-aminobenzimidazole (115), and the second (in very low yield) was 6-amino-1- 
ethoxybenzimidazole (114), both isolated as hydrochlorides. This result claiified the reason 
for isolation of poor yields in the previous attempts; hydrogenolysis of the N-O bond had 
occurred in addition to the reduction of the nitro group, to furnish ethanol and the water- 
soluble 5-aminobenzimidazole as the products.
OoN
N
I ">
OpN
(90)
H2(g)
|sj Pd/C, EtOH
(90)
O
i)H2(g).Pd/C, EtOH^
ii)HCI (g)
HoN
N
I 1>
*HaNcr
N
o
(114)
Cl
(113)
N 
N
O 
H
(115)
Further attempts at the reduction of the nitro group were undertaken using the same 
conditions but with l-(3-hydroxypropoxy)-6-nitrobenzimidazole (107). However the only 
product obtained was 5-aminobenzimidazole (115) which was isolated as its hydrochloride: 
this crystallised from solution after removal of the catalyst and saturation with hydrogen 
chloride gas. The reductive cleavage of the N-O bond apparently occurred to a greater 
extent with the hydroxypropoxy side chain. The reason for this is not immediately obvious.
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H
OoN
N
I ">N
HO (107)
Pd/C. EtOH 
ii)HCI (g)
cr
(115)
O
In the work of Harnden^^ et al. directed towards the synthesis of the drug Famvir 
(see chapter 1, p i3) hydrogenolysis of a benzyl group in the presence of an N-O-C linkage 
between a hydroxypropoxy group and an adenine derivative was accomplished 
successfully using hydrogen and palladium on carbon catalyst in formic acid.
These aforementioned conditions were applied to the reduction of
l-(3-hydroxypropoxy)-6-nitrobenzimidazole (107). Yet again however, hydrogenolysis of 
the N-O-C linkage occurred, with no evidence of the desired product in the nmr 
spectrum, the aromatic region only showing the protons associated with 
5-aminobenzimidazole. The final hydrogenative method attempted involved the dissolution 
of the nitrobenzimidazole oxide (88) in sodium hydroxide solution due to its insolubility in 
normal hydrogenative solvents. The attempted hydrogenation of the nitro group under these 
conditions with palladium/carbon catalyst produced no reaction; the starting material (88) 
was returned unchanged.
OoN (107)
H2(g). Pd/C 
HCOgH
H2(g)
Q- (88)
mixed products
Pd/C, NaOH no reaction
With no success using hydrogenative methods for the required reduction, other 
more selective and milder conditions were considered. Iron is a metal widely used in the
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reduction of nitro groups to amines, however other susceptible groups are often affected 
and the N-O-C link has already proved to be easily cleaved under hydrogenative 
conditions. It has been reported^^ that the iron-ammonium chloride system is a mild 
reductive protocol for the production of amine products in quantitative yields from nitro 
compounds in the presence of reducible groups such as nitriles and ketones. Application of 
the literature procedure to l-(3-hydroxypropoxy)-6-nitrobenzimidazole (107), however, 
resulted in the detection of no discernable product. The nmr showed no evidence of 
either unreacted starting material or products, and the tic showed a variety of products; the 
method was abandoned, the conditions presumably being too hai'sh and resulting in the 
decomposition of the starting material or products.
OoN
Fe/NH4C1 mixed products
HO—1 (107)
An extremely mild method^ ^  for the reduction of aromatic nitro compounds to 
aromatic amines and utilises titanium trichloride in hydrochloric acid as the reductant. The 
starting material (107) had already proved stable under prolonged heating in concentrated 
hydrochloric acid and the proposed conditions were certainly less drastic than those 
associated with tin or iron in hydrochloric acid.
OoN
N
I N
TiCI,HCI  ^
cyclohexane
HO- (107)
O
no reaction
Unfortunately in practice, these conditions also proved ineffectual as a method for 
the reduction of the nitro group and returned the starting material unchanged, with the 
N-O-C bonds intact. This did show however, that reductive conditions did not necessarily
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to the cleavage of the N-O bond. With no success imminent however in the search for a 
protocol for the reduction of the nitro functionality in the presence of the N-O-C linkage, it 
was decided that the synthetic route ought to be redesigned to dispose of the need for such 
a reaction.
2.5 A non-reductive route to the desired guanoslne analogue
In theory, several possibilities were available which could be manipulated to 
provide an amine and lead to the desired nucleoside analogues: i) the reduction of the nitro 
group before O-alkylation of the N-oxide, ii) the production of a suitably functionalised 
benzimidazole A^-oxide which could furnish the amine upon reaction with a nitrogen 
nucleophile, or iii) commencement of the synthetic route with the nitrogen at the correct 
oxidation level and suitable protection of the amine.
The reduction of the nitro group at a different stage of the synthesis was 
immediately discounted due to the difficulties incurred by previous workers^^ (see p41) in 
trying to isolate species in pure form. Secondly, alkylation specifically on the oxygen atom 
may then become a problem as the amine could also be susceptible to alkylation; and 
finally, reaction of the 2-carboxylate ester and the amine functionalities may introduce the 
possibility of self-condensation.
The second possibility involving funtional group transformation via nucleophilic 
displacement was also disregarded, as such a reactive position could prove problematic 
throughout the synthetic route.
Hence the most promising option was the protection of the amino functionality from 
the outset, beginning with the nitrogen at the correct oxidation level, and introducing two 
extra steps to the synthesis: a protective step at the beginning and a deprotective step at the 
end. A protected amino group, although not electron withdrawing by nature, is electron 
withdrawing by inductive effect, hence the ring should not differ too much in reactivity 
from the dinitrophenylglycine in the cyclisation step. In view of previous work, 81,82,87
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protection of the potential 5-amino group as its acetamide was considered to be the most 
straightforward route.
The amino group of 4-fluoro-3-nitroaniline (116) was protected through its reaction 
with acetic anhydride, yielding 4-fluoro-3-nitroacetanilide (117). This was in turn reacted 
with glycine ethyl ester hydrochloride and sodium bicarbonate in dimethyl sulphoxide, 
furnishing the nitrophenylglycine (118). The stronger reaction conditions (cf. 
chlorodinitrobenzene and nitrophenylglycine) were required to effect the nucleophilic 
substitution reaction in the absence of a second strongly electron-withdrawing substituent 
on the ring.
NO.
acetic
anhydride
(116)
NHCHpCQpEt.HCI, 
NaHCOs, DMSO
NHAc
(117)
NHCHgCOgEt 
NOg
NHAc
(118)
The cyclisation to ethyl 5-acetamidobenzimidazole-2-carboxylate 3-oxide (119) was 
effected under the now standard conditions of reflux in ethanol with potassium caibonate as 
the base. The protection of the amino group has a two-fold purpose; firstly the amino group 
is unable to participate in self condensation reactions with the carboxylate ester either 
before, during or after the cyclisation stage; and secondly, the strong electron-donating 
nature of the amino group would create difficulties in the reaction with the glycine 
nucleophile and also reduce the electrophilicity of the ortho-mito group. Although ring 
substituent effects have not been systematically studied for intramolecular reactions 
involving nitro groups, it has been noted^^ that the presence of an amino group, even 
where there are two nitro groups present, prevents cyclisation, whereas with an acetamide 
the cyclisations proceed as expected.
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NHCHgCOgEt 
NO2 K9CO3, 
EtOH AcHN
NHAc
(118)
H
j ))—  C02Et 
N+1
0 “
(119)
In the case of ethyl 5-acetamidobenzimidazole-2-carboxylate 3-oxide (119), the 
conditions required for hydrolysis/decarboxylation in concentrated acid would lead to the 
hydrolysis of the acetamide before the alkylation had been carried out, the foremost reason 
for the protection of the amine; O-alkylation of the benzimidazole oxide (119) was thus 
attempted prior to the removal of the ester group.
The alkylation of this benzimidazole (119) was effected in the usual way by 
treatment with potassium carbonate in DMF, but in this instance a characteristic colour 
change did not occur to indicate the presence of the anion in solution [as in the case of the 
5-nitrobenzimidazole 3-oxide (88)]. A small degree of precipitation occurred but the 
precipitate was resolubilised by the addition of a further aliquot of DMF. After the addition 
of 3-bromopropan-I-ol (104) the desired product (120) was isolated, the hydroxyalkylation 
having occurred on the oxygen with no significant side reactions involving the ester or the 
acetamide. The reaction yields were rather disappointing, hence the reaction was 
reattempted, both at low temperature (0°C) over a greater time period to suppress side 
reactions, and also for a shorter period at higher temperature (-lOO^C) but these resulted in 
no discernable improvement in the reaction yields.
AcHN
(119)
H 
N
I ^—C02Et
N+Io~
DKgCOg, DMF 
ii)HO(CH2)3Br,
DMF AcHN
HO-
N
V -C O a E t
N
O
(120)
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The effectiveness of bromide as a leaving group in the alkylation reaction was next 
brought under scrutiny. Using the Finkelstein reaction, 3-bromopropan-l-ol (104) was 
reacted with sodium iodide in acetone to yield 3-iodopropan-1 -ol (121). Reaction times 
were increased from the literature procedure^^»^^’^  ^ to ensure an adequate yield of the 
3-iodopropan-l-ol (121). Distillation of the reaction mixture separated the product from 
unreacted starting materials. Exchange of the iodide for bromide resulted in a drastic shift in 
the signal for the methylene group attached to the halide. There was a 30ppm upfield 
shift in the halogenomethylene resonance, probably due to the shielding effects of the 
iodine p  and d orbitals.
The use of 3-iodopropan-l-ol (121) in the hydroxyalkylation of ethyl 
5-acetamidobenzimidazole-2-carboxylate 3-oxide (119) using potassium carbonate in DMF 
did not produce a notable increase in the yield, not justifying the extra preparative step in 
the reaction route.
AcHN -,
(119) O
Nal
A cetone
pKgCOa, DMF  ^
ii)HO(CH2)3l,
DMF AcHN
(121)
■ ^ C O a E t
HO- (120)
O
Although, thus far in all this synthetic work, the use of substituted A-cyanomethyl- 
o-nitroanilines as starting materials had been avoided due to the cyanométhylation step 
requiring the use of potassium cyanide, old stocks of 4-acetamido-A-cyanomethyi-2- 
nitroaniline (122) were available for cyclisation. The reaction was carried out for a direct 
comparison with that of the ethyl ester in both the cyclisation and alkylation stages. The 
cyclisation, using potassium carbonate as the base, proceeded smoothly, yielding the 
product (123) but in a fairly low yield; however the hydroxyalkylation of 5-acetamido-2-
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cyanobenzimidazole 3-oxide proceeded very well and furnished the product (124) in high 
yield- in fact, the best yield of any of the alkylations attempted.
AcHN
NHCHgCN 
NO2
NHAc (122)
H 
N
:>— CN 
N+
(123) cr
K2CO3,
EtOH AcHN
V -C N
QKgCOs, DMF^  
iOHGCCHglsBr,” 
DMF AcHN
(123) O"
HO-
CN
(124)
O
A selection of these alkoxybenzimidazoles was subjected to antiviral testing.This is 
covered in chapter 5.
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Chapter 3 
Other benzimidazole A^-oxides
3.1 Introduction
Recent work carried out by Townsend et a/.^3,54 jn Michigan into benzimidazole 
ribonucleosides resulted in the discovery of the activity against HCMV of two compounds, 
TCRB (38) and BDCRB (39), both derivatives of DRB^l (36) (see chapter 1, p l6). A 
great variety of nucleoside analogues were initially synthesised before the highly potent and 
selective compounds (38) and (39) were discovered. With only one exception^^, 
derivatives of the initial compound, DRB (36), with modification to the benzene ring 
halogens or movement of the halogens to different positions on the benzene ring resulted in 
poorer antiviral activity. Replacement of the ribose sugar with other sugars producing 
sugar-modified analogues also resulted in weaker antiviral activity except in the cases of 
both the xylo and lyxo analogues which possessed activity against HSVl and HSV2^5
N
V ~ B rN
HO HO HO—
HO HO HO HO HO HO
DRB (36) TCRB (38) BDCRB (39)
Analogues of (38) and (39) in which the ribose sugar was replaced by an acyclic 
moiety at N-1 [analogous to acyclovir (21) (chapter 1, p ll)  or ganciclovir (23) (chapter 1,
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pl2), two of the commercially available treatments for HCMV] also resulted in compounds 
(125, R=H or CH2OH) which were either only weakly active or inactive against HCMV or 
HSV196.
The final variation in structure which was investigated was the atom or group at C-2 
(125, R' is a variety of substituents). The introduction of a chlorine or bromine at C-2 
resulted in a notable improvement in the activity of (38) and (39) against HCMV and 
selectivity relative to DRB. Several other substituents were investigated at C-2 but none 
showed an improvement in activity over (38) and (39). The lone heterocycles of the 
benzimidazole nucleosides were also tested for antiviral activity and showed promise in 
plaque reduction assays, but the activity was not well separated from toxicity53’^ 4,96
Cl V"R'
01
HO
R
(125)
RzzCHgOH or H 
R'zzNHg, NHGH3, N(CH3)2. 
S-Bn, SH, H, SCH3, 
SO2CH3 GtC.
These observations indicated that the requirements for HCMV activity for 
benzimidazole ribonucleosides, especially at C-2, are extremely naiTOw and specific. This 
work prompted an interest in the synthesis of dichlorobenzimidazole V-oxides; research 
into these compounds had never before been undertaken. The synthesis and O-alkylation of 
5,6-dichlorobenzimidazole 3-oxide was of particular interest. The two possible synthetic 
precursors of this type of benzimidazole oxide were the ester (129) and the nitrile (127). It 
was expected that there might be difficulties in the synthesis of (127) from 4,5-dichloro-2- 
nitroaniline (126), paraformaldehyde, potassium cyanide and zinc c h l o r i d e ^ ^  The quantity 
of zinc chloride required varies with the basicity of the amine'73, a large excess (7-8 mol.
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equiv.) being required even for monochloro-nitroanilines, and so there was the possibility 
that an even larger proportion might be necessary in the case of dichloronitroanilines. This 
method was therefore not investigated further and attention was concentrated on the 
synthesis of the ester (129).
NHCHgCN 
(CHsOln ^NOg
.KCJV
ZnClg
AcOH
In the reaction of l,2,4-trichloro-5-nitrobenzene (128) with an uncharged nitrogen 
nucleophile, there remained the theoretical possibility that the ortho-, para- or indeed both 
chlorines may be displaced by the glycine. In any case, such a substitution was known to 
occur and displace the desired ortho-chXonwQ as in the reaction of l,2,4-trichloro-5- 
nitrobenzene (128) with hydrazine hydrate to furnish 5,6-dichloro-1 -hydroxy- 
benzotriazole^? (discussed in chapter 4). In such a reaction involving glycine, the reaction 
conditions used could not be as severe as those involved in the reaction of a simple nitrogen 
nucleophile such as hydrazine. The reaction of l,2,4-trichloro-5~nitrobenzene (128) was 
investigated by Marr^S and although the desired ester product (129) was furnished, the 
nitrogen nucleophile displacing the orfAo-chlorine, the yield was very poor. This was 
presumably due to the poor polarisability of the C-Cl bond and its much poorer lability 
compared to e.g. a fluorine^^.
Cl NHCHgCOgEt
NOgNH2CH2C02Et.HCI 
NagCOa
EtOH Cl
( 128)
NO
Cl
01
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The use of a nitro group as a suitable leaving group was also investigated by 
Marr^9. ortho-Dichlordb&nzene (130) was dinitrated 1^ 0 to give a mixture of products 
including the desired l,2-dichloro-4,5-dinitrobenzene (131). It was reported that nitro 
groups may be substituted with nitrogen nucleophiles Although such a substitution 
reaction was investigated by Marr^^ and the desired dichloronitrophenylglycine ethyl ester 
isolated, it was only isolated in a very poor yield; the route was not investigated further due 
to both the poor yield of the substitution reaction and the mixture of products isolated from 
the dinitration of o-dichlorobenzene (130).
HNOg
H2SO4
NO.
NO.
Cl
01
(131)
Clrr
01
(132)
3.2 Synthesis of 5,6-dichlorobenzimidazole 3-oxide
The route followed to the dichlorobenzimidazole N-oxide was similar to that 
undertaken for the synthesis of 5-nitrobenzimidazole 3-oxide; the cyclisation of a 
nitrophenylglycine derivative to the benzimidazole N-oxide with functionality at C-2 was 
followed by either hydrolysis/decarboxylation or by O-alkylation depending on whether or 
not the ester group was required at C-2 of the final product. Commercially available 
l,2-dichloro-4-fluoro-5-nitrobenzene (133) was heated in ethanol with glycine ethyl ester 
hydrochloride and sodium bicarbonate to furnish the desired l ,2-dichloro-4 - 
nitrophenylglycine ethyl ester (129) in good yield.
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NO-
Cl
Cl
HgNCHgCOgEt MCI 
NaHCOa 
EtOH Cl
NHCHgCOgEt 
NOg
(133)
The dichloronitrophenylglycine ester (129) was then cyclised in ethanol with 
potassium carbonate to yield ethyl 5,6-dichlorobenzimidazole-2-carboxylate 3-oxide (134) 
using the now familiar conditions. The product was isolated in a rather disappointing yield 
(ca. 50%) but was found to be pure spectroscopically, and no optimisation of the reaction 
conditions was undertaken. However, one of the later attempts at this reaction was left 
overnight before the work-up procedure was carried out, and upon analysis of the crude 
product by iR nmr it was found that a substantial amount of hydrolysis/decarboxylation 
had occurred; a downfield resonance for H-2 was apparent and the integration of the 
upfield aliphatic resonances was incorrect. It was presumed that if the base used for the 
cyclisation was a good enough nucleophile, then attack at the ester was possible and 
following ester hydrolysis, decarboxylation would be spontaneous^^ and furnish a mixture 
of products (134) and (135). This hydrolysis/decarboxylation of the C-2 functionality by a 
nucleophilic base had not been previously noticed and was a distinct possibility in all such 
reactions. The poor yields of earlier cyclisations were probably due to this fact. The crude 
mixture of products (134) and (135) was heated under reflux in an excess of concentrated 
hydrochloric acid to complete the hydrolysis/decarboxylation and this p r o c e d u r e ^ ^  %ed to 
the isolation of the hydrochloride (135a) in a good overall yield.
NHCHgCOgEt
T  n />— COaEtaOH 'N+
6 ‘
(134)
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As discussed in the introduction to this chapter (p50 and p51), the benzimidazole 
ribonucleosides synthesised by Townsend et a/. 53,54,96 required functionality at C-2 for the 
maintenance of activity against HCMV; although many substituents were experimented 
with, no alkyl esters were investigated.
Two possible routes were available in the synthesis. The ester (134) could be O- 
alkylated to yield a product with functionality at C-2. Hydrolysis/decaitoxylation of the 
ester (134) to remove the C-2 functionality followed by O-alkylation was the alternative. 
Both possibilities were investigated in order to highlight any differences in activity due to 
the presence or absence of functionality at C-2.
Ethyl 5,6-dichlorobenzimidazole-2-cai'boxylate 3-oxide (134) was heated under 
reflux in concentrated hydrochloric acid and the 2-unsubstituted V-oxide isolated as its 
hydrochloride (135a). The free V-oxide (135) was obtained after a simple work-up in 
ammonia solution and identified by the upfield shift of the H-2 resonance relative to the 
chemical shift of H-2 in the hydrochloride (135a)73.
01
01
NH
I V-OOgEtN+
O'
(134)
HCI
01
01
NH
I ^
N+
OH or
(135a)
NH3.H2O
01
01
NH
I
N+
O'
(135)
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3.3 O-Alkylation of the dichlorobenzimidazole oxides
O-Alkylation of the AT-oxide (135) was carried out next using 3-bromopropan-l-ol 
in the first instance; the use of ethyl iodide in preliminary attempts and protection of the 
hydroxyl group of 3-bromopropan-l-ol were previously proved to be unnecessary (see 
chapter 2, p39). Sodium ethoxide was initially used as the base in the O-alkylation but as in 
the case of 5-nitrobenzimidazole 3-oxide (chapter 2, p40) the yields were very poor. The 
use instead of potassium carbonate greatly improved the O-alkylation reaction yield. An 
attempt to furnish (136) using triethylamine as the base also resulted in a poor yield.
Cl
01
NHI 
N^+
I0“
(135)
base
DMF
Br(CH2)30H %Cl
HOi (136)
The corresponding O-alkylation of the ester (134) using potassium carbonate as the 
base furnished the desired product (137) in 43% yield. This reaction was also attempted at 
low temperature (0°C) and high temperature (90°C): the reaction at high temperature 
resulted in the partial hydrolysis/decarboxylation at C-2 and furnished a mixture of 
products (136) and (137). The low temperature reaction furnished the expected product 
(137) as normal but with no improvement in yield.
Cl
Cl
(135)
NH
^-COgEt
N+
I0 “
K2C03
DMF
Br(CH2)30H
Cl
Cl
N
'^ C O g E t
N
HO (137)
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The mixture of carboxylated (137) and decarboxylated (136) material obtained for 
the high temperature O-alkylation was heated under reflux in concentrated hydrochloric acid 
to yield the entirely hydrolysed/decarboxylated material (136). In this type of reaction there 
was no evidence of any cleavage of the N-O-C linkage under the hydrolytic conditions. 
There was also no evidence of protonation at N-3, hence isolation of hydrochloride salts of 
the product. In all cases where hydrolysis/decarboxylation was carried out on an 
0-alkylated benzimidazole oxide there was no evidence of protonation at N-3. The chemical 
shift of H-2 was always in the more upfield region of the spectmm as expected when 
comparing the chemical shifts of H-2 in free benzimidazole A -^oxides relative to H-2 in the 
hydrochloride salts. The low melting points of all the O-alkylated benzimidazoles indicated 
very little hydrogen-bonding between the molecules, cf. imidazole and imidazole N-oxide.
3.4 Polychloro benzimidazole oxides
The reaction of pentachloronitrobenzene (138) with glycine ethyl ester 
hydrochloride in a solution of ethanol and toluene using sodium bicarbonate as the base 
was attempted. Analysis of the crude reaction mixture by tic and iH nmr showed that no 
reaction had occurred. The reaction was pursued no further as the attempt had only been 
carried out due to the availability of the starting material in the laboratory. It was suspected 
that the reaction did not occur due to steric reasons.
Cl
Cl NO.
Cl
Cl
NHgCHgCOgEt
NaHCOa
EtOH
(138)
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The products of paiticular biological interest and with similar functionality similar to 
Townsend's compounds are (136) and (137) and their activity against HSVl is discussed 
in chapter 5.
3.5 Synthesis of benzimidazole 3-oxide
It was decided to synthesise the parent benzimidazole 3-oxide (143), unsubstituted 
on the benzene ring and at N-1, to act as a guide to the substituent effects on the activity of 
the compounds tested in an antiviral assay. The synthesis of benzimidazole 3-oxide was 
attempted using the conditions utilised in all the previous syntheses in this thesis. 
o-Fluoronitrobenzene was heated under reflux with glycine methyl ester hydrochloride and 
sodium bicarbonate in methanol but the major and only material isolated from the reaction 
mixture was unreacted starting material. In such reactions, cyclisation of the 
nitrophenylglycine ester formed may proceed under the conditions of the substitution 
reaction, and the cyclisation product may react further still. In this particular case it is far 
more convenient to react o-fluoronitiobenzene (139) with glycine and esterify in a sepaiate 
step to enable complete cyclisation to be carried out when required and avoid the isolation 
of a complex mixture of products.
o-Fluoronitrobenzene (139) was heated under reflux with sodium bicarbonate and 
glycine to yield «^-nitrophenylglycine (140). A small amount of the esterified product (141) 
was also isolated as a by-product. This was presumed to have occurred since the crude 
product (140), when dissolved in the recrystallisation solvent (ethanol), still contained 
some hydrochloric acid from the work-up proceduie.
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U
(139)
NOc HgNCHgCOÿ
NaHCOa
EtOH
NHCHgCOgH 
NO2 Hqi
EtOH
(140)
NHCHgCOgH 
NO2
(140)
NHCH2C0 2 Ët
(141)
2-Nitrophenylglycine ethyl ester (141) was obtained from o-nitrophenylglycine 
(140) through estérification in acidic ethanol. The cyclisation to ethyl benzimidazole-2- 
carboxylate 3-oxide (142) was carried out, as previously perfected, with potassium 
carbonate. In the majority of attempts however, this reaction did not stop at the desired 
product but proceeded to the decarboxylated benzimidazole (143), hence furnishing a 
mixture of products. As previously mentioned (chapter 3, p54), the accompanying 
hydrolysis/ decarboxylation was due to the nucleophilic nature of the base used; an added 
complication in this particular case was the water solubility of the product of such a 
reaction: benzimidazole 3-oxide. The yield over the two stages of cyclisation and 
hydrolysis/ decarboxylation was reasonable. In only one case was the ester (142) isolated 
alone.
NHCH2C0 2 Et
KgCOa
EtOH
(141)
) — C0 2 Et +
(142) O' aNH N+(143) 0 “
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As has been mentioned previously, the ethyl benzimidazole-2-carboxylate 3-oxide
(143) could either undergo O-alkylation or hydrolysis/decarboxylation first. 
Hydrolysis/decarboxylation will be dealt with initially. With the cyclisation reaction 
generally providing a mixture of products (142) and (143), the hydrolysis/decarboxylation 
was usually carried out on such a mixture. The hydrochloride (143a) was obtained in the 
first instance as the only product in the reaction and the parent benzimidazole oxide (143) 
isolated after a simple work-up in aqueous ammonia.
a mixture of 
com pounds 
(142) and (143)
HÇL I NH3H20
N+
(143a) OH cr (143) Q-
3,6 O-Alkylation of the benzimidazole oxide
In the early 0-alkylations of the benzimidazole 3-oxide (143), as in the case of 
5-nitrobenzimidazole 3-oxide (chapter 2, p38) , protection of the hydroxyl group of 
3-bromopropan-l-ol (104) was thought to be necessary. In the reaction of benzimidazole 
3-oxide (143) with the THP ether (105) and sodium ethoxide, the desired product (144) 
was detected and isolated, and purification attempted on a column of silica. This method of 
purification was unsuccessful and the attempted distillation of the product at reduced 
pressure was also unsuccessful as the alkylated benzimidazole (144) proved to be too 
thermally unstable and decomposed. The purification prior to the removal of the THP 
protective group was not investigated further as deprotection was necessary before the final 
product (145) was reached and purification could then be carried out more thoroughly. The 
reaction of (142) was undertaken using potassium carbonate as the base, but once again the
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product (146) was only isolated in a very small yield; this was presumed to be due to steric 
factors. The THP protective group was removed using pyridinium p-toluenesulphonate 
(PPTS) as the catalyst. Although the product (145) was isolated and the correct iH and l^C 
nmr resonances identified, (145) could not be obtained in pure form, proving too polar to 
purify on a column of silica and too thennally unstable, like its THP protected precursor 
(144), for distillation at reduced pressure.
(143) O
i)NaOEt, EtOH 
il)THPO(CH2 )3 Br, 
DMF
Nj PPT^
N
(144)
I %N
(145)
aNH/V-COgEtN+(142) Ô- K2CO3THPO(CH2)3BrDMF
(146)
N
N
O
V "  COaEt
On finding that a protective group for the hydroxyl function of 3-bromopropan-l-ol 
was an unnecessary precaution, indeed possibly a hindrance on steric grounds (all the O- 
alkylations involving the THP ether gave poor yields of products), the reaction was carried 
out with unprotected 3-bromopropan-l-ol (104). Initially sodium ethoxide was used as the 
base, where further attempts to purify the crude isolate by distillation at low pressure also 
led to decomposition, and as before, the replacement of sodium ethoxide with potassium 
carbonate improved the yields of (145) but it could still not be isolated in a pure enough 
form for use in the antiviral assay.
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(143)
O"
\) N aO E t EtOH, 
ii) Br(CH2)3 0 H, 
DMF a>
(145)
The reaction of ethyl benzimidazole-2-carboxylate 3-oxide (142) with 3-bromo­
propan-l-ol (104) with potassium carbonate as the base furnished the desired product (147) 
in good yield. There was no evidence of loss of the functionality from C-2 under the
O-alkylation conditions. Hydrolysis/decarboxylation of (147) was not attempted since
(145) could not be isolated in a sufficiently pure form.
^— COgEt 
N+
(142) O'
KpC03
Br(CH2)30H
DMF
(147)
Ethyl l-(3-hydroxypropoxy)benzimidazole-2-carboxylate (147) was of particular 
interest for its activity against HSV1 and is discussed in chapter 5 but the C-2 unsubstituted
l-(3-hydroxypropoxy)benzimidazole (145) was not submitted for antiviral testing as any 
activity discovered could not be attributed solely to the desired compound as the sample 
was contaminated with unknown impurities.
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3.7 O-Alkylation of other substituted benzimidazole oxides
A few benzimidazole A/-oxides with a variety of substituents on the benzene ring, 
and a number of their synthetic precursors, were already available in the laboratory in 
sufficient quantities to enable the investigation of their O-alkylation. Many of these 
compounds had been synthesised via the cyclisation of A^-cyanomethyl-o-nitroanilines, and 
hence possessed the nitrile functionality at C-2. Such products were invaluable in attempts 
to build a structure-activity relationship for these benzimidazole nuceosides' action against a 
number of selected viruses.
N-cyanomethyl-4-fluoro-2-nitroaniline (148) was cyclised to 2-cyano-5- 
fluorobenzimidazole 3-oxide (149) by heating under reflux in ethanol with potassium 
carbonate. Subsequent reaction of (149) with 3-bromopropan-l-ol (104) yielded the 
desired product (150) in good yield. Previous workers had found difficulty in such 
reactions using sodium ethoxide as the base. In their attempted O-alkylations it had been 
found that such strongly nucleophilic bases not only brought about deprotonation of the 
N-oxide but, also attacked the electrophilic centre of the nitrile to furnish imidate esters. 
The and ^^C nmr spectra of compounds (149) and (150) were both very complex due to 
the iH-l^F and I3(%_19p couplings.
l^HCHgCN 
NOa
(148)
KgCOj
EtOH
(149)
NH 
/>— CN 
1)1+
O"
(149) O
K2CQ3Br(CH2)30H
DMF
N
CN
N
(150)
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Two other benzimidazole N-oxides were available for O-alkylation. Both 2-cyano- 
5-methyl- (151) and 2-cyano-5-methoxybenzimidazole 3-oxide (152) were reacted with
3-bromopropan-l-ol (104) to yield their corresponding hydroxypropoxy derivatives (153) 
and (154) respectively. Unfortunately, (154) could not be isolated in pure form to enable its 
testing against HSVl. Although peaks of a chemical shift corresponding to that of the 
desired product were evident, only a very small yield of the crude material was isolated. 
This was presumed to be due to the electron-donating nature of the methoxy group 
upsetting the electronic nature of the N-oxide and reducing the acidity of the N-1 proton.
HpC
NH 
I CN 
N+
(151) O"
K2CO3
Br(CH2)30H
DMF
I 7—CN
H3CO
NHI y-cN
N+
(152) O'
K2CO3
Br(CH2)30H
DMF H3CO
^ C N
(154)
The antiviral testing of the above compound (153) and those previously mentioned 
in this chapter will be discussed in chapter 5. The activity of a number of a selected 
compounds will also be discussed regarding their activity against a more varied panel of
viruses.
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Chapter 4 
Analogues with additional functionality
4.1 Introduction
The myriad of antiviral agents discussed in chapter 1 illustrates that nucleoside 
analogues may have a host of sugais or acyclic moieties attached to the base, other than the 
natural sugars, ribose and 2-deoxyribose. Ara-C (12) and Ara-A (13) (chapter 1, p.5) have the 
base attached to an arabinose sugar. In AZT (17) the thymine is attached to a dideoxy sugar in 
which both 2 '- and 3'-hydroxyl groups are missing, the 3'-hydroxyl being replaced by azido; 
other such dideoxy nucleosides include ddC (15) and ddl (16) (chapter 1, p7). Ganciclovir 
(23) (chapter 1, p. 12) and a number of the SmithKline Beecham compounds (chapter 1, p i3) 
synthesised on the way to famvir (29) possess a novel dihydroxy side-chain in which C-2' of 
the "sugar" is missing; in acyclovir (21) (chapter 1, p l l )  both C-2' and C-3' (i.e. the entire 
bottom half of the sugar) have been removed.
In all of the alkylations of benzimidazole N-oxides discussed previously in the present 
work, the alkylating agent has either been ethyl iodide, 3-bromopropan-l-ol, or a hydroxyl- 
protected 3-bromopropan-l-ol. The use of 3-bromopropan-l-ol introduces an acyclic portion to 
the resultant nucleoside analogue which is equal in "length" to that of acyclovir (i.e. the 
terminal OH is separated from the heterocycle by a chain containing the same number of 
atoms), but it produces a compound with an N-O-C rather than an N-C-O linkage between the 
base and the "sugar".
In the synthesis of those benzimidazole nucleosides previously discussed, all the 
benzimidazole N-oxides were synthesised prior to the O-alkylation step which yielded (in most 
cases) the desired product. It was thought worthwhile at this stage, however, to consider how
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acyclovir, and ganciclovir and famvir with their more complex acyclic groups, were 
synthesised, and how such syntheses might be applicable, or adaptable, to the synthesis of 
N-alkoxybenzimidazoles with more complex alkoxy groups.
4.2 Synthesis of antiviral nucleoside analogues with more complex 
side-chains
In the initial repoits^^ about the activity of acyclovir (21), the synthesis was carried out 
via the N-alkylation of a suitably substituted purine (155) with the protected acyclic group
(156), followed by the relevant functional group transformations and deprotection steps from
(157) to the product, acyclovir (21). Through this general synthesis, other nucleoside 
analogues could also be produced. A subsequent unambiguous synthesis was reported by 
Kelley and Schaeffer^^^ in which 7-formamido-5-methylthio-[l,2,5]-oxadiazolo-[3,4-<7]- 
pyrimidine (158) is N-alkylated (at the eventual N-9 of the purine) with (156) prior to the 
formation of the imidazole ring of the final product (21): hence ring closure, deprotection of the 
side-chain, and formation of the correct functionality are carried out with the N(9) -  C(l') bond 
intact.
Cl
011
N
Nl-
(155)
CgH gCOgCHgCHgOCHgCI
(156)
CgHgCOg
Ni) NHn, MeOH HN r. ^
ii) HNOg, A -  A - m 
NHa/MeOH HgN N
O.
(21)
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NHCHO
(158)
CqH 5CO2CH 2CH2OCH 2CI 
(156)
HN
H2Î
O.
Et^ N
DMF NCHOCHqS
(159)
Zn, AcOH
HgN 
N N
(2 1 )
^ MeNHg, H2 O I  Tj \\
ii) NaNOa, AcOH U /
iii) NH3 , EtOH CH3S N N
C6H5CO2
(160)
9-[(l,3-Dihydroxy-2-propoxy)methyl]guanine, DHPG, or ganciclovir (23) may be 
synthesised by a procedure similar to the acyclovir (21) synthesis above. An analogue of the 
guanine base (161) is simply alkylated using the protected acyclic group (162) followed by 
simple deprotection steps to yield the desired product (23)34,
The phosphonate isosteres of both a c y c l o v i r  1(^ 3 and D H P G  ^  04 were also synthesised by 
the alkylation of suitable purines with protected alkylating agents.
The work of Harnden, Jarvest et a/.4l-46 at SmithKline Beecham's laboratories 
generally used both approaches to the final nucleoside analogue: both alkylation of the purine 
(164) with a protected acyclic moiety (165) and the alkylation of a functionalised pyrimidine 
(167) before closure of the imidazole ring (169). Where the final product possessed a 
carbocyclic side-chain (i.e. no "ribose" oxygen was present) (166), the alkylation was carried 
out on the preformed purine (164). In cases where the final product (171) contained an N-O-C 
linkage between the base and the "sugai*", a suitably functionalised pyrimidine (167) was 
alkylated before the closure of the imidazole ring. The latter nucleoside analogues are of
68
particular interest to the present study, as the benzimidazole nucleosides synthesised previously 
(chapters 2 and 3) contain an N-O-C linkage, and the more complex side-chains used in the 
syntheses of the commercial products may also be utilised in this work.
HNHN jP-TsOt^
sulfolane AcNHAcNH Ac
(161) BnO (163)
p O B n
— OCHgOAc
— OBn 
(162)
OBn
HN
HO
(23)
HO
NaH
DMFNH
(164)
(166)
(165)
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Cl
OHCNH N
Cl
NHCHO (i-Pr)gNEt^  
digiyme
Cl
/ o—/  0 -N H 2
(168)
A ^OHCNH N 
O
O
NHCHO
NH
O (169)
i) AcOCH(OEt)2
ii) NH3, MeOH
Cl
AcO
AcO
i) Pd/C, NH^+HCOg"
^  MeQH____
ii) H2NNH2/H2O, 
MeOH 
iii) AcOH
N
O (171)
OHCNH
N
A N'
O (170)
O
The benzimidazole nucleosides TCRB (38) and BDCRB (39) (chapter 3, p50) produced 
by Townsend et al. 53,54,96 were synthesised from suitably protected ribose sugars (175) and 
the desired benzimidazole (173) in a simple alkylation step followed by deprotection. Where an 
acyclic alkyl group was required (174), the heterocycle (173) was again directly coupled with 
the suitably protected alkyl moiety, as was the case for both acyclovir (21) and ganciclovir 
(23).
AcO
R-t—  I 7— X +
(173)
OAc
AcO AcO
(175)
CH3CN
AcO AcO
(177)
R-
N BnO—I
V - R ' .
NH ^
(173) BnO
NaH,
CHgCN 
BnO- 
X = leaving group
O'
(176)
BnO
70
Benzimidazole and benzotriazole 77-oxides (178) and (178a) had also been alkylated by 
Grochowksi and Paient-Kwastowa^^ with suitably protected sugars (179) to produce 
nucleosides (180 and 180a) with an N-O-C linkage between the base and the sugar. In contrast 
to the work of Harnden and Jarvest^ ^ ’^ 6, these alkylations were carried out on preformed 
benzimidazoles and benzotriazoles.a:>N 
OH
(178) Z=C-CN 
(178a) Z=N
AcOCH
+
AcO
AcO
AcO
(179)
NaOEt
CHgCN A c O C H g
AcO
(180) Z=C-CN 
(180a) Z=N
AcO
4.3 Synthesis of a more complex alkylating agent
It seems logical to assume that the production of a more complex alkylating agent like 
that used by Harnden et should pose no problem in the majority of cases, and in this
chapter approaches to more complex side-chains will be discussed. In order to produce a 
dihydroxy side-chain similar to those incorporated in ganciclovir (23) and famvir (29) the work
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of Hamden and Jarvest^^ was modified to produce the proposed synthetic route shown below. 
To facilitate the formation of an alkyl substituent of the correct "length", with the correct 
N-O-C linkage, the alkylating agent (185) was required to contain one carbon less than that 
used in the SmithKline Beecham synthesis; hence diethyl malonate (181) was reacted with 
ethyl chloroformate rather than ethyl chloroacetate.
O
C2H5O
C2H5O
(181)
HO
OHHO
t
X = leaving 
group
0 - \  \  P
Q—/  X ^  OH
(185) (184)
The acylation of diethyl malonate (181) was attempted under the conditions of Rathke 
and C o w a n  105. Two equivalents of base (triethylamine) were used, in order to prevent reaction 
of the enolate with the product; the latter, being a stronger acid than diethyl malonate, would be 
expected to reprotonate the malonate if only one equivalent of base were used, and thus prevent 
the desired reaction proceeding beyond 50% completion. According to Rathke and C o w a n  105, 
magnesium chloride was present in order to enhance the acidity of the malonate protons 
through complexation, so as to enable the use of a weaker base which would not react 
destructively with the chloroformate acylating agent. In any event, the reaction was 
unsuccessful, producing only unchanged diethyl malonate (181) and a high-melting yellow 
solid of as yet unknown constitution.
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C2 H5 O CICO^Et EtqN
/  MQCllf \  O  M O
C 2 H 5 O - 4  MeCN ^ 2^ 5°
(181) °  (182)
OC2H5
The failure of the above reaction was deemed unimportant, as a second route to the 
required protected diol had been devised, beginning from the well-documented Meldmm's acid 
(2,2-dimethyl-l,3-dioxane-4,6-dione, or isopropylidene malonate) (186). The route contained 
one step less than the SmithKline Beecham-based route^2 and appeared simple to carry out. 
Acylation of Meldmm's acid by ethyl chloroformate, followed by reduction to the protected 
triol (184) and bromination, would yield the desired alkylating agent (185). This chemistry had 
also been previously reported elsewherel®^.
(186) O
OH
L
OHOEt
(187) O (184) (185)
i) acylation, ii) reduction, iii) X = leaving group
Once again, the reaction with ethyl chloroformate was not as straightforward as 
expected. Under the conditions e m p l o y e d u s i n g  pyridine as the base, an unexpected 
product containing aromatic protons in the iH nmr spectmm was isolated. This product (188) 
was presumed to be an adduct formed between one equivalent each of the pyridine, Meldmm's 
acid and ethyl chloroformate. The mechanism proposed for the formation of the isolated 
product is shown below; a search of the literature revealed that the product was in fact a known 
compoundl® .^
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c il
o Lcr
OEt
G (188)
o x ;Tbase
O OEt
OEt
O
The reaction between ethyl chloroformate and Meldmm's acid (186) was repeated using 
triethy lamine as the base [in order to prevent the formation of complex adducts such as (185)], 
but no reaction apparently occurred.
(186) O
CICOgEt
EtgN
DCM
(187) O
The previous two proposed synthetic routes having "fallen at the first hurdle", a third 
approach was tried. A complete synthesis of 2-hydroxymethylpropane-1,3-diol had been 
found^09^ and could be utilised with modification required only for the final step. The 
synthesis involved the reaction of diethyl malonate (181) with formaldehyde and protection of
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the diol (189) formed as the dioxane derivative (190). Decarbethoxylation followed by 
reduction then yields the required protected triol (192), with a suitable leaving group (193) 
reaction with a benzimidazole iV-oxide may be possible.
HO OCpH
HO
,0O
OH
(192)X = leaving group
(193)
Diethyl malonate (181) was reacted with an aqueous solution of formaldehyde in the 
presence of potassium hydrogen carbonate^ the desired product was isolated but proved 
very difficult to purify. The low-melting solid was eventually recrystallised by stirring the 
crude product at very low pressure, to allow the evaporation of trapped residues of solvent, 
starting materials and water. Thereafter, in all repetitions of this step seeding with pure ciystals 
was employed to produce the desired solid product.
HgCO, HÿO
OCjHs HO-
(181)
0>- OC2H5
-  OC2H5
0 (189)
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Protection of the diol (189) was undertaken using isobutyraldéhyde with a catalytic 
amount of p-toluenesulphonic acid. Reaction in the initial solvent, petroleum (bp 40-60°C)l^l, 
yielded only a very small amount of the product; however, the use of toluene as solvent 
delivered the product in a much more respectable yield.
O O
H o - ^  . O - ^  OC,H,
H O ^ ^ O C gH g '  O -^ ^ O C gH s
O (189) O (190)
The diester (190) then underwent decarbethoxylation according to the method of 
Krapcho er to yield a mixture of diastereomeric monoesters. Sodium chloride is
required to promote the decarbethoxylation. The and nmr spectra both clearly show the 
mixture of diastereomers, but the proportion of each cannot be determined from the integration, 
since the resolution is not good enough. The isopropyl group is expected always to assume the 
more stable equatorial position, and hence both axial and equatorial ethoxycarbonyl groups will 
be evident. Presumably the more thermodynamically stable stereoisomer will be the trans 
isomer, in which one conformation will have both the isopropyl and ethoxycarbonyl groups in 
equatorial positions.
OCoHg H2O 0 - \  O
DMSÇ
OCoHg '  O—/  OC2H5
(190) (191)
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The mixture of cis~ and trans- 5-ethoxycarbonyl-2-isopropyl-l,3-dioxanes was reduced 
to the corresponding mixture of cis- and trans- 5-hydroxymethyl-2-isopropyl-1,3-dioxanes 
using lithium aluminium hydride in TH pm . The product was purified by distillation: a second 
distillation was required to remove all traces of the starting material.
\  O—\ O \  oV_y uAiH/  \  /  \  THF/  O - ^  OC2H5  ^ OH
(191) (192)
The final stage of the synthesis was the conversion of the hydroxyl of (192) to a 
suitable leaving group. It was thought that the most simple method to provide a good leaving 
group was tosylation. This process would introduce a labile tosyl group for the reaction of 
(193) with a benzimidazole iV-oxide.
/  OH ^ ^ /  O—/  X
(192) (193)
The reaction of (192) with tosyl chloride did not succeed under a variety of conditions, 
even after the recrystallisation of tosyl chloride to remove traces of p-toluenesulphonic acid. 
The addition of 4-dimethylaminopyridine (DMA?) did nothing to promote the reaction^ In 
each case the nmr showed a small trace of the desired product but tosyl chloride continued 
to precipitate out of the isolated oily material; it was proposed that the tosyl chloride had either
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dissolved in the starting material (192) and was crystallising out of solution or that the reaction 
had succeeded but was reversible.
4.4 Alkylation of functionalised benzotriazole A-oxides
Benzotriazole A-oxides or 1-hydroxybenzotriazoles have long been used in the 
synthesis of peptides in order to prevent the racémisation at stereogenic centres during peptide 
c o u p l i n g !  14, Benzotriazole A-oxides have a very similar structure to benzimidazole A-oxides 
and may also be similarly functionalised on the benzene ring [like benzimidazole A-oxides, 
benzotriazole A-oxides (194) are tautomeric with 1-hydroxybenzotriazoles (195)]. The reaction 
of benzotriazoles with acyclic alkylating agents had been previously investigated! and 
benzotriazole A-oxides have also been alkylated on the oxygen, but in this case with protected 
s u g a r s ^ 9  The resultant compounds would presumably possess similar functionality to the 
previously synthesised benzimidazole nucleosides but bear different functionality at the
2-position; a nitrogen atom would replace the carbon or functionalised carbon. This would 
prove very interesting in an antiviral assay as Townsend et al.^^ had deemed a chlorine or 
bromine a necessity at C-2 for the maintenance of the activity and absence of toxicity.
(194 O
R-
(195) OH
N
In the first instance commercially available 1-hydroxybenzotriazole (196) was reacted 
with 3-bromopropan-1 -ol (104) in DMF using potassium carbonate as the base. The reaction 
yielded the desired product (197) which was isolated and purified by distillation. On standing
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in the atmosphere, the clear oily product darkened in colour but the nmr showed no change 
to have occurred in the product and further distillation at reduced pressure removed the 
discolouration.
œ
(196) OH
KgCO^
HO(CH2)3Br
DMF
HO
N
N
N
O
(197)
As the synthesis of (197) had proved so simple it was decided to synthesise the
5.6-dichlorobenzotriazole A-oxide to enable a direct comparison of the effects at the 2-position 
upon 5,6-dichloro-substituted nucleoside analogues [cf. (136) and (137), chapter 3, p56].
Substituted 1-hydroxybenzotriazoles may be synthesised via the heating of a suitably 
substituted o-halogenonitrobenzene with hydrazine hydrate in ethanol under reflux! 
Nucleophilic substitution of the halogen occurs, followed by spontaneous cyclisation to the 
benzotriazole A-oxide. This involves attack of the lone pair of the second nitrogen at the 
electrophilic centre of the o-nitro group.
1,2,4-Trichlorobenzene (198) was nitrated with fuming nitric acid at room temperature 
to yield the desired l,2,4-trichloro-5-nitrobenzene9^’!!^. The trichloronitrobenzene (128) was 
then heated under reflux in ethanol with hydrazine hydrate to yield directly
5.6-dichlorobenzotriazole 1-oxide (199)ü^.
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Cl
Fuming
Cl
Cl
NO2 Cl EtOH,
H2NNH2.H2O
(128)
%N
OH
(199)
The benzotriazole iV-oxide (199) could then be alkylated in the normal manner with 
3-bromopropan-l-ol (104). The desired product (200) was isolated in good yield.
Cl
Cl
%N
OH
(199)
HO(CH2)3Br
DMF HO-V - i  (2 0 0 )
Several attempts were made to synthesis 4,5,6,7-tetrachlorobenzotriazole 1-oxide (202) 
from pentachloronitrobenzene (201). The solvent required, according to the literature 
method was toluene in order to maintain the lipophilic pentachloronitrobenzene in solution, 
but in each case the desired product was not isolated.
Cl
Cl NO.
Cl
Cl
H9 NNH9 H9 O
TOLUENEX
(201 )
Cl
Cl
Cl
OH
(202)
The compounds (197) and (200) were submitted for antiviral testing (chapter 5).
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4.5 Attempts to synthesise 1-hydroxybenzimidazole 3-oxides.
It was mentioned in chapter 1 that the iV-oxides of several purines possessed biological 
activity. It was postulated that the synthesis of 1-hydroxybenzimidazole 3-oxides (203), like 
benzimidazole 3-oxides, could be alkylated on one of the oxygen atoms to furnish a nucleoside 
analogue (204) with an iV-oxide at one nitrogen and an N-O-C linkage to the acyclic side chain 
at the other. Such compounds would have points of similarity with the purine //-oxides 
mentioned above (chapter 1, p20) and also with other nucleoside analogues.
Q-I
(203) OH
R'
HO
0 “
N+
^ — R 
N
(204)
O
1-Hydroxybenzimidazole 3-oxides (205) may also be used for the introduction of 
substitution at C-2 (208), dictated as a necessity for activity by the results of Townsend et al.^^ 
(see below).
R i .
O'
(205) OH
PQQI3 R‘
( ^ O C I ;
(206) OH
01
R‘
HO
1 -
(208)
O
R'
N
n"
(207) OH
Cl
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1-Hydroxybenziimdazole 3-oxides may be synthesised from benzofurazan //-oxides by 
reaction with a variety of carbanions. Such syntheses also yield quinoxaline-di-A^-oxidesll^; 
the product furnished depends upon the carbanion used. It was reported! that the reaction of 
benzofurazan AT-oxide with nitromethane would furnish 1-hydroxybenzimidazole 3-oxide, 
unsubstituted on the benzene ring.
In the first instance benzofurazan //-oxide (209) was heated under reflux in chloroform 
with triethylamine and nitromethane using the conditions of Meth-Cohn et but no
evidence of the desired product (210) was found. The reaction was repeated after 
recrystallisation of the benzofurazan AAoxide (209) and the drying of both the nitromethane and 
chloroform. This time the product was identified spectroscopically through nmi' analysis of 
the crude reaction mixture, but the desired product could not be isolated in a usable amount.
%
(209) (210) OH
i) CH3NO2, EtgN, CHCI3, ii) CH3NO2, EtOH, NH3
The above reaction was then attempted using different conditions!^!), ammonia 
dissolved in ethanol as the base for the creation of the carbanion from nitromethane. Again the 
reaction was not a success, returning only the unreacted starting material.
In parallel with the above work, the synthesis of 5,6-dichlorobenzofurazan //-oxide 
was attempted to enable the eventual synthesis of 1-hydroxy-2,5,6-trichlorobenzimidazole
3-oxide. 3,4-Dichloroacetanilide (212) was synthesised from 3,4-dichloroaniline (211) by 
reaction with acetic anhydride!21. The acetanilide (212) was nitrated under the conditions of
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for the synthesis of the 5,6-dichlorobenzofurazan A -^oxide. 4,5-Dichloro-2-nitroaniline (214) 
was obtained from the o-nitroacetanilide (213) by reflux in acid.
NHAcNH
(212 )
(211)
AcOH
H2SO4
HNO3
NH NHAc
NO- NO.
(213)
(214)
As attempts to synthesise the 1-hydroxybenzimidazole 3-oxide had failed, the synthesis 
of 5,6-dichlorobenzofurazan 3-oxide was pursued no further.
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Chapter 5 
Antiviral assays
5.1 Introduction
The activities of acyclovir (21), ganciclovir (23), famvir (29) and its analogues, and the 
benzimidazole nucleosides (38 and 39) produced by Townsend et a l . against a variety of viruses 
have already been covered in chapter 1. In the following three chapters, the syntheses of various 
nucleoside analogues have been described. The nucleoside analogues produced possess 
functionality similar to that of the commercial products and of those others of proven antiviral 
activity. In this chapter the testing of some of these new compounds against herpes simplex virus 
1 (HSVl) will be described. An outline of the procedure is described first, and the results then 
discussed.
A number of the iV-alkoxy-benzimidazoles and -benzotriazoles synthesised by the author, 
and some benzimidazole A-oxides arising from previous work in the group, have also been 
submitted to the Wellcome Research Laboratories (now part of Glaxo Wellcome) for testing 
against a panel of viruses. The results of these tests are given later in this chapter.
5.2 The basic assay
(A more detailed account of the experimental methods and the materials used is given in 
the experimental section of the thesis)
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Vero cells were grown to a confluent monolayer in a 96-well microtitre plate over 48
hours.
The virus stock solution was diluted 1 in 100 000 with Glasgow-modified Eagle's 
medium and 10% calf serum (G-MEM/10% CS), and the solutions of the compounds for testing 
were also diluted to a maximum of ca. 200 |iM with cell medium (G-MEM).
In a 96-well microtitre plate, 150 pi of the HSVl-infected cell medium was added to each 
well. To the top well of each column, a further 150 pi of the compound in cell medium at 200 
pM was added, and two-fold serial dilutions made down the column. This was repeated for each 
compound (one compound per column). One column was tested with DMSG alone, at the same 
concentration used in the testing solutions, as a control.
2-fold
serial
dilutions
one compound per column 
A B O D E  F G H  I J K Loooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooo
 V-------
HSVl infected
 V------
uninfected
J
200^
100
50
25
12.5
6.25
3
conc.
pM
toxicity 
activity 
cpe shown
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In half of the assays, the plate was only infected with HSVl in columns A-F. Columns 
G-L being left uninfected as a test for toxicity of the benzimidazole derivatives. In the other 
cases, two plates were set up; one infected with the vhiis and the other only containing the testing 
compounds, again as a toxicity test.
The contents of each 96-well microtitre plate were then transferred to the plates containing 
the cells after the removal of the old cell medium. 100 jjtl of solution was placed in each well. The 
cells were then incubated at 37°C for up to 72 hours, with checking every 8-12 hours.
After analysis of the cells under the microscope, they were fixed with 2 % formalin and 
stained with crystal violet.
5.3 Assay 1
In assay 1 the general procedures previously outlined were followed except that the 
96-well microtitre plate used had columns A-F infected with HSV1 and columns G-L were kept 
uninfected.
The compounds tested were as follows (continued overleaf):
OoN
(89a)
OoN
OoN
HO
1 ^ 0
(107)
^  GO2M6
(89b)
8 6
%N
HO
■ ^ o
(197)
%Cl
HO
O
(200 )
2 0 0  107 89b  2 0 0  107  89b
197 89a 197 89a
A B O D E  F G H  I J K  L
F and L 
contain only 
DMSO
2-fold
serial
dilutions
1
2
3
4
5
6
7
8
oooo»ooo#o#ooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooo
 Y--------
HSVl infected
Y
uninfected
J
200^
100
50
25
12 .5
6 .2 5
3
1.5_y
conc.
|xM
toxicity 
activity 
(2 ^  cpe shown
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In this assay the cells were incubated for 48 hours post-infection before fixing and 
staining.
 ^ In all but one case, the monolayer of cells showed considerable viral cpe at all
\ concentrations of compound. In the uninfected monolayers, there was only one case of toxicity.
Compound (107), however, had intact monolayers at up to ca, 25-6 jxM concentrations. 
In the uninfected cells, however, at concentrations of ca. 200 p-M (the highest concentration of 
compound tested), there was evidence of toxicity.
In the infected monolayer of cells containing compound (89b) at 200 pM concentration 
there was slightly less fusion due to the cpe of the vims, but again in the uninfected cells there 
was evidence of toxicity at 200 pM.
5.4 Assay 2
Assay 2 was, strictly speaking, a repeat of assay 1. The microtitre plates were set up as 
for assay 1, but in triplicate using the same compounds. A repeat was necessaiy to ascertain if 
the test was reproducible and if a plausible activity was due to the compound being tested and not 
to accidental contamination. The plates were fixed and stained at three different periods post 
infection, this was to establish if the compounds were slowing the replication of the vims or 
stopping replication altogether.
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5.4 Asëay 2
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The monolayers of cells in the first microtitre plate were fixed and stained at 32 hours 
post infection and the other two plates at 56 and 80 hours. In each case the activity and toxicity 
results were very similar to those of assay 1. Only compound (107) showed any activity at 32 
hours post-infection; the activity in this assay was at a lowest concentration of 25 pM. In 
conjunction with this, evidence of toxicity was displayed at ca. 200 pM in the uninfected 
monolayer. As time progressed, the concentration at which activity was displayed became 
higher, being between 25 and 50 pM with 56 hours post infection, and at much higher 
concentrations at 80 hours post infection. In contrast, as time progressed, the toxic effects were 
observed at lower concentrations, 100-50 pM at 80 hours post infection. Obviously the virus
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was not prevented from replicating, and the compounds tested in this case were merely slowing 
down the progress of the virus. The slowing of the viral cycle was probably due to the 
benzimidazole nucleosides having a toxic effect on the cells. The virus, being only a parasitic 
mixture of proteins and fragments of nucleic acids requires a healthy cell with which to interact 
and replicate. The cell machinery which is 'hijacked' is required to be in perfect working order. 
Where a cell is exhibiting evidence of toxicity (e.g. due to the effects of a foreign compound) its 
biochemical machinery is not functioning correctly, and so the virus cannot replicate. Hence the 
virus cannot display its normal cpe in infected cells, and as a result an intact monolayer is seen. 
In the absence of virally uninfected cells which manifest this toxicity in a number of ways, the 
intact monolayer may be mistakenly interpreted as representing antiviral activity in infected cells.
5.5 Assay 3
In this assay two microtitre plates were used, one was infected with HSV1 and the other 
left uninfected. Compound (107) was included in this assay as a marker for the levels of 
concentration at which viral progress was slowed over time and also at which level toxicity was 
detected. The compounds tested were as follows:
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THPO
j Q r V c o , E t
HO-
' ^  O 
(111)
I y-COaEt
AcNH AcNH 
HO o
(124)
X V c N
HO—I
(153)
IXX»
HO—I I HO—I
L ^ o  l ^ ^ o
(137) (136)
C h ; V o o , e ,
1- ,
(147)
Of the compounds tested in this assay and fixed/stained after 48 hours, only one further 
compound seemed to exhibit any activity, but this was accompanied by toxicity at high 
concentration. Compound (106) the THP-protected ether of compound (107), showed activity at 
slightly lower concentration (25 p.M) than compound (107) itself (50 jiM). The uninfected plate 
showed that this compound also displayed toxicity at this low concentration. Compound (111),
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an analogue of (107) with ester functionality at C-2, did not display activity- cpe was shown at 
all concentrations- but it did show evidence of toxicity at ca. l(X)|iM.
5.5 Assay 3
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Toxicity was also displayed with compounds (139) and (136) at ca. 200pM, but in the 
corresponding infected monolayers viral cpe was displayed at all concentrations.
After only 24 hours of incubation, all of the compounds displayed marked cpe of the 
virus at lower concentrations. The higher concentrations of compound showed no cpe but this 
was presumably due to toxicity of a lesser degree.
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5.6 Assay 4
This assay involved an almost identical repeat of assay 3, with two plates being set up: 
one uninfected and the other infected. In the spare colunm, acyclovir (supplied by ICN 
Pharaiaceuticals Ltd.) was placed at a maximum dilution of ca. 200 |iM in fresh DMSO.
HN
Hz
HO
(2 1 )
The acyclovir was used as a positive control in the assay, to establish if the concentration 
of virus being used was controllable with a known, highly effective and commercially available 
therapy. Many variables are present in this type of assay, and the use of a known product as a 
control allows a more valid comparison of the activity and toxicity of the compounds tested with 
other, known compounds. A repeat of assay 3 was also required in any case to confirm the 
reproducibility of the results.
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5.6 Assay 4
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The results obtained in this assay proved to be almost identical to those of assay 3. 
Acyclovir proved to be active at concentrations as low as 12.5 jxM with no toxicity displayed at 
any level.
The tests carried out on these newly synthesised benzimidazole nucleoside analogues 
have shown them to possess an activity against HSV1 which is linked closely to the toxic effects 
which these compounds exert upon the uninfected cells. In the tests carried out in parallel with 
acyclovir, the activity of the market leader was shown to be excellent, with no trace of toxicity.
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Table 5.1 Activities of benzimidazole nucleosides against HSVl
compound activity pM toxicity
137 -  200
136 -  200
106 25 25
111 -  100
107 -  100
5.7 Activity against other viruses
Several benzimidazole iV-oxides (some arising from the present work and others from 
previous investigations), and some benzimidazole- and benzotriazole-based nucleoside analogues 
arising in the early stages of this project, were submitted for testing against a panel of vimses by 
staff of the Wellcome Research Laboratories. The compounds were tested against the following 
viruses/(cell lines): HSV2 (vero), HCMV (MRC5), HIV-1 (HeLa), and papilloma; and they were 
also tested for toxicity.
The nucleoside analogues [(197), (200), (107), (136) and (111)] and V-oxides (see 
below) tested were as follows:
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(216) O
O
(215)
H,C
(217)
NH
' k^ ° '
I
O '
H X
(218)
NH
1 ^ O C H a
I
O '
H X
(219)
NHI OCH3
I
O '
Just as for the compounds tested 'in-house' against HSVl, these compounds seemed in 
the majority of cases to possess no activity. Where activity against one of the panel of viruses 
was found, it was closely accompanied by toxicity in an uninfected cell-line.
Compound (200), which showed neither activity nor toxicity against HSVl, possessed 
activity against HCMV between 100 and 10 |xM, but displayed toxicity at 456 |iM. Compound 
(107) showed activity against HSV2, but as in the case of HSVl this was due to toxicity at the 
very low concentration of 116 jxM.
The only other compound to display any activity was the V-oxide (219), against HCMV 
and HIV at concentrations between 100 and 10 |LiM. Again, activity was not well separated from 
cytotoxicity, 471 jiM being the level at which this was displayed.
Several compounds, although not displaying activity at any of the concentrations tested, 
showed toxicity. Compounds (215), (136) and (111) showed toxicity at 351, 227 and 443 jiM 
respectively.
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Table 5.2 Activity of selected compounds against a panel of viruses
cpd. no. HSV2 HCMV HIV PAPILLOMA tox.
197 >100 >100 >100 >100 >500
200 >100 >10<100 >100 <100 456
216 >100 >100 >100 >100 >500
217 >100 >100 >100 >100 >500
218 >100 >100 >100 >100 >500
219 >100 > 10<100 >10<100 >100 471
215 >100 >100 >100 <100 351
136 >100 >100 >100 <100 227
107 >10<100 >100 >100 >100 116
111 >100 >100 >100 >100 443
(results given as CC50 in pM, 96 hours incubation)
5.8 Conclusion
The compounds which have been tested against both HSV 1 and the Wellcome panel of 
viruses (HSV2, HCMV, HIV and papilloma) have shown that any activity displayed against 
these viruses is very closely linked to toxicity against uninfected cells. Very little can be said at 
this early stage about the relationship between the substituents in these nucleoside analogues and 
their activity or toxicity. Many more analogues need to be synthesised in order to ascertain if 
substituents may be added to, or omitted from, the molecule in order to retain the activity while 
removing the toxicity. The two processes may of course be inseparable: it has been shown, 
however, that such nucleoside analogues do possess a valid and possibly exploitable biological 
activity which is open to further investigation.
Experimental
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Numbering diagrams:
NH
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Chapter 2 
Experimental
IR spectra were recorded on a Perkin Elmer 1710 Infrared Fourier Transform 
Spectrophotometer, and samples were run as thin films or Nujol mulls; nmr spectra were 
recorded at 200MHz on a Varian Gemini or as specified on a Bruker AM300 at 300MHz, and 
nmr spectra at 50MHz or 75MHz, respectively, for solutions in d^-DMSO relative to TMS 
(5jj = 0, 5jj = 0) and J are given in Hz. Melting points were carried out on a Electrothermal 
9100 digital melting point apparatus, and mass spectra were generated under electron impact on 
an A.E.I. MS-50 spectrometer unless otherwise stated. Column Chromatography was carried 
using Merck silica gel 60 (230-400 mesh), and tic using 0.25mm layers of silica gel on glass 
sheets. Solvents were distilled from calcium hydride when required anhydrous. Petroleum 
used was the fraction boiling from 40-60 °C. The concentrated mineral acids used were (sp. 
gr.): hydrochloric, 1.18, sulphuric, 1.83, nitric, 1.5. The concentrated ammonia solution used 
was sp. gr. 0 .88.
In all compounds containing alkoxy or hydroxyalkoxy groups, the vicinal coupling 
constants were approximately 7 Hz.
2.4-Dinitrophenylglycine ethyl ester 186al
1 -Chloro-2,4-dinitrobenzene (85) (50.0g), glycine ethyl ester hydrochloride (34.5g) 
and sodium bicarbonate (41.6g) were heated under reflux for 2h in ethanol (450ml), the 
reaction mixture then being allowed to cool and a precipitate forming. The reaction mixture was 
then poured on to ice and water (500 ml), the precipitate isolated by filtration, washed with 
ethanol and finally recrystallised from acetic acid: yield 51.4g (78%), m.p.l42-143“C (lit. 1^ 3 
144“C). Vmax.3340 (N-H), 1750cm-l (C=0), Sh 1.25 (3H, t, CH2CH3), 4.20 (2H, q,
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H-3), 9.05 (IH, t, NH-CH2), 15,6= 10.0 , 13,5=2 .5 , Jnh-CH2=5A 8c 14.0 (CH2ÇH3), 44.6 
(NH-CH2), 61.2 (ÇH2CH3), 115.8 (C-3), 123.2 (C-6), 129.8 (C-5), 130.1 (C-1), 135.6 
(C-2), 147.8 (C-4), 168.9 (C=0).
2.4-Dinitrophenylglycine methyl ester (86bl
l-Chloro-2,4-dinitrobenzene (85) (20.4g), glycine methyl ester hydrochloride (12.6g) 
and sodium bicarbonate (16.8g) were heated under reflux for 3h in methanol (500 ml) then 
allowed to cool, a precipitate forming. The above work up procedure was then followed; yield 
17.4g (68%), m.p.ll8-119°C (lit.124 114.1 i 5”c), Vmax.3348 (N-H), 1758 (C=0), 1524 and 
1337cm-1 (NO2), 8 h  3.85 (3H, s, CH3), 4.20 (2H, d , CH2), 6.80 (IH, d, H-6), 8.30 (IH, 
d d , H-5), 8.95 (IH, bs, NH), 9.15 (IH, d , H-3), J 5 , 6 = 1 0 . 0 ,  J3,5=2 .5 , J c H 2 - N H = 5 . 0 ,  5c 
44.5 (NH-CH2), 52.3 (CH3), 115.8 (C-3), 123.2 (C-6), 129.8 (C-5), 130.2 (C-1), 135.7 
(C-2), 147.9 (C-4), 169.4 (C=0).
Attempted cyclisation of (86a^  to ethyl 5-nitrobenzimidazole-2-carboxvlate 3-oxide
(87a)
Previous to the experimental procedure illustrated below, the cyclisation of
2,4-dinitrophenyIglycine ethyl ester (86a) was attempted under a variety of conditions based 
upon the literature p r o c e d u r e ^ 3  whereby the base used was piperidine. In each case the yield 
was very low and changes to the base, reaction time and conditions are tabulated below. The 
major product isolated fiom each reaction was shown to be unchanged starting material.
Reaction time/process change Base Yield (%)
Ih reflux piperidine 19
2h reflux " 31
3h refux " 15
base redistilled " 6
base dried/2h reflux " 30
different base, (see below) K2CO3 69
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Ethyl 5-nilTobenzimidazole-2-carboxylate 3-oxide (87al
2.4-Dinitrophenylglycine ethyl ester (86a) (49.Ig) and potassium carbonate (25.2g) 
were heated under reflux in ethanol (500ml) for 5h, then allowed to cool. The reaction mixture 
was partitioned between dichloromethane and water, the water layer being kept and carefully 
acidified with concentrated hydrochloric acid to yield a yellow precipitate with evolution of 
CO2 gas. The precipitate was reciystallised from ethanol: yield 31.5g (69%), m.p.l92-194“C 
(lit. 125 209-210“C), Vmax.1729 (C=0), 1529, 1505 and 1348cm-l (NO2), ôy 1.40 (3H, t, 
CH2ÇH3), 4.50 (2H, q, CH2CH3), 7.95 (IH, d, H-7), 8.15 (IH, dd, H-6), 8.40 (IH, d, 
H-4), Je,7=9 .0 , J4,6=3.0, 6c  14.2 (CH2ÇH3), 62.3 (ÇH2CH3), 107.5 (C-4), 118.4 (C-7),
122.1 (C-6), 132.1 (C-3a), 140.8 (C-2), 142.1 (C-5), 144.6 (C-7a), 157.7 (C=0).
Methyl 5-nitrobenzimidazole-2-carboxvlate 3-oxide f87b)
2.4-Dinitrophenylglycine methyl ester (86b) (17.4g) and potassium carbonate (9.5g) 
were heated under reflux in methanol (500 ml) for 2h then allowed to cool. The reaction mixture 
was then worked up as for (87a), above: yield 4.6g (29%), m.p.l98-199°C (lit. 2^5 205- 
206T), Vmax.1733 (C=0), 1525, 1501 and 1354cm-l (-NO2), 65  4.00 (3H, s, CH3), 8.00 
(IH, d, H-7), 8.20 (IH, dd, H-6), 8.40 (IH, d, H-4), Je,7=9 .0 , J4,6=3.0, 6c  53.3 (CH3),
107.4 (C-4), 118.6 (C-7), 122.3 (C-6), 132.2 (C-3a), 140.8 (C-2), 141.9 (C-5), 144.9 
(C-7a), 158.0 (C=0), mJz =237 (M+ ).
As mentioned in the results and discussion, the benzimidazole A-o?<;ide may be reached 
by a variety of routes: below, method A refers to hydrolysis/decarboxylation in concentrated 
hydrochloric acid and method B to hydrolysis/decarboxylation in sodium hydroxide.
5-Nitrobenzimidazole 3-oxide 1881
Method A (from ethyl 5-nitrobenzimidazole-2-carboxylate 3-oxide (87a))
Ethyl 5-nitrobenzimidazole-2-carboxylate 3-oxide (87a) (29.0g) was heated under 
reflux in concentrated hydrochloric acid (725ml) (25ml per l.Og reactant) for 1.5h then allowed 
to cool, a precipitate forming. The hydrochloride of (88) was collected by filtration and
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recrystallised from ethanol: m.p.236-242°C (lit73 ca. 240°C), 6^  7.95 (IH, d, H-7), 8.30 
(IH, dd, H-6), 8.60 (IH, d, H-4), 9.85 (IH, s, H-2), J6,7= 10.0 , 14,6=3 .0 , 6c  (300MHz)
107.4 (C-4), 118.4 (C-7), 119.2 (C-6), 129.7 (C-3a), 137.8 (C-5), 142.8 (C-2), 144.1 
(C-7a).The hydrochloride salt of (88) was then stirred in aqueous ammonia {d 0.88; 40ml per 
Ig of product) (600ml) for approximately 20 minutes and the solution then concentrated to 
precipitate a yellow solid: yield 11.8g (64%), m.p.276-278°C (lit.23 274-276"C),
1400, 1350, 1338 and 1318cm-l (NO2), ôy 7.60 (IH, d, H-7), 7.85-7.93 (2H, m, H-6 , 
H-4), 8.40 (IH, s, H-2), J6,7= 10.0 , ôc (300MHz) 106.2 (C-4), 116.0 (C-7), 119.7 (C-6),
131.0 (C-3a), 142.1 (C-5), 143.4 (C-7a), 144.4 (C-2).
Method A (from methyl 5-nitrobenzimidazole-2-carboxylate 3-oxide (87b))
Methyl 5-nitrobenzimidazole-2-carboxylate 3-oxide (87b) (3.5g) was reacted in 
concentrated hydrochloric acid following the above procedure including the reaction in 
ammonia solution: yield 2.2g (84%), m.p.267-268°C (lit.23 274-276"C) v^^^x.l^^O, 1400, 
1350, 1338 and 1318cm-l (NO2), Ôy 7.63 (IH, d, H-7), 7.86 (2H, m, H-6 , H-4), 8.43 (IH, 
s, H-2), J6,7=10.0 , J4,6=2.5, ÔC (300MHz) 106.4 (C-4), 115.8 (C-7), 119.8 (C-6), 131.2 
(C-3a), 141.8 (C-5), 143.4 (C-7a), 144.2 (C-2).
Method B (from ethyl 5-nitrobenzimidazole-2-carboxylate 3-oxide (87a))
Ethyl 5-nitrobenzimidazole-2-carboxylate 3-oxide (87a) (0.25g) was stined at 50 °C in 
sodium hydroxide (2M, 10ml) and water (10ml) for 4h. Acidification of the cooled reaction 
mixture yielded a yellow precipitate which was collected by filtration and washed with water. 
This was tentatively identified as the hydrochloride salt of the expected product: yield 0.2g 
(93%), m.p. 240-242°C (decomp.) (lit.23 ca. 240T), Vmax.1560, 1400, 1350, 1338 and 
1318cm-1 (N0 2 ),Ôh 7.85 (IH, d, H-7), 8.10 (IH, dd, H-6), 8.36 (IH, d, H-4), 8.78 (IH, s, 
H-2), J6,7=10.0 , 14,6=2 .5 , m/z =179 (M+ )
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Method B (from methyl 5-nitrobenzimidazole-2-carboxylate 3-oxide (87b))
Methyl 5-nitrobenzimidazole-2-carboxylate 3-oxide (87b) (0.5g) was dissolved in 
sodium hydroxide (2M, 15ml) and stirred at room temperature for 30 minutes. The precipitate 
formed was collected by filtration, dissolved in water and acidified with concentrated 
hydrochloric acid. The solid was collected and recrystallised from ethanol: yield 0.2g, 
m.p.216-217°C (decomp.) (lit.23 240“C), m/z =179 (M+*)> The nmr spectrum indicated 
that the product was probably a mixture of the AT-oxide and its hydrochloride; this reaction was 
not investigated further.
Attempted formation of l-ethoxy-6-nitrobenzimidazole (901
To a stirred solution of 5-nitrobenzimidazole 3-oxide (88) (0.5g) dissolved in ethanol 
(50ml), a solution containing 1 equivalent of sodium ethoxide in ethanol (25ml) was added, 
and stirring continued for a further Ih over which time a precipitate developed. Addition of 
extra ethanol (50ml) and ethyl iodide (0.44g) with continued stirring saw the precipitate persist. 
The precipitate was isolated by filtration and shown to be the sodium salt of the anion of (88),
Success was achieved in this reaction via the use of DMF as the solvent, but yields 
were still fairly low. Formation of the anion in the reaction medium was next carried out by the 
addition of the sodium ethoxide solution, removal of the ethanol solvent after stirring for Ih, 
dissolution of the residue in DMF and addition of the ethyl iodide. Improvement in the yield 
was finally realised by the addition of solid sodium ethoxide to a solution of the starting 
material (88) in DMF, whereupon the formation of the anion in solution gave rise to a deep red 
colour. Traces of starting material were still present in the final product; these were removed by 
washing the organic layers in the work-up with aqueous sodium hydroxide followed by 
washing with water.
The best methodology for the reaction is cited overleaf:
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1 -Ethoxv-6-nitrobenzimidazole (90)
To a stirred solution of 5-nitrobenzimidazole 3-oxide (88) (2.1g) in DMF (50ml) was 
added solid sodium ethoxide (0.8g), giving a red solution. Ethyl iodide (1.83g) was then 
added, and stirring was continued for 12h. The reaction mixture was then poured into water 
(100ml) and extracted three times with dichloromethane (3x50ml); the extracts were combined 
and washed with sodium hydroxide (O.IM, 50ml) followed by three washes with water 
(3x150ml) and drying over magnesium sulphate. Concentration of the organic layers yielded a 
yellow solid which was recrystallised from ethanol: yield 0.6g (23%), m.p.99-100°C. (Found:
C, 52.5; H, 4.3; N, 20.7. C9H9N3O3 requires C, 52.2; H, 4.35; N, 20.3%), V^ax.l^lO and 
1343cm-1 (NO2), ÔH (CDCI3) 1.40 (3H, t, CH2CH3), 4.50 (2H, q, CH2CH3), 7.90 (IH, d, 
H-4), 8.20 (IH, dd, H-5), 8.30 (IH, d, H-7), 8.45.(1H, s, H-2), J4 5= 10.0 , J5j = 2 .5 , ôc 
(CDCI3) (300MHz) 13.8 (CH2ÇH3), 76.6 (CH2CH3), 105.9 (C-7), 118.3 (C-5), 121.3 
(C-4), 129.4 (C-3a), 142.7 (C-2), 143.4 (C-7a), 144.4 (C-6), m/z =207 (M+ ).
2-Methoxy-5-nitrobenzimidazole ri031 from the attempted formation of l-ethoxy-6- 
nitrobenzimidazole (901
Sodium methoxide (0.20g) was added to a solution of 5-nitrobenzimidazole 3-oxide 
(88) (0.32g) in DMF (30ml), the solution becoming dark red in colour. Ethyl iodide (0.30g) 
was then added, stirring being maintained overnight. The reaction mixture was then poured 
into water (300ml) and extracted with dichloromethane (3x50ml); the organic extracts were 
combined, washed with water (150ml), dried over magnesium sulphate, filtered and 
concentrated to yield a yellow solid which was recrystallised from methanol: yield 0 .20g 
(47%), m.p.l86-187°C, ôy 4d5 (3H, s, CH3), 7.50 (IH, d, H-7), 8.0 (IH, dd, H-6), 8.15 
(IH, s, H-4), 14,5= 10.0 , 15,7=2 .5 .
No further spectroscopic data were gathered, the assignment being tentatively made on 
the evidence of the ^H nmr and the knowledge of the possible addition-élimination reaction. 
Further use of the product was not envisaged.
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Ethyl l-ethoxy-6-nitrobenzimidazole-2-carboxylate (89a)
Ethyl 5-nitrobenzimidazole-2-carboxylate 3-oxide (87a) (0.5g) was dissolved in DMF 
(10ml) and added with stirring to a solution of DMF (25ml) containing sodium ethoxide 
(0.16g). Ethyl iodide (0.35g) was then added and stirring maintained for 1.5h. The solvent 
was removed by evaporation, the yellow solid was washed with water and recrystallised from 
ethanol: yield 0.3g (57%), m.p.l21-122T. (Found: C, 51.8; H, 4.3; N, 14.9. C12H 13N3O5 
requires C, 51.6; H, 4.7; N, 15.05%), V^^^ \142 (C=0), 1560, 1519, 1501, 1349 and 
1319cm-l (NO2), ÔH (CDCI3) (300MHz), 1.53 and 1.58 (6H, 2t, 2CH2CH3), 4.58 and 4.63 
(2H, 2q, 2CH2CH3), 8.02 (IH, d, H-4), 8.20 (IH, dd, H-5), 8.60 (IH, d, H-7), 14,5= 11.0 , 
15,7=3 .0 , ÔC 13.7 (CH2CH3), 14.3 (CO2CH2ÇH3), 69.1 (CH2CH3), 76.9 (CO2ÇH2CH3),
107,1 (C-7), 119.4 (C-4), 122.9 (C-5), 131.3 (C-7a), 140.8 (C-2), 141.5 (C-6), 145.8 
(C-3a), 157.2 (C=0), m/z =279 (M+-).
Attempted svnthesis of methvl l-ethoxy-6-nitrobenzimidazoIe-2-carboxvIate (89bl
Methyl 5-nitrobenzimidazole-2-carboxylate 3-oxide (87b) (1.5g) was dissolved in DMF 
(50ml) and sodium ethoxide (0.4g) in DMF (30ml) added, the solution turning dark red. Ethyl 
iodide (0.9g) was then added, and the reaction left to stir overnight, after which time the daik 
red colour had returned to the initial pale yellow of the starting solution. After isolation and 
characterisation the product was shown to be a mixture of methyl l-ethoxy-6- 
nitrobenzimidazole-2-carboxylate and ethyl l-ethoxy-6-nitrobenzimidazole-2-carboxylate, 
exchange having occurred between the ester and the anion of the base.
Methvl l-ethoxy-6-nitrobenzimidazole-2-carboxylate 189bl
Methyl 5-nitrobenzimidazole-2-cai*boxylate 3-oxide (87b) (1.5g) was dissolved in DMF 
(50ml) before addition, with stirring of a solution of sodium methoxide (0.3g) in DMF (30ml). 
Ethyl iodide (0.94g) was then added, the reaction being left to stir overnight (ca. 12h), after 
which time the dark red colour of the anion in solution had returned to a pale yellow. The 
reaction mixture was poured into water (100ml) then extracted twice with dichloromethane 
(2x75ml). The organic extracts were combined and washed with water (150ml), dried over
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magnesium sulphate, filtered and concentrated in vacuo to a dark solid. This was recrystallised 
from methanol with charcoal to yield a white solid: yield 0.04g (3%), m.p.l25-129“C. (Found: 
C, 50.0; H, 4.15; N, 16.1. requires C, 49.8; H, 4.15; N, 15.85%). Vmax.1734
(C=0), 1515, 1502, 1349 and 1311cm-1 (NO2), ôy (CDCI3) 1.60 (3H, t, CH2CH3), 4.15 
.(3H, s, CH3), 4.65 (2H, q, CH2CH3), 7.95 (IH, d, H-4), 8.25 (IH, dd, H-5), 8.50 (IH, d, 
H-7), 14,5= 10.0 , 15,7=2 .5, ÔC (CDCI3) 13.7 (CH2ÇH3), 31.0 (CH2CH3), 53.6 (CO2ÇH3),
107.1 (C-7), 119.4 (C-4), 122.9 (C-5), 131.3 (C-7a), 140.8 (C-2), 141.2 (C-6), 145.9 
(C-3a), 157.6 (C=0).
As mentioned previously, method A refers to hydrolysis/decarboxylation in 
concentrated hydrochloric acid and method B to hydrolysis/decarboxylation in sodium 
hydroxide, as cited earlier.
l-Ethoxv-6-nitrobenzimidazole (901
Method A (from ethyl l-ethoxy-6-nitrobenzimidazole-2-carboxylate (89a))
Ethyl l-ethoxy-6-nitrobenzimidazole-2-carboxylate (89a) (0.3g) was heated under 
reflux in concentrated hydrochloric acid (10ml) for 1.5h. After cooling, concentrated ammonia 
was added with stirring before concentration in vacuo to yield a pale yellow solid: yield 0.3g, 
m.p. ca. 300°C (decomp.), Vj^ax.l^lOcm-l and 1343cm-^ (NO2), ôy  (CDCI3) 1.38 (3H, t, 
CH2CH3), 4.50 (2H, q, CH2CH3), 7.91 (IH, d, H-4), 8.16 (IH, dd, H-5), 8.54 (IH, d, H- 
7), 9.01 (IH, s, H-2), 14,5=10.0 , 15 7=2 .5 , m/z = 208 (M+1+-).
The very high melting point and downfield position of H-2 in the ^H nmr of this 
sample may indicate that the product isolated here is in fact the ammonium salt of the anion; but 
the success of method B (below) made fuither investigation of method A unnecessary.
Method B (from ethyl l-ethoxy-6-nitrobenzimidazole-2-carboxylate (89a))
Ethyl l-ethoxy-6-nitrobenzimidazole-2-carboxylate (89a) (l.Og) was dissolved in DMF 
(30ml), to give a pale yellow solution. Sodium hydroxide (2M, 40ml) was then added, the 
solution turning a deep red colour followed by immediate precipitation. The reaction was then
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heated to around 50° C and maintained at this temperature for 2h. On cooling, the precipitate 
reformed but disappeared when the reaction mixture was poured into water (300ml). 
Acidification with concentrated hydrochloric acid precipitated a product. The aqueous layer was 
further extracted with dichloromethane (50ml), the extracts being combined, washed with 
water (50ml), dried over magnesium sulphate, then filtered and concentrated to leave a yellow 
solid. The product was then recrystallised from ethanol: yield 0.6g (77%), m.p.l00-102°C; ôjj 
(CDCI3) 1.50 (3H, t, CH2CH3), 4.45 (2H, q, CH2CH3), 7.85 (IH, d, H-4), 8.20 (IH, dd, 
H-5), 8.30 (IH, d, H-7), 8.40 (IH, s, H-2), J4 g=10.0, J5j = 2 .5 , ôc (CDCI3) 13.9 
(CH2ÇH3), 76.6 (ÇH2CH3), 106.0 (C-7), 118.3 (C-4), 121.3 (C-5), 142.9 (C-2), 143.5 
(C-6), 144.3 (C-3a).
2-f 3-Bromopropoxyltetrahydropyran 11051 
Pyridinium p-toluenesulphonate (PPTS)
p-Toluenesulphonic acid (5.70g) was dissolved in an excess of pyridine (20ml) and 
stirred for approximately 20 minutes, the excess pyridine then being removed in vacuo. The 
white solid collected was recrystallised from acetone: yield 4.7g (56%), m.p. 119-120°C (lit.84 
120°C).
To a solution of 2,3-dihydropyran (9.2g) and 3-bromopropan-1 -ol (104) (lOg) in 
anhydrous dichloromethane (250ml), PPTS (1.8g) was added with stirring. Stirring was 
continued for 24h, the colour changing through light green to a very dark green. The solution 
was then diluted to approximately 750ml with ether, extracted once with half-saturated brine 
and finally concentrated to a brown oil in vacuo. The crude product was distilled to yield the 
pure product as a yellow oil: the oil darkened upon sitting in the atmosphere, but iH nmr 
showed no evidence of decomposition despite this colour change: yield 13.6g (56%), b.p.75°C 
/ 2 mmHg (lit.126 69°C / 1.2 mmHg), Bg (CDCI3) 1.35-1.84 (6H, m, H-2',H-3',H-4'), 2.05 
(2H, quin., CH2-CH2-CH2), 3.43 (2H, t, CHjBr), 3.49 (2H, t, THPO-CH2), 3.79 (2H, m, 
H-5'), 4.55 (IH, s, H-1), 8c  (CDCI3) 19.3 (C-3'), 25.3 (CH2-CH2-CH2). 30.4 (C-4'), 32.5 
(C-2'), 59.7 (CHzBr), 62.0 (THPO-CH2), 64.7 (C-5'), 98.6 (C-P), m/z =223 (M+ ).
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Attempted production of l-r3-(tetrahvdropyran-2-vloxv)propoxy1-6-nitrobenziimdazole
(1061
5-Nitrobenzimidazole 3-oxide (88) (0.5g) was dissolved in sodium ethoxide solution 
(2.5ml) [sodium (l.Og) dissolved in ethanol (30ml)] and ethanol (10ml), stirred for several 
minutes and concentrated in vacuo. The solid was dissolved in the minimum of DMF (10ml) 
and 2-(3-bromopropoxy)tetrahydropyran (105) (0.69g) added, stirring at room temperature 
being maintained for 24h. Attempts were made to purify the materials isolated from the reaction 
by distillation but on analysis these were found to be mainly the starting THP ether (105). A 
second attempt at the reaction looked a little more promising, but chromatography of the 
product mixture on a column of silica gel again yielded none of the desired product. Success 
was only achieved when the base used was changed to potassium carbonate.
l-[3-(Tetrahvdropyran-2-vloxvlpropoxyl-6-nitrobenzimidazole ( 1061
5-Nitrobenzimidazole 3-oxide (88) (1.3g) was dissolved in DMF (35ml) before the 
addition of potassium carbonate (1.3g). 2-(3-Bromopropoxy)tetrahydropyran (105) (2.0g) was 
then added, with stirring, at room temperature, and the stirring continued for 24h. The reaction 
mixture was poured into water (100ml), extracted with dichloromethane (3x50ml), the organic 
layers combined, washed with water and dried over magnesium sulphate. Concentration of the 
organic layers yielded a pale yellow solid. The product was purified on a column of silica and 
recrystallised from toluene: yield 0.55g (20%), m.p.68-70°C. (Found: C, 55.8; H, 6.0; N,
12.8. C15H 19N3O5 requires C, 56.1; H, 6.0; N, 13.1%), ôg 1.47-1.75 (6H, m, H-2', H-3', 
H-4’), 2.06 (2H, quin., CH2-CH2-CH2), 3.63 (2H, m, CH2-OTHP), 3.85 (2H, m, H-5'),
4.54 (2H, t, CH2-O-N), 4.64 (IH, d, H-1'), 7.89 (IH, d, H-4), 8,14 (IH, dd, H-5), 8.55 
(IH, d, H-7), 8.99 (IH, s, H-2), 14,5=8 .8 , 15,7=2 .2 , Ôq 18.4 (C-2'), 25.1 (C-4'), 28.1 
(C-3'), 30.4 (CH2-ÇH2-CH2), 61.7 (THPO-ÇH2), 62.9 (C-5'), 77.9 (N-O-ÇH2), 98.4 
(C-F), 106.1 (C-7), 117.8 (C-4), 120.9 (C-5), 129.5 (C-3a), 143.1 (C-6), 143.6 (C-2),
144.7 (C-7a).
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(C-F), 106.1 (C-7), 117.8 (C-4), 120.9 (C-5), 129.5 (C-3a), 143.1 (C-6), 143.6 (C-2),
144.7 (C-7a).
Attempted production of l-G-Hvdi’oxypropoxyV6-nitrobenzimidazole (107)
l-[3-(Tetrahydropyran-2-yloxy)propoxy]-6-nitrobenzimidazole (106) (0.25g) was 
dissolved in ethanol and PPTS (0.03g) added. The reaction mixture was then stirred at 55°C 
and monitored by tic. After 3.5h the starting material had all diminished and the solvent was 
evaporated off to yield a gum. Purification of the highly polar product was attempted on a 
column of silica, eluted with 10% methanol / 90% ethyl acetate, but the product remained at the 
baseline. Attempted purification by distillation under high vacuum only furnished carbonaceous 
material, the product being too thermally unstable.
3-Benzyloxy-1 -bromopropane f 1081 
from 3-bromopropan-l-ol (104)
3-Bromopropan-1 -ol (104) (5.0g), benzyl chloride (15.9g) and powdered potassium 
hydroxide (6.0g) were heated under reflux in a solution of toluene (65ml) and 1,4-dioxan 
(18ml) for 5h. The reaction mixture was allowed to cool before the addition of watef (200ml), 
followed by acetic acid, to pH 7. The organic layer was separated, washed with water and 
dried over magnesium sulphate, followed by concentration in vacuo at high temperature to 
distil off any excess benzyl chloride. The residue was dissolved in a mixture of ethanol (50ml) 
and hydrochloric acid (0.02M, 50ml) and heated under reflux for a further 2h then allowed to 
cool. The solution was concentrated to half volume, neutralised with sodium bicarbonate and 
extracted with dichloromethane (3x50ml). The extracts were combined, washed with water, 
dried over magnesium sulphate and finally concentrated to a yellow oil. The pure product was 
obtained by distillation on the Kugelrohr at low pressure; yield l.Og (12%), b.p. 135°C / 2 
mmHg, (lit.86 130“C / 5 mmHg), 8h 1.88 (2H, quin., CH2-CH2-CH2), 3.59 and 3.63 (4H, 
2t, CH2-O and CH2-Br), 4.54 (2H, s, PI1CH2), 7.35 (5H, s, Ph).
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from 3-be;izyloxypropan-l-ol (109)
A mixture of 3-benzyloxypropan-l-ol (109) (0.5g) and triphenylphosphine (0.79g) 
was cooled to ~5“C in an ice water bath with stirring. A-Bromosuccinimide (0.54g) was then 
added portionwise, while keeping the temperature constant. Stirring was continued for 24h. 
The reaction mixture was filtered, the filtrate then being washed several times with toluene, the 
toluene fractions were combined and washed with 5% sodium thiosulphate (25ml), sodium 
hydroxide (O.IM, 2 x 25ml) and brine (25ml), dried over MgSO^ and concentrated to an oily 
residue. The product was distilled at low pressure on the Kugelrohr: yield 0.40g (58%), b.p. 
100°C / 2 mmHg, (lit.86 130°C / 5 mmHg), Ôy 2.01 (2H, q, CH2-CH2-CH2), 3.52 and 3.59 
(4H, 2t,CH2-Br, O-CH2), 4.48 (2H, s, CIi2-Ph), 7.32 (5H, s, Ph).
l-(3-BenzvloxypropoxyV6-nitrobenzimidazole Ü 101
5-Nitrobenzimidazole 3-oxide (88) (0.5g) was dissolved in sodium ethoxide solution 
(2.5ml of a solution made from l.Og of sodium dissolved in 40ml of ethanol) and stirred for 30 
minutes before concentration and dissolution in DMF. 3-Benzyloxy-1-bromopropane (108) 
(0.4g) was then added with stirring and the stirring continued for 24h. The reaction mixture 
was poured into water (75ml) and extracted with dichloromethane (3x50ml). The organic 
layers were combined, washed with water (150ml), dried over magnesium sulphate and 
concentrated to a yellow oil. Attempts to purify the product, which was detected by ^H nmi', on 
a column of silica proved fruitless, as did the attempted distillation as (110) was too thermally 
unstable.
l-(3-HvdroxvpropoxvV6-nitrobenzimidazole ( 1071
5-Nitrobenzimidazole 3-oxide (88) (l.lg ) was dissolved in sodium ethoxide solution 
(5ml of a solution made from l.Og of sodium dissolved in 40ml of ethanol) and stined for a 
0.5h. The ethanol was evaporated off to yield a orange solid that was then dissolved in DMF 
(20ml). 3-Bromopropan-1 -ol (0.85g) was then added and the reaction mixture stirred at room 
temperature for 24h, the dark red colour changing to yellow over this period. The reaction 
mixture was poured into water (150ml) then extracted with dichloromethane (3x75ml). The
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dichloromethaneJiayers were combined, washed with sodium hydroxide solution (2M, 50ml), 
water, dried over magnesium sulphate and concentrated to a yellow solid which was 
reciystallised from propan-l-ol: yield 0.5g (40%), m.p.l20-12TC, (Found: C, 50.7; H, 4.5; 
N, 17.5. C10H 11N3O4 requires C, 50.6; H, 4.7; N, 17.7%), Ôh (300MHz) 2.10 (2H, quin. 
CH2-CH2-CH2), 3.81 (2H, q, CH2-OH), 4.54 (2H, t, CH2-O-N), 4.79 (IH, t, -OH), 7.99 
(IH, d, H-4), 8.18 (IH, dd, H-5), 8.55 (IH, d, H-7), 8.98 (IH, s, H-2); 14,59.6 , 15,7= 1.9 , 
J h o , C H 2 = 4 . 5 H z ,  Ô C  30.9 (CH2-ÇH2-CH2), 56.9 (HO-GH2), 77.9 (CH2-O-N), 106.0 (C-7),
117.6 (C-4), 120.8 (C-5), 129.1 (C-7a), 143.0 (C-6), 143.6 (C-3a), 144.4 (C-2), m/z =237 
(M+-).
Ethvl 1 -f3-hydi'oxvpropoxyl-6-niti'obenzimidazole-2-carboxylate (111)
Ethyl 5-nitrobenzimidazole-2-carboxylate 3-oxide (87a) (2.5g) was dissolved in the 
minimum of dried DMF (50ml) with the exclusion of moisture (silica gel) and the mixture 
stirred for 18h. Potassium carbonate (1.5g) and 3-bromopropan-l-ol (1.5g) were added. After 
addition of the base, the reaction mixture turned a deep red colour which disappeared in time. 
The reaction mixture was poured into water (200 ml), extracted with dichloromethane 
(3x75ml), and the organic layers combined and washed with water (2x200ml). The solution 
was then dried over magnesium sulphate and evaporated to a yellow solid which was 
recrystallised from toluene: yield 1.6g (52%), m.p.l29-13TC, (Found: C, 50.8; H, 4.75; N,
13.8. C13H 15N3O6 requires C, 50.5; H, 4.9; N, 13.6%), Ôh 1.40 (3H, t, CH2CH3), 2.03 
(2H, quin., CH2-CH2-CH2), 3.69 (2H, t, CH2-OH), 4.46 (2H, q, CH2CH 3), 4.55 (2H, t, 
CH2-O-N), 4.48 (IH, bs, CH2-OH), 7.92 (IH, d, H-4), 8.13 (IH, dd, H-5), 8.53 (IH, d, 
H-7), 14,5=8.8, J5 7=2 .5, Jc H2,CH3=2.0, JcH2,OH=5 .0 , Jc H2,CH2=6.2, Ôc  13.8 (CH2ÇH3), 
30.9 (CH2-GH2-CH2), 57.1 (HO-ÇH2), 62.4 (GH2CH3), 78.0 (ÇH2-O-N), 107.2 (C-7),
118.8 (C-4), 122.4 (C-5), 130.7 (C-3a), 140.5 (C-2), 141.5 (C-6), 145.3 (C-7a), 156.8 
(C=0).
i n
6-Amino- l-ethoxy-benzimidazole 11131
6-Amino-l-ethoxy-benzimidazole (90) (0.05g) was dissolved in ethanol (100ml), 
palladium/carbon catalyst (5%, 75mg) was added and the flask evacuated of air and stirring 
continued under an atmosphere of hydrogen. After hydrogen uptake had ceased (ca. 175ml 
hydrogen absorbed), the catalyst was removed by filtration and the solvent evaporated off to 
yield a dark brown, viscous oil. The product was purified on a column of silica gel, the pure 
product being a yellow/brown solid: yield 0.05g (9%), m.p. 98-100°C, ôy (CDCI3) 1.35 (3H, 
t, CH2CH3), 4.30 (2H, q, CH2CH3), 5.20 (2H, bs, NH2), 6.60 (2H, m, H-5 and H-7), 7.30 
(IH, d, H-4), 8.15 (IH, s, H-2), 14,5= 10, ôc (CDCI3) 14.0 (CH2ÇH3), 75.1 (ÇH2CH3),
93.4 (C-7), 112.9 (C-5), 121.5 (C-4), 131.2 (C-3a), 133.2 (C-7a), 136.9 (C-2), 143.8 (C-6), 
m/z =177 (M+ ).
Upon storage the product (113) darkened in colour and fuither purification yielded no 
product. The hydrochloride salts of the A-oxides were easier to handle and isolate hence in the 
following reaction the reaction mixture was treated with hydrogen chloride gas prior to the 
work-up procedure.
6-Amino-1 -ethoxv-benzimidazole hydrochloride H141
1 -Ethoxy-6-nitrobenzimidazole (90) (0.7g) was dissolved in ethanol (50ml), the 
palladium on carbon catalyst (lOOmg) was added and stirring continued under an atmosphere 
of hydrogen for 12h. The catalyst was filtered off, and the solution was then saturated with 
hydrogen chloride gas resulting in decolourisation. Upon standing, a precipitate formed and 
was collected; on further standing a second crop developed which was also collected. 
Spectroscopic analysis showed these to be different products: crop 1 was found to be 
5-aminobenzimidazole hydrochloride (115), yield 0.30g (53%), m.p.240°C (decomp.), Ôy
7.55 (IH, dd, H-6), 7.95 (2H, d, H-7, H-4), 9.70 (IH, s, H-2). Crop 2: l-ethoxy-6- 
aminobenzimidazole hydrochloride (114); O.lg (14%), m.p.l86-188°C,0y 1.12 (3H, t, 
CH2CH3), 4.28 (2H, q, CH2CH3), 7.20 (IH, dd, H-5), 7.55 (IH, d, H-7), 7.65 (IH, d, 
H-4), 9.45 (IH, s, H-2), 8.13-8.88 (2H, bs, NH2).
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Spectroscopic analysis showed these to be different products: crop 1 was found to be 
5-aminobenzimidazole hydrochloride (115), yield 0.30g (53%), m.p.240°C (decomp.), 6y
7.55 (IH, dd. H-6), 7.95 (2H, d, H-7, H-4), 9.70 (IH, s, H-2). Crop 2: l-ethoxy-6- 
aminobenzimidazole hydrochloride (114); O.lg (14%), m.p.l86-188°C,6y 1.12 (3H, t, 
CH2CH3), 4.28 (2H, q, CH2CH3), 7.20 (IH, dd, H-5), 7,55 (IH, d, H-7), 7.65 (IH, d, 
h-4), 9.45 (IH, s, H-2), 8.13-8.88 (2H, bs, NH2).
Attempted hydrogénation to 5-aminobenzimidazole 3-oxide hydrochloride
5-Nitrobenzimidazole 3-oxide hydrochloride (0.6g) (88) was dissolved in two 
equivalents of sodium hydroxide solution (2M, 3ml) and water (5ml). The palladium catalyst 
(5% on carbon) was then added and the reaction mixture left stirring over 18h under an 
atmosphere of hydrogen. Removal of the catalyst was followed by the acidification of the 
reaction mixture with concentrated hydrochloric acid and evaporation of the water in vacuo. 
Analysis showed only unreacted starting material to have been returned.
Attempted hydrogenations of l-(3-hydroxvpropoxyV6-nitrobenzimidazole (1071
l-(3-Hydroxypropoxy)-6-nitrobenzimidazole (107) (O.lg) was dissolved in a mixture 
of propan-l-ol (25ml) and ethanol (25ml), the palladium on carbon catalyst (lOOmg) was 
added and stirring continued under an atmosphere of hydrogen for 18h. The solution was 
saturated with hydrogen chloride gas after removal of the catalyst. The solvent was removed in 
vacuo. iH nmr analysis of the crude isolate showed it to be 5-aminobenzimidazole 
hydrochloride (115)^27^
l-(3-Hydroxypropoxy)-6-nitrobenzimidazole (107) (O.lg) was dissolved in formic acid 
(10ml, 80%), the palladium on carbon catalyst (lOOmg) added and stirring was continued 
under an atmosphere of hydrogen for 45 minutes. The catalyst was removed by filtration and 
the solution concentrated in vacuo. The residue was suspended in a solution of water (10ml) 
and ammonia solution (1.0ml) and heated under reflux for 15 minutes. After cooling the 
solvent was removed in vacuo. ^H nmr analysis of the crude isolate showed it to be 5- 
aminobenzimidazole hydrochloride (115)^27,
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filtered hot and the residue washed with hot methanol. Evaporation of the solvent and analysis 
of the crude product by tic (which showed many spots) and nmr showed no discernable 
product or evidence of unchanged starting material.
l-(3-Hydroxypropoxy)-6-nitrobenzimidazole (O.lg) (107) was dissolved in a solution 
of titanous chloride in hydrochloric acid (12.5% w/v, 3ml) and the flask evacuated at the water 
pump to yield a clear solution. The reaction mixture was then shaken for 24h followed by 
basification with ammonia solution and extraction with dichloromethane (3x75ml). The 
dichloromethane layers were combined, washed with water (150ml), dried with magnesium 
sulphate and concentrated to a yellow solid which was found to be unreacted stalling material 
(107).
4-Fluoro-3-nitroacetanilide ( 1171
4-Fluoro-3-nitroaniline (116) (l.Og) was stirred in acetic anhydride (1.96g) for Ih at 
room temperature. The reaction mixture was then poured onto ice and water (100ml). The 
brown solid formed was collected by filtration and reciystallised from aqueous ethanol (with 
chai'coal), to yield a pale yellow crystalline solid: yield l.lg  (87%), m.p. 138-140“C (lit.87 
139°C), ÔH 2.10 (3H, s, COCH3), 7.54 (IH, m, H-6), 7.84 (IH, dd, H-5), 8.52 (IH, t, 
H-2), J5 F=12.0, 15,6=9 .0 , 12,6=2.0, J2,F=2 .0 , ôc 24.2 (CH3), 115.2 (C-2), 118.2 (C-5),
126.1 (C-6), 136.2 (C-1,3), 150.0 (C-4), 168.8 (C=0), J4,f=257.9, J6,f=8.0, J5 f=22.0, 
J2,f=2 .1, m/z =198 (M+).
N-t4-Acetamido-2-nitrophenvllglycine ethyl ester Q 181
4-Fluoro-3-nitroacetanilide (117) (12.5g), glycine ethyl ester hydrochloride (9.7g) and 
sodium bicarbonate (10.6g) were heated in DMSO (40ml) with stirring at approximately 50°C 
for 6.5h; as time progressed the reaction mixture became dark red in colour. The reaction 
mixture was poured onto ice and water (500ml) to yield a red precipitate which was collected 
by filtration. The solid was recrystallised from ethanol to yield an orange crystalline solid: yield 
l . lg  (43%), m.p.l62-164°C (lit.87 164-165°C), ôy 1.24 (3H, t, CH2CH3), 2.04 (3H, s, 
CH3), 4.19 (2H, q, CH2CH3), 4.26 (2H, d, NH-CH2), 6.93 (IH, d, H-6), 7.66 (IH, dd.
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H-5), 8.30 (lH ,,t, NH-CH2), 8.51 (IH, d, H-3), 10.02 (IH, s, NH), J5,6=9.3, J3,5=2 .4 , 
J c H 2 . C H 3 = 7 . 2 ,  J n h , C H 2 = 5 . 4 ,  Ô C  14.2 (CH2CH 3), 23.9 (CH3), 44.4 (NH-ÇH2), 61.1 
(CH2CH3), 115.1 (C-5) and (C-6), 128.7 (C-4), 129.4 (C-3), 130.6 (C-2), 141.3 (C-1),
168.4 (CH3ÇO), 170.0 (C=0), m/z =281 (M+ ).
Ethvl 5-acetamidobenzimidazole-2-carboxylate 3-oxide (119)
4-Acetamido-2-nitrophenylglycine ethyl ester (118) (6.0g) and potassium carbonate 
(3.2g) were heated together in ethanol (75ml) under reflux for 8.5h. The solvent was then 
evaporated off to yield a dark red solid which was dissolved in the minimum water and 
carefully acidified to pH 1 with concentrated hydrochloric acid. A precipitate was collected and 
recrystallised from ethanol and water to yield an orange crystalline solid: yield 3.7g (66%), 
m.p.l33-138°C (lit.87 133-134“C), %  1.44 (3H, t, CH2CH3), 2.21 (3H, s, CH3), 4.49 (2H, 
q, CH2CH3), 7.38 (IH, dd, H-6), 7.77 (IH, d, H-7), 8.33 (IH, d, H-4), 10.37 (IH, s, 
NH-CH2), 12.22 (IH, bs, NH/OH), 14,6= 1.2 , 16,7=8 .8 , JcH2,CH3=7.2, ôc (75 MHz) 14.1 
(CH2ÇH3), 24.1 (ÇH3CO), 61.5 (ÇH2CH3), 99.2 (C-4), 116.9 (C-7), 121.3 (C-6), 133.2 
(C-5 and -7a), 137.3 (C-2), 137.5 (C-3a), 158.0 (CH3CO), 168.7 (C=0).
Ethyl 6-acetamido-l-r3-hvdroxvpropoxv^benzimidazole-2-carboxvlate ( 1201
Ethyl 5-acetamidobenzimidazole-2-carboxylate 3-oxide (119) (0.5g) was dissolved in 
the minimum of anhydrous DMF (20ml) and potassium carbonate (0.3g) added resulting in a 
precipitate a precipitate forming. 3-Bromopropan-1 -ol (104) (0.3g) was then added to the 
mixture and stirring maintained under a calcium chloride guard for 24h, the precipitate 
redissolving over time. The reaction mixture was then poured into water (75ml) and extracted 
with dichloromethane (3x25ml), the organic layers were combined, washed with water 
(100ml) and dried over magnesium sulphate, and the solvent was removed in vacuo to yield a 
dark oil which crystallised on standing. The solid was recrystallised from toluene: yield 0.08g 
(13%), m.p. 161-163°C, (Found: C, 56.2; H, 6.0; N, 13.1. C15H 18N3O5 requires C, 56.2; 
H, 5.7; N, 13.1%), Ôh 1.34 (3H, t, CH2CH3), 1.94 (2H, quin., CH2-CH2-CH2), 2.11 (3H, 
s, CH3), 3.65 (2H, m, CH2-OH), 4.37-4.50 (4H, m, CH2-ON and CH2CH3), 4.65 (IH, bs.
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CH2-OH), 7.36XIH, dd, H-5), 7.75 (IH, d, H-4), 8.19 (IH, d, H-7), 10.28 (IH, s, NH), 
ÔC 14.0 (CH2ÇH3), 24.0 (CH3), 31.2 (CH2-CH2-CH2), 57.3 (HO-CH2), 61.4 (ÇH2CH3),
77.2 (CH2-O-N), 98.7 (C-7), 117.4 (C-4), 121.7 (C-5), 131.6 (C-6), 132.9 (C-3a), 136.6 
(C-7a), 137.8 (C-2), 168.2 (CH3ÇO), 168.6 (C=0).
The above procedure was repeated at both 0°C and 100°C in an attempt to improve the 
yield of the reaction while monitoring its progress by tic. The product was isolated in both 
cases but the best yield obtained was 30% in the reaction at room temperature.
A second change to the procedure was the replacement of 3-bromopropan-l-ol (104) 
with 3 -iodopropan-1 -ol (121) but again no improvement in yield resulted.
3-Iodopropan- l-ol 11211
3-Bromopropan-1 -ol (104) (5.0g) and sodium iodide (5.5g) were heated under reflux 
in anhydrous acetone (50ml) for 17h. The reaction mixture was allowed to cool before the 
removal of the acetone in vacuo. The resultant oil was then dissolved in dichloromethane 
(50ml), washed with water (2x50ml) and then with sodium thiosulphate until the organic layer 
was decolourised. The organic layer was then dried over magnesium sulphate. Distillation at 
high vacuum yielded a colourless oil: Yield 1.5g (22%), b.p. 30°C / O.lmmHg, (lit.^27 g8°C), 
ÔH 2.03 (2H, quin., CH2-CH2-CH2), 3.29 (2H, q, CH2-OH), 3.42 (IH, bs, CH2-OH), 3.68 
(2H, bs, CH2-I), ÔC 4.0 (CH2-I), 36.1 (CH2-ÇH2-CH2), 62.5 (ÇH2-OH).
5-Acetamido-2-cyanobenzimidazole 3-oxide (1231
4-Acetamido-N-cyanomethyl-2-nitroaniline (122) (4.0g) and potassium carbonate 
(3.2g) were heated together in ethanol (250ml) under reflux for 2h. The solvent was 
evaporated off and the resultant solid dissolved in water (200ml) and acidified to pH 1 with 
concentrated hydrochloric acid. The precipitate was collected and recrystallised from water and 
ethanol: yield 1.15g (31%), m.p.234-238°C (lit.87 233-234°C), ôy 2.12 (3H, s, CH3), 7.31 
(IH, dd, H-6), 7.69 (IH, d, H-7), 8.27 (IH, d, H-4), 10.30 (IH, bs, NH-CH2), 14,6= 1.2 ,
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4-Acetamido-Ar-cyanomethyl-2-nitroanilme (122) (4.0g) and potassium carbonate 
(3.2g) were heated together in ethanol (250ml) under reflux for 2h. The solvent was 
evaporated off and the resultant solid dissolved in water (200ml) and acidified to pH 1 with 
concentrated hydrochloric acid. The precipitate was collected and recrystallised from water and 
ethanol: yield 1.15g (31%), m.p.234-238°C (lit.87 233-234°C), ôy 2.12 (3H, s, CH3), 7.31 
(IH, dd, H-6), 7.69 (IH, d, H-7), 8.27 (IH, d, H-4), 10.30 (IH, bs, NH-CH2), 14,6= 1.2 , 
1 6 , 7 = 8 . 8 ,  1 c H 2 ,C H 3 = 7 .2 ,  Ô c ( 7 5  MHz) 24.4 (ÇH3CO), 98.4 (CN), 111.1 (C-5), 117.7 (C-7),
121.6 (C-4), 131.8 (C-3a), 134.5 (C-7a), 138.4 (C-6) and (C-2), 169.0 (CH3CO).
6-Acetamido-2-cvano-1 -G-hydroxvpropoxvlbenzimidazole ( 124)
5-acetamido-2-cyano benzimidazole3-oxide (123) (0.4g) was dissolved in the minimum 
of anhydrous DMF (20ml) and potassium carbonate (0.3g) added. 3-Bromopropan-l-ol (104) 
(0.3g) was then added to the mixture and stirring maintained under a calcium chloride guard for 
24h. The reaction mixture was then poured into water (75ml) and extracted with 
dichloromethane (3x25ml), the organic layers were combined, washed with water (100ml) and 
dried over magnesium sulphate. The solvent was removed in vacuo and the solid recrystallised 
from water and ethanol: yield 0.41g (81%), m.p. 166-167°C, (Found: C, 51.6; H, 5.6; N, 
18.6. C13H 14N4O 3. I .5H2O requires C, 51.8; H, 5.2; N, 18.6%), 6h 1.97 (2H, quin., 
CH2-CH2-CH2), 2.10 (3H, s, CH3), 3.61 (2H, q, CH2-OH), 4.60 (2H, t, CH2-ON), 4.74 
(IH, bs, CH2-OH), 7.42 (IH, d, H-5), 7.77 (IH, d, H-4), 8.24 (IH, s, H-7), 10.34 (IH, s, 
NH), ÔC 24.1 (CH3), 31.2 (CH2-ÇH2-CH2), 57.0 (HO-ÇH2), 78.5 (QH2-O-N), 98.3 (C-7), 
110.3 (C-3a), 118.0 (C-4), 121.7 and 121.8 (CN and C-5), 130.2 (C-6), 134.1 (C-7a), 138.8 
(C-2), 168.8 (C=0).
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Chapter 3 
Experimental
N^-r4.5-DichlorO"2-nitrophenvDgiycine ethyl ester (129)
l,2-Dichloro-4-fluoro-5-nitrobenzene (133) (25.Ig), glycine ethyl ester hydrochloride 
(17.0g) and sodium bicarbonate (19.5g) were heated under reflux in ethanol (450ml) for 4h. 
The reaction was poured into ice/water (200ml), and the resultant precipitate was collected and 
recrystallised from ethanol to give yellow needles: yield 29.2g (83%), m.p.ll9-120°C (lit.^^^ 
122°C), 6h 1.25 (3H, t, CH^CHg), 4.20 (2H, q, CH2CH3), 4.31 (2H, d, CH2-NH), 7.29 
(IH, s, H-6), 8.25 (IH, s, H-3), 8.43 (IH, t, NIi-CH2), JcH2,CH3=^-l’
14.0 (CH2ÇH3), 44.5 (NH-CH2), 61.1 (CH2CH3), 116.5 (C-6), 117.4 (C-4), 127.0 (C-3),
130.6 (C-2), 139.5 (C-5), 143.6 (C-1), 169.4 (C=0), m/z =292 / 294 / 296 (M+ ).
Ethvl 5.6-dichlorobenzimidazole-2-carboxylate 3-oxide 11341
N-(4,5-Dichloro-2-nitrophenyl)glycine ethyl ester (129) (27. Ig) and potassium 
carbonate (12.9g) were heated under reflux in ethanol (300 ml) for 3h. The reaction mixture 
was partitioned between dichloromethane (250ml) and water (250ml), the organic phase being 
extracted with water (500ml). The combined water layers were extracted with dichloromethane 
(250ml) and then acidified with concentiated hydrochloric acid. The yellow precipitate formed 
was collected and recrystallised from ethanol: yield 9.0g (35%), m.p.212-220°C (decomp.) 
(lit.98 2 18-22rc), ÔH 1.38 (IH, t, CH2CH3), 4.44 (2H, q, CH2CH3), 7.91 and 8.12 (2H, 
2s, H-4 and H-7), J c H 2 , C H 3 = 7 . 0 ,  Ô c  (75 MHz) 14.0 (CH2ÇH3), 61.9 (ÇH2CH3), 111.7 
(C-7), 122.4 (C-4), 126.2 (C-5), 128.2 (C-6), 132.1 (C-3a), 136.1 (C-7a), 139.7 (C-2),
157.5 (C=0 ), m/z =274 / 276 / 278 (M+-).
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Production of a mixture of ethvl 5.6-dichlorobenzimidazole-2-carboxylate 3-oxide 
1134  ^and 5.6-dichlorobenzimidazole-2-carboxvlate 3-oxide (135)
iV-(4,5-Dichloro-2-nitrophenyl)glycine ethyl ester (129) (20.6g) and potassium 
carbonate (lO.Og) were heated under reflux in ethanol (250 ml) for 4h and the mixture left to 
cool overnight and then worked up following the above procedure for (134). On analysis of the 
crude product by nnu- it was found that the material isolated was a mixture of the desired 
product (134) and its decarboxylated counterpart (135). Rather than try to separate the mixture 
it was taken directly through to the hydrochloride by refluxing in concentrated hydrochloric 
acid (see procedure below).
5.6-Dichlorobenzimidazole 3-oxide hydrochloride Q35ai from a mixture of compounds 
034) and 0351
A mixture of crude ethyl 5,6-dichlorobenzimidazole-2-carboxylate 3-oxide (134) and
5,6-dichlorobenzimidazole-2-carboxylate 3-oxide (135) was heated under reflux in 
concentrated hydrochloric acid (450ml) for 3h. The reaction mixture was concentrated in vacuo 
and allowed to cool, crystallisation occurring. The product was collected by filtration, and a 
second crop of crystals obtained from the filtrate: yield 8.3g (49%, over the cyclisation and 
hydrolysis/decarboxylation stages), m.p.212-214°C (decomp.) (lit.^^ 204-207“C, decomp.).
5.6-Dichlorobenzimidazole 3-oxide hvdiochloride 1128a)
Ethyl 5,6-dichlorobenzimidazole-2-carboxylate 3-oxide (127) (5.0g) was heated under 
reflux in concentrated hydrochloric acid (125ml) for 5h; after cooling a precipitate had formed 
which was collected and recrystallised from concentrated hydrochloric acid to yield opaque 
needles: yield 2.0g (46%), m.p.212-214°C (lit.^^ 204-204°C, decomp.), ôfj 8.04 and 8.12 
(2H, 2s, H-4 and H-7), 9.25 (IH, s, H-2), ôc (75 MHz) 109.7 (C-5), 113.0 (C-4), 117.8 
(C-7), 128.4 (C-3a), 129.9 (C-6), 130.5 (C-7a), 139.8 (C-2).
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5.6-DichlQrobenzimidazole 3-oxide (135)
The 5,6-dichlorobenzimidazole 3-oxide hydrochloride (135a) (2.0g) was dissolved in 
ammonia solution (80ml), stirred for 0.5h then concentrated in vacuo to ca. 40ml. The resultant 
precipitate was collected by filtration and recrstallised from ethanol/water: yield 1.5g (41%), 
m.p.200-210“C (lit.98 224-226T), Ôh 7.72 and 8.00 (2H, 2s, H-4 and H-7), 8.50 (IH, s, 
H-2), ÔC (75 MHz) 111.1 (C-4), 121.6 (C-7), 124.7 (C-6), 125.8 (C-5), 131.4 (C-3a), 139.1 
(C-7a), 142.8 (C-2).
5.6-Dichloro-1 -f3-hvdroxvpropoxv)benzimidazole (136)
i) with sodium ethoxide as the base
To a solution of 5,6-dichlorobenzimidazole 3-oxide (135) (0.3g) in ethanol (30ml), a 
solution of sodium ethoxide (1.2ml) was added, [sodium (0.6g) dissolved in ethanol (20ml)] 
with stirring. After 0.5h the reaction was evaporated to dryness and the white solid dissolved 
in the minimum of DMF (10ml). 3-Bromopropan-1 -ol (0.2g) was then added and stirring 
maintained for 24h. The reaction mixture was poured into water (50ml) and extracted with 
dichloromethane (3x25ml). The organic extracts were combined, washed with a dilute solution 
of sodium hydroxide (O.IM, 10ml) and then twice with water (2x75ml) followed by drying 
over magnesium sulphate. The solvent was removed in vacuo and the white solid obtained was 
recrystallised from toluene: yield O.lOg (31%), m.p.70-72°C. (Found: C, 44.5; H, 4.1; N, 
10.3. C10H 10CI2N2O2 O.5H2O requires C, 44.5; H, 3.7; N, 10.4%). &H 194 (2H, quin., 
CH2-CH2-CH2), 3.62 (2H, q, HO-CH2), 4.49 (2H, t, CH2-ON), 4.75 (IH, t, HO-CH2),
8.00 (2H, s, H-4 and H-7), 8.71 (IH, s, H-2), J c h 2 , C H 2 = 6 . 2 ,  J c h , O H = 5 . 2 ,  Ô c  30.8 
(CH2-ÇH2-CH2), 56.9 (ÇH2-OH), 77.4 (N-O-ÇH2), 110.7 (C-7), 121.5 (C-4), 125.1 (C-6),
126.2 (C-5), 129.3 (C-3a), 138.5 (C-7a), 142.0 (C-2).
ii) with potassium carbonate as the base
5.6-Dichlorobenzimidazole 3-oxide (135) (0.5g) was dissolved in the minimum of 
dried DMF (5ml), potassium carbonate (0.34g) was then added followed by
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3-bromopropan-l-ol (0.34g) and stirring continued for 18h. The reaction mixture was poured 
into water (20ml) and extracted with dichloromethane (3x20ml), the organic extracts were 
combined, washed with water (2x50ml), dried over magnesium sulphate and concentrated to a 
pale yellow liquid which crystallised in the freezer over a few days and was recrystallised twice 
from toluene, once with charcoal: yield 0.26g (39%), m .p.69-?rc.
iii) with triethylamine as the base
5,6-Dichlorobenzimidazole 3-oxide (135) (0.5g) was dissolved in ethanol (25ml) along 
with triethylamine (0.27g) and 3-bromopropan-l-ol (0.38g). The reaction mixture was heated 
under reflux for 3h with a further aliquot of triethylamine (0.14g) added after 2h. After cooling 
a crude product was isolated from the reaction mixture and recrystallised from ethanol/toluene: 
yield 0.1 g (16%), m.p.69-70°C.
Ethyl 5.6-dichloro-l-G-hydroxypropoxy)benzimidazole-2-carboxylate 1137)
Ethyl 5,6-dichlorobenzimidazole-2-carboxylate 3-oxide (134) (0.25g) was dissolved in 
the minimum of DMF (20ml); addition of potassium carbonate (0.14g), led to the formation of 
a precipitate. This was dissolved by the addition of further DMF (5ml) followed by 3- 
bromopropan-1 -ol (0.13g). The mixture was stirred overnight and then poured into water 
(50ml) and extracted with dichloromethane (3x50 ml). The organic layers were combined and 
washed twice with equal volumes of water (2x 100ml) then dried over magnesium sulphate. 
The solution was concentrated to an oil which crystallised upon cooling; the solid was 
recrystallised from ethanol yielding pale needle-like crystals: yield 0.13g (43%), m .p .ll6- 
118“C. (Found: C, 47.3; H, 4.5; N, 8.2. C13H 14CI2N 2O4 requires C, 46.9; H, 4.2; N, 
8.4%). 6 h 1.39 (3H, t, CH2C H 3), 2.10 (2H, quin., CH2-CH.2-C H 2), 3.65 (2H, q, 
CH2-OH), 4.40-4.55 (4H, m, CH2-ON, CH2CH3), 4.73 (IH, t, CH2-OH), 8.12 and 8.17 
(2H, 2s, H-4 and H-7), JcH 2,CH 3=7 .3, Ôc 14.1 (CH2ÇH3), 31.0 (CH2-ÇH2-CH2), 57.2 
(ÇH2CH3), 62.4 (ÇH2-OH), 77.6 (N-O-ÇH2), 112.1 (C-4), 123.0 (C-7), 127.0 (C-5), 129.1 
(C-6), 130.9 (C-3a), 136.2 (C-2), 139.5 (C-7a), 157.1 (C=0), m/z =332 / 334/ 336 (M+ ).
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The reaction was also repeated at low temperature following the above reaction 
procedure. The ethyl 5,6-dichlorobenzimidazole-2-carboxylate 3-oxide (134) (0.25g) was 
dissolved in DMF (20ml) and the solution cooled to -30“C before the addition of the potassium 
carbonate (0.14g) and 3-bromopropan-l-ol (0.13g). After 4h at -30“C the reaction mixture was 
allowed to heat up gradually to 0°C and was then held at that temperature for 2h followed by a 
further 2h at room temperature. The correct product was isolated and chacacterised as above 
but was in a rather low yield: yield O.lg (17%), m.p.l 15-117°C.
The reaction to produce (137) was also repeated with heating at 90'"C. Ethyl
5,6-dichlorobenzimidazole-2-carboxylate 3-oxide (135) (2.0g) was dissolved in the minimum 
of DMF (40ml), followed by the addition of potassium carbonate (l.lg ) and stirring for 0.5h.
3-Bromopropan-l-ol (l.lg ) was then added and the reaction heated to 90°C and held at that 
temperature for 6h. The reaction was worked up as previously, whereupon a mixture of 
products was isolated and found by nmr to consist of 90% of the decai'boxylated compound
(136) and 10% of the desired compound (137). Separation of the mixture of products was not 
attempted, but the mixture was hydrolysed/decarboxylated in concentrated hydrochloric acid 
(see below).
Hydrolvsis of a mixture of ethvl 5.6-dichloro-1 -13-hydioxypropoxy)benzimidazole-2- 
carboxylate 1137) and 5.6-dichloro-l-G-hvdroxvpropoxv)benzimidazole 1136)
A mixture of ethyl 5,6-dichloro-1 -(3-hydroxypropoxy)benzimidazole-2-carboxylate
(137) (10%) and 5,6-dichloro-l-(3-hydroxypropoxy)benzimidazole (136) (90%) (0.75g) was 
heated under reflux in concentrated hydrochloric acid (40ml) for 3h. On cooling, a solid 
precipitated from the reaction mixture and was recrystallised from ethanol/toluene: yield 0.30g 
(16%), m.p.67-68°C, Ôh 1.90 (2H, quin., CH2-CH.2-CH2), 3.63 (2H, t, CH2-OH), 4.46 
(2H, t, N-O-CH2), 4.79 (IH, bs, CH2-OE), 7.98 (2H, s, H-4 and H-7), 8.72 (IH, s, H-2), 
ÔC 31.0 (CH2-ÇH2-CH2), 57.1 (ÇH2-OH), 77.5 (N-O-CH2), 111.0 (C-7), 121.2 (C-4),
125.0 (C-6), 125.9 (C-5), 129.4 (C-3a), 138.5 (C-7a), 142.2 (C-2).
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Attempted reaction of pentachloronitrobenzene and glvcine ethyl ester hydrochloride
Pentachloronitrobenzene (138) (l.lg), glycine ethyl ester hydrochloride (0.6g) and 
sodium bicarbonate (0.7g) were heated under reflux in ethanol (30ml) and toluene (30ml) for 
4h. Tic and nmr analysis of the crude reaction mixture showed no reaction to have 
occurred.
Attempted synthesis of N-lo-nitrophenyl) glvcine methyl ester
To a solution of o-fluoronitrobenzene (139) (l.Og) in methanol (20ml), glycine methyl 
ester hydrochloride (0.9g) and sodium bicarbonate (1.2g) were added and the mixture heated 
under reflux for 3h. The reaction mixture was concentrated in vacuo, and partitioned between 
dichloromethane (50ml) and water (50ml). The aqueous layer was extracted with 
dichloromethane (3x25ml) and the organic layers combined, washed with water and dried over 
magnesium sulphate. The solvent was removed to yield a yellow oil which upon analysis was 
found to be a complex mixture of products comprising mainly of the starting material (139).
The separation of the mixture was not attempted as an easier method was available for 
the synthesis of o-nitrophenylglycine ethyl ester (141).
N-to-NitrophenvDglvcine 1140)
A solution of o-fluoronitrobenzene (139) (5.0g) in ethanol (130ml) was added to a 
solution of glycine (2.7g) and sodium bicarbonate (11.9g) in water (80ml) with stirring, a 
white precipitate forming. The reaction mixture was then heated under reflux for 8h and 
allowed to cool. The mixture was concentrated in vacuo, and partitioned between ether (100ml) 
and water (100ml). The aqueous layer was then acidified with concentrated hydrochloric acid 
to yield an orange/yellow precipitate which was recrystallised from ethanol: yield 2.9g (50%), 
m.p.l88-190°C (lit. 129 199”C), 3375 (N-H), 1718 (C=0), 1505, 1357 and 1320cm-1
(NO2), Sh 4.20 (2H, d, NH-CH2). 6.75 (IH, t, H-5), 6.95 (IH, d, H-6), 7.55 (IH, t, H-4), 
8.10 (IH, d, H-3), 8.40 (IH, t, NH-CH;), 13,4=10.0, Ja,5=4.9 Jn h -CH2=5-2, ô c  44.2 
(NH-CH2). 114.9 (C-5), 115.7 (C-4), 126.0 (C-3), 131.5 (C-1), 136.4 (C-6), 144.4 (C-2),
170.9 (C=0).
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N-f^-NitrgphenvDglvcine ethyl ester (141)
N-((?-Nitrophenyl)glycine (140) (2.7g) was dissolved in ethanol (250ml) and the 
solution saturated with hydrogen chloride gas over 1.5h. The acidified solution was then 
heated under reflux for 8h and allowed to cool. The solvent was evaporated off to yield an 
orange/yellow solid which was recystallised from propan-2-ol alcohol yielding a yellow 
ciystalline solid: yield 1.80g (60%), m.p.77-79°C (lit.^^^ 80°C), Ôg 1.25 (3H, t, CH2CH3), 
4.20 (2H, q, CH2CH3), 4.30 (2H, d, CH2-NH), 6.75 (IH, t, H-5), 6.95 (IH, d, H-6), 7.55 
(IH, t, H-4), 8.15 (IH, d, H-3), 8.40 (IH, bs, N H -C H 2), 13,4= 10 .0 , 13,5= 2 .6 , 
J n h - C H 2 = 5 . 1 ,  Ô C  14.6 (CH2ÇH3), 44.9 (ÇH2CH3), 115.4 (C-5), 116.5 (C-4), 126.6 (C-3),
132.0 (C-1), 137.0 (C-6), 145.0 (C-2), 170.3 (C=0).
Synthesis of a mixture of N-ro-nitrophenyI) glvcine (140) and N-(o-nitrophenvl) glvcine 
ethyl ester (141)
A solution of o-fluoronitrobenzene (139) (15.0g) in ethanol (390ml) was added to a 
solution of glycine (8.0g) and sodium bicarbonate (35.7g) in water (240ml) with stirring, a 
white precipitate forming. The reaction mixture was then heated under reflux for l lh  and 
allowed to cool before the work-up procediure was followed as above. Two crops of crystals 
were isolated from the recrystallisation solvent, ethanol. Crop 1: yield lO.Og (57%), m.p.l76- 
178°C (lit. 1^ 9 199”C) was identified as compound (140). Crop 2: yield 3.8g (16%), m.p.78- 
80"C (lit. 130 80“C) was identified as compound (141).
Ethyl benzimidazole-2-carboxylate 3-oxide H42)
N-(o-Nitrophenyl)glycine ethyl ester (141) (6.0g) was dissolved in ethanol (200ml) 
and heated under reflux with potassium carbonate (4.1g) for 2h then allowed to cool. The 
reaction mixture was concentrated in vacuo then partitioned between dichloromethane (150ml) 
and water (150ml). The aqueous layer was then acidified with concentrated hydrochloric acid, 
no precipitate forming but gas being evolved; concentration in vacuo then led to a yellow solid 
product which was recrystallised from ethanol/toluene: yield 3.5g (63%), m.p.l66-167°C 
(lit.l3> 166-167°C), 5h 1.40 (3H, t, CH2CH3), 4.45 (2H, q, CH2CH3), 7.50 (2H, m, H-5
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and H-6), 7.82 <2H, m, H-4 and H-7), J4,6=5.8, Jg,6=5.8, Ôc 14.0 (CH2Ç H 3), 62.6 
(ÇH2CH3), 111.8 (C-7), 118.5 (C-4), 125.9 (C-5), 126.5 (C-6), 132.0 (C-7a), 132.8 (C-3a),
135.9 (C-2), 156.1 (C=0).
Synthesis of a mixture of ethvl benzimidazoIe-2-carboxvlate 3-oxide (142) and 
benzimidazole 3-oxide ( 143)
N-(o-Nitrophenylglycine ethyl ester (141) (8.7g) was dissolved in ethanol (150ml) and 
the solution heated under reflux with potassium carbonate (5.8g) for 2h then allowed to cool. 
The reaction mixture was concentrated in vacuo and the residue then partitioned between 
dichloromethane (175ml) and water (175ml). The aqueous layer was then acidified with 
concentrated hydrochloric acid, no precipitate forming but gas being evolved; and concentration 
in vacuo gave a yellow solid product. ^H nmr analysis of the crude product showed it to be a 
mixture of the desired product (134) and its decarboxylated counterpart (135): yield 13.0g 
(>100%), m.p.l60-164°C, the ratio of (142) : (143) was approximately 2.5 : 1.
Benzimidazole 3-oxide hydrochloride (143a)
The above mixture of ethyl benzimidazole-2-carboxylate 3-oxide (142) and 
benzimidazole 3-oxide (143) (12.9g) was heated under reflux in concentrated hydrochloric acid 
(325 ml) for 2 h, then allowed to cool.The reaction mixture was concentrated in vacuo to an 
orange solid which was recrystallised from propan-2-ol: yield 4.0g (40% based on the ester), 
m.p.206-208“C (lit.73 199-200T), Ôh (300MHz) 7.62-7.71 (2H, m, H-5,6), 7.89-7.96 (2H, 
m, H-4,7), 10.03 (IH, s, H-2), J4,5=35,6=7 6 , ôc 111.9 (C-7), 114.9 (C-4), 126.1 (C-5),
126.7 (C-6), 128.5 (C-3a), 129.1 (C-7a), 136.7 (C-2).
Benzimidazole 3-oxide (143)
Benzimidazole 3-oxide hydrochloride (143a) (1.5g) was dissolved in ammonia 
solution (60ml) and stirred for 0.5h. The solution was concentrated in vacuo to aid 
precipitation. The product was isolated by filtration and recrystallised from ethanol: yield 0.70g 
(85%), m.p.211-213°C, (lit”  2I4-216°C), Ôg 7.15 and 7.25 (2H, 2t, H-5 and H-6), 7.50
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and 7.61 (2H, 2d, H-4 and H-7), 8.38 (IH, s, H-2), J4,5=^5,6=7.8, 5c 109.5 (C-7), 119.9 
(C-5), 121.9 (C-6), 122.9 (C-4), 131.9 (C-3a), 139.3 (C-2), 140.0 (C-7a).
1 -r(3-Tetrahvdropvran-2-vloxv)propoxvlbenzimidazole ( 136)
Benzimidazole 3-oxide (143) (0.5g) was dissolved in ethanol (10ml) and sodium 
ethoxide solution (3.2ml) added [sodium (0.65g) dissolved in ethanol (20ml)] with stirring. 
After 0.5h, concentration in vacuo led to a white solid. This solid was then dissolved in the 
minimum of DMF (10ml) and the solution stirred for 24h at room temperature with the THP 
ether (105) (l.Og). The reaction mixture was poured into water (100ml) and extracted with 
dichloromethane (3x75ml), the organic layers were combined, washed with sodium hydroxide 
(O.IM, 75ml), followed by water (2x 100ml) then dried over magnesium sulphate. The solvent 
was removed under reduced pressure and the purification of crude product attempted on a 
column of silica. The gummy product could not be purified completely by column 
chromatography and proved too thermally unstable to be distilled at low pressure. ^H nmr 
showed the correct resonances to be present but with incorrect integration; the product was 
therefore taken through to the next synthetic stage in an impure form. Yield 0.5g (48%), 5^ 
1.36 -1.81 (6H, m, H-2 ', H-3' and H-4,), 2.13 (2H, quin., CH2-CH2-CH2), 3.31-3.93 (4H, 
m, CH2-OTHP and H-5'), 4.46 (2H, t, N-O-CH2), 4.53 (IH, s, H-1'), 7.24-7.41 (2H, 2t, 
H-5 and H-6), 7.62 (IH, d, H-4), 7.75 (IH, d, H-7), 8.58 (IH, s, H-2), 14,5=7 .5,
Jc H2,CH3=7.0.
Ethyl 1 - rr 3-tetrahvdropyran-2-vloxv)propoxv1benzimidazole-2-carboxylate ( 146)
Ethyl benzimidazole-2-carboxylate 3-oxide (142) (0.50g) was dissolved in DMF 
(20ml) and potassium carbonate (0.74g) added. The resultant mixture was stirred for Ih at 
room temperature before the addition of the THP ether (105) (0.60g), and stirring was then 
continued for a further 24h. The reaction mixture was then poured into water (100ml) and 
extracted with dichloromethane (3x50ml). The organic layers were combined and washed with 
water (150ml), dried over magnesium sulphate and concentrated to a gum which was purified 
on a column of silica. Yield 0.04g (5%), 5^ 1.35 (3H, t, CH2CH3), 1.46 -1.75 (6H, m, H-2',
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H-3’ and H-4'), 2.10 (2H, quin., CH2-CH2-CH2), 3.43-3.91 (4H, m, CH2-OTHP and 
H-5'), 4.40 (2H, q, CH2CH3), 4.50 (2H, m, N-O-CE2), 4.63 (IH, s, H-a), 7.36 (IH, t, 
H-6), 7.48 (IH, t, H-5), 7.70 (IH, d, H-4), 7.81 (IH, d, H-7), 34,5=8.2 , 3ch2,CH3=7.0, Ôc
14.1 (CH2Ç H 3), 19.8 (C-2’), 25.5 (C-4'), 28.6 (C-3’), 30.8 (CH2-CH 2-CH 2), 62.0 
(CH2CH3), 62.3 (ÇH2-OTHP), 63.6 (C-5'), 77.3 (N-O-ÇH2), 98.7 (C-1'), 110.5 (C-7),
122.0 (C-4), 124.5 (C-6), 126.6 (C-5), 131.8 (C-3a), 137.3 (C-2), 137.4 (C-7a), 157.9 
(C=0).
l “r3-Hydroxypropoxv)benzimidazole H45) from the reaction of (144) with pvridinium 
p-toluenesulphonate (PPTS)
(For the synthesis of PPTS see chapter 2 experimental, p i06)
l-[(3-Tetrahydropyran-2-yloxy)propoxy]benzimidazole (144) (0.2g) was dissolved in 
ethanol (5ml) and PPTS (0.02g) added with stirring and heating to ca. 55°C. The temperature 
and stirring were maintained for 5h. The reaction mixture was concentrated in vacuo and 
purification attempted on a column of silica, but the product was found to be extremely polar 
and difficult to elute from the column, hence the gum isolated was not a completely pure 
product. Like compound (144), (145) was also found to be too thermally unstable to be 
distilled at low pressure. The data shown relates to the impure product: yield 0.05g (38%), ôg
1.95 (2H, quin., CH2-CH2-CH2), 3.64 (2H, t, CH2-OH), 4.56 (2H, t, N-O-CH2), 7.17 (IH, 
d, H-4), 7.56 (2H, d, H-5 and H-6), 7.86 (IH, d, H-7), 9.45 (IH, s, H-2), 34 5=35 g=7.5, 
JcH2,CH3=6 .5, ÔC 30.8 (CH2-ÇH2-CH2), 57.0 (ÇH2-OH), 78.1 (N-O-ÇH2), 111.0 (C-3a), 
116.2 (C-7a), 125.8 (C-4 and C-7), 127.1 (C-5 and C-6), 128.6 (C-2).
l-(3-Hvdroxvpropoxv)benzimidazole ( 145)
Benzimidazole 3-oxide (143) (O.lg) was dissolved in sodium ethoxide solution (4.0ml) 
[sodium (O.lg) dissolved in ethanol (20ml)] and stirred for 0.5h. The solution, when 
concentrated under reduced pressure, yielded a solid which was then dissolved in DMF (10ml) 
and stirred for 24h at room temperature with 3-bromopropan-l-ol (O.lg). The reaction mixture 
was then poured into water (100ml) and extracted with dichloromethane (3x75ml). The organic
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layers were combined and washed with sodium hydroxide (O.IM, 75ml) then water 
(2xl00ml), dried over magnesium sulphate and concentrated to a viscous oil. ôjj 1.93 (2H, 
quin., CH2-CH2-CH2), 3.69 (2H, q, HO-CH2), 4.48 (2H; t, CK2-O-N), 4.86 (IH, t, 
CH2-OH), 7.33 (2H, 2t, H-5,6), 7.63 (IH, d, H-4), 7.74 (IH, d, H-7), 8.61 (IH, s, H-2), 
J4,5=7 .5, JcH2,CH3=6 '5 , JcH2,OH=5-0 - Attempts to purify the product as above also failed and 
the attempted reaction at 75°C resulted in no detection of any discernable product presumably 
due to the thermal instability of the product.
The above reaction was repeated with potassium carbonate as the base, following the 
same procedure. Although the product (145) was furnished in a slightly greater yield, (145) 
was never isolated in a pure enough form to undergo C/H/N analysis.
Ethyl 1 3-hydroxypropoxy)benzimidazole-2-caiboxvlate (147)
Ethyl benzimidazole-2-carboxylate 3-oxide (147) (l.Og) was dissolved in DMF (20ml) 
and potassium carbonate (0.74g) added. The resultant mixture was stirred for 0.5h at room 
temperature, 3-bromopropan-l-ol (0.74g) was added and stirring maitained for a further 24h. 
The reaction mixture was then poured into water (100ml) and extracted with dichloromethane 
(3x50ml). The organic layers were combined, washed with water (150ml), dried over 
magnesium sulphate and concentrated to give an oil which crystallised on standing. The solid 
collected was purified on a column of silica and recrystallised from toluene/ethanol: yield 0.1 Og 
(8%), m.p. 92-94“C. (Found: C, 58.7; H, 6.2; N, 10.3. C13H 16N2O4 requires C, 59.1; H, 
6.1; N, 10.6%). ÔH 1.36 (3H, t, CH2CH3), 1.99 (2H, quin., CH2-CH2-CH2), 3.67 (2H, q, 
HO-CH2), 4.39-4.55 (4H, m, CH2CH3 and CH2-O-N), 4.86 (IH, t, CH2-OH), 7.37-7.56 
(2H, 2t, H-5 and H-6), 7.71-7.85 (2H, 2d, H-4 and H-7), 14,5=7 .0 , 34,6= 1.2 , 3c h 2,CH3=7 .2 , 
^CH2,CH2=6 .4 , ÔC 14.5 (CH2Ç H 3), 31.5 (CH2-Ç H 2-CH 2), 57.5 (C.H2-OH), 62.3 
(ÇH2CH3), 77.5 (N-O-ÇH2), 110.6 (C-4), 122.0 (C-7), 124.5 (C-6), 126.6 (C-5), 131.8 
(C-3a), 137.4 (C-7a), 137.2 (C-2), 157.9 (C=0).
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2-Cvano-5-fluorobenzimidazole 3-oxide (149)
AT-Cyanomethyl-4-fluoro-2-nitroaniline (4.0g) (148) was dissolved in hot ethanol 
(250ml) before the addition of potassium carbonate (3.0g) and the mixture was then heated 
under reflux for 3h. The solvent was evaporated in vacuo and the resultant solid dissolved in 
water (150ml) before acidification with concentrated hydrochloric acid. The precipitate formed 
was recrystallised from aqueous methanol: yield 1.5g (42%), m.p.220-222“C (lit.73 231- 
232'C), ÔH 7.27 (IH, dt, H-6), 7.57 (IH, dd, H-4), 7.83 (IH, dd, H-7), J6,p=9.8, J4,p=8.4,
37 F=4.8, 36,7=7.4, 34,6=2 .4 , ÔC 97.0 (C-4), 110.8 (CN), 113.9 (C-6), 123.3 (C-7), 124.2 
(C-7a), 132.1 (C-3a), 135.3 (C-2), 159.0 (C-5), 3g,p=242.2, 34,p=27.0, 33a,p=12 .0 ,
37,f =3 .0 .
2-Cy ano-6-fluoro-1 3-hvdroxvpropoxv)benzimidazole ( 150)
i
2-Cyano-5-fluorobenzimidazole 3-oxide (149) (0.50g) was dissolved in the minimum 1
of dried DMF (15ml), potassium carbonate (0.4g) was then added followed by
3-bromopropan-l-ol (0.4g), and stirring continued for 20h. The reaction mixture was poured 
into water (50ml) and extracted with dichloromethane (3x25ml), the organic extracts were 
combined, washed with water (2x75ml), dried over magnesium sulphate and concentrated to 
give a pale coloured liquid which crystallised in the freezer over a few days and was then 
recrystallised from toluene: yield 0.40g (58%), m.p.66-67°C. (Found: C, 56.5; H, 4.4; N,
18.1. C11H 10FN3O2 requires C, 56.2; H, 4.3; N, 17.9%). ôh 2.01 (2H, quin., CH2-CH9- 
CH2), 3.67 (2H, q, HO-CH2), 4.64 (2H, t, CH2-ON), 4.77 (IH, t, HO-CH2), 7.35 (IH, dt, 
H-5), 7.77 (IH, dd, H-7), 7.93 (IH, dd, H-4), 3y,F=8.4, 35,p=11.8 3gj=2.4, 34,6=2.4, ôc
30.9 (CH2-ÇH2-CH2), 56.8 (ÇH2-OH), 78.6 (N-O-CH2), 96.6 (C-7), 109.8 (CN), 
114.0(C-5), 123.3 (C-4 and C-3a), 130.1 (C-7a), 134.7 (C-2), 161.5 (C-6), 36,p=243.0, 
3 5  p=26.0, 3 4  p =  10.0 .
2-Cvano-1 -r3-hvdroxvpropoxv)-6-methvlbenzimidazole ( 153)
2-Cyano-5-methylbenzimidazole 3-oxide (151) (0.50g) was dissolved in the minimum 
of dried DMF (10ml); potassium carbonate (0.4g) was then added and the mixture stined for
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Ih. 3-Bromopropan-l-ol (0.40g) was then added and stirring continued for a further 18h. The 
reaction mixture was poured into water (50ml) and extracted with dichloromethane (3x25ml). 
The organic extracts were combined, washed with water (150ml), dried over magnesium 
sulphate and concentrated to a pale yellow liquid which crystallised in the freezer overnight to 
yield a yellow solid which was recrystallised from toluene: yield 0.15g (22%), m.p.72-74“C. 
(Found: C, 62.35; H, 5.5; N, 18.0. C 12H 13N3O2 requires C, 62.3; H, 5.7; N, 18.2%). Ôh
1.95 (2H, quin., CH2-CH2-CH2), 2.52 (3H, s, CH3), 3.68 (2H, t, HO-CH2), 4.60 (2H, t, 
CH2-ON), 4.76 (IH, bs, HO-CH2), 7.30 (IH, dd, H-5), 7.60 (IH, d, H-7), 7.72 (IH, d, 
H-4), 35,7= 1.8 , 34,5=8 .4 , ÔC 22.0 (ÇH3), 31.3 (CH2-CH2-CH2), 57.3 (ÇH2-OH), 78.9 
(N-O-GH2), 108.9 (CN), 110.0 (C-3a), 121.6 (C-7), 122.3 (C-6), 127.4 (C-4), 130.5 (C-5),
137.0 (C-7a), 138.1(C-2).
2-Cvano-l-f3-hvdroxypropoxy)-6-methoxvbenzimidazole T154)
2-Cyano-5-methoxybenzimidazole 3-oxide (152) (0.25g) was dissolved in the 
minimum of dried DMF (10ml), potassium carbonate (0.15g) was then added, the mixture 
stirred for 0.5h and finally 3-bromopropan-l-ol (0.15g) was added. The reaction mixture was 
then stirred for 18h before being poured into water (50ml) and extracted with dichloromethane 
(3x25ml). The organic extracts were combined, washed with water (150ml), dried over 
magnesium sulphate and concentrated to a pale yellow liquid which could not be crystallised 
from any solvent. As for compounds (136) and (146), purification was attempted on a column 
of silica gel but the product could not be isolated in a pure form. Due to the extreme polarity of 
(154), base-line impurities were always eluted with the product and evidence of these 
impurities is apparrent with the desired product in the ^H nmr.
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Chapter 4 
Experimental
Diethvl 2-ethoxvcarbonylnialonate (182)
To freshly distilled acetonitrile (50ml) was added anhydrous magnesium chloride (2.38g) 
under an atmosphere of nitrogen. Diethyl malonate (181) (7.6ml) was then added and the 
reaction mixture cooled to 0“C before the addition of triethylamine (14.0ml) and after 15 minutes' 
stirring, ethyl chloroformate (6.2ml). After the temperature had been kept at 0“C for 1.5h, the 
reaction mixture was allowed to heat up to room temperature and stirring continued for a further 
18h. The reaction mixture was cooled in an ice bath, hydrochloric acid (5M, 30ml) added and the 
solution then extracted with ether (3x40ml). The organic layers were combined and concentrated 
to give an oil which was distilled on the Kugelrohr (b.p.70“C / 0.4mmHg) but was found to be 
mainly unreacted starting material containing traces of a high melting product which could not be 
identified.
Reaction of Meldrum's acid f l86) with ethvl chloroformate
i) 5-( 1 -Ethoxycarbonyl-4f 1H]-pyridylidene)-1,3-dioxane-4,6-dione (188)
A solution of Meldrum's acid (186) (l.Og) in anhydrous dichloromethane (25ml) was 
cooled to 0“C under an atmosphere of nitrogen. Anhydrous pyridine (2.7ml) was added 
dropwise over 10 minutes followed by the addition over 2h of a solution of freshly distilled ethyl 
chlorofonnate (0.7ml) in dichloromethane (5ml). Stirring was continued for a further Ih at 0°C 
followed by another Ih at room temperature. A further aliquot of dichloromethane (20ml) was 
added, and the solution poured into hydrochloric acid (2M, 5ml) and ice (45ml). The aqueous 
layer was extracted with dichloromethane (2x50ml) and the organic layers combined and washed 
with hydrochloric acid (2M, 2xl5ml), saturated brine (25ml), dried over sodium sulphate and 
concentrated in vacuo to yield a red crystalline solid which was reciystallised from ethyl acetate:
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yield 0.3g (15%), m.p.l42-144“C (lit.l®  ^ 147-148°C), 5h 141 (3H, t, CH2CH3), 1.63 (6H, s, 
2xCH3), 4.53 (2H, q, CH2CH3), 8.53 (4H, s, H-2', H-3', H-5' and H-6’), JcH2.CH3=7 .2 , 6c
14.6 (CH2CH3), 27.1 (2xCH3), 67.6 (CH2CH3), 88.9 (C-2), 102.3 (C-5), 117.0 (C-5' and 
C-3'), 136.1 (C-6 ' and C-2'), 149.7 (C-4'), 157.2 (C=0), 164.3 (C-6 and C-4), m/z =293 
(M+).
ii) Using triethylamine as the base
A solution of Meldrum's acid (186) (l.Og) in anhydrous dichloromethane (25ml) was 
cooled to 0°C under an atmosphere of nitrogen. Anhydrous triethylamine (2.4ml) was added 
dropwise over 10 minutes followed by the addition over 1.5h of a solution of ethyl 
chloroformate (0.7ml) in dichloromethane (2ml). Stirring was continued for a further Ih at 0"C 
followed another Ih at room temperature. The reaction mixture was diluted with dichloromethane 
(20ml) then poured into hydrochloric acid (2M, 5ml) and crushed ice (45ml). The mixture was 
extracted with dichloromethane (3x50ml) and the organic layers combined and washed with 
hydrochloric acid (2m, 2x25ml), and saturated brine (2x50ml), dried over magnesium sulphate 
and concentrated in vacuo to yield an orange oil.
Distillation at reduced pressure on the Kugelrohr showed no evidence of the desired 
product, only carbonaceous material. ^H nmr analysis of the recovered material only showed of 
the starting material.
Diethvl bisihvdroxymethvDmalonate il 89)
Potassium bicarbonate (6.0g) suspended in formaldehyde solution (130ml, 35w/v) was 
mechanically stirred while being cooled at 5“C and diethyl malonate (181) (120.0g) was added 
dropwise over Ih. After a further Ih of stirring, the reaction mixture was poured into a saturated 
solution of ammonium sulphate (300ml); this was extracted with diethyl ether (2x150ml), the 
ether layers being separated and dried over magnesium sulphate. The clear, viscous product was 
then held at very low pressure (0.5 mmHg) with stirring at room temperature to aid 
crystallisation of the product: yield 125.8g (76%), m.p.45-47°C (lit.HO 48-50°C), Ôh 1.27 (6H, 
t, CH2C H 3), 3.93 (2H, bs, CH2OH), 4.08 (4H, s, CH2OH), 4.22 (4H, q CH2CH 3),
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J c H2,CH3=7,0, Ôg 13.6 (CH3), 61.0 [(H0CH2)2Ç], 61.4 and 61.5 (ÇH2OH and CH2CH3),
169.0 (C=0).
5.5-Bisrethoxvcarbonvl-2-isopropyl-1.3-dioxane ( 190)
Diethyl bis(hydroxymethyl)malonate (189) (7.9g), isobutyraldéhyde (2.6g) and 
p-toluenesulphonic acid (catalytic amount) were all heated under reflux in toluene (100ml) for 6h 
incorporating a Dean-Stark apparatus and the exclusion of water (calcium chloride guard). After 
cooling, the reaction mixture was washed with sodium hydroxide (O.IM, 2x100ml) and 
saturated sodium chloride solution (2x 100ml) and dried over magnesium sulphate. The toluene 
was evaporated off at reduced pressure to yield a viscous oil which was purified by distillation 
on the Kugelrohr: yield 6.4g (65%), b.p.l22°C / 2 mmHg (lit.HI 99-102°C / 0.4 nunHg°C), Ôh 
0.90 (6H, d, CH3), 1.24 and 1.28 (6H, 2t, CH2CH3), 1.78 [IH, m, (CH3)2CE], 3.90 (2H, d, 
H-6 and H-4), 4.20 [5H, m, CH2CH3 and H-2], 4.68 (2H, d, H-6 and H-4), JcH2,CH3=7.7, 
ÔC 14.3 (CH2ÇH3), 17.1 (CH3), 32.8 [CH(CH3)2], 53.8 (C-5), 62.1 and 62.2 (CH2CH3),
69.6 (C-4 and C-6), 106.1 (C-2), 167.3 and 168.3 (C=0). A 135" DEPT experiment was run to 
help with the assignment of the carbon signals.
cis- and trans-5-Ethoxycarbonyl-2-isopropvl-l.3-dioxane (191)
5.5-Bis(ethoxycarbonyl-2-isopropy 1-1,3-dioxane (190) (45.0g) and sodium chloride 
(9.7g) were heated under reflux for 12h in a mixture of water (5.9g) and DMSO (250ml). After 
cooling the reaction mixture was poured into saturated brine (650ml) and extracted with ether 
(3x250ml), the ether layers were combined, washed with water (2x750ml) and dried over 
magnesium sulphate. The solvent was removed in vacuo to yield a brown oil which was purified 
by distillation at reduced pressure: yield 11.9g (36%), b.p.l45"C / 5 mmHg (lit. 1^ 9 75_80"C / 
0.3 mmHg), Ôh 0.85 and 0.95 [6H, 2d, (CH3)2)CH], 1.20-1.39 (6H, m, CH2CH3), 1.68-1.89 
[2H, m, (CH3)2CH], 2.30 and 2.90 (2H, 2m, H-5a/e), 3.60-4.70 (8H, m, H-4a/e, H6-a/e, 
H-2a/e, CH2CH 3), ôc 14.3 and 14.4 (CH3), 17.0 andl7.1 (CH2Ç H 3), 36.1 and 36.4 
[£H(CH3)2], 39.0 and 40.4 (C-5), 60.8 and 61.0 (ÇH2CH3), 67.0 and 67.8 (C-4 and C-6),
105.8 and 106.3 (C-2), 170.2 and 170.3 (C=0).
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cis- and trans-5-Hvdroxymethvl-2-isopropy 1-1.3-dioxane (192)
To a solution of lithium aluminium hydride (1.6g) in dried THF (20ml) was added a 
solution of cis- and trans-5-ethoxycarbony 1-2-isopropyl-1,3-dioxane (191) (11.5g) in dried THF 
(60ml) at such a rate as to generate gentle reflux. Cooling of the reaction mixture was required 
initially. Upon complete addition of the reactant, the reaction was heated under reflux for 4h. 
After cooling the reaction was diluted with ethyl acetate (50ml) and then extracted with ethyl 
acetate (3x50ml). The organic layers were combined, washed with brine (150ml) then water 
(3x150ml) to neutrality (pH=7) and dried over magnesium sulphate. The solvent was removed 
and the clear oily product purified by distillation at reduced pressure: yield 1.5g (16%), 
b.p.l20"C / 3 mmHgHl, by 0.72-0.78 [6H, m, (CH3)2)CH], 1.40-1.57 [IH, m, (CH3)2CH],
1.83 (2H, t, CH2OH), 1.99-2.19 and 3.13-3.30 (2H, m, H-5a/e, H-2), 3.55-4.20 (5H, m, 
H-4a/e, H-6a/e, CH2OH), 5c 17.2 (CH3), 32.8 [C.H(CH3)2], 37.5 (C-5), 60.9 and 62.5 
(ÇH2OH), 67.4 and 68.9 (C-4 and C-6), 106.1 (C-2) 170.9 (C=0).
Attempted tosylation of cis- and trans-5-hydroxvmethvl-2-isopropy 1-1.3-dioxane (192)
p-Toluenesulphonyl chloride (0.7g) (recrystallised from petroleum) was added 
portionwise over 0.5h to a stirred solution of pyridine (5ml) cooled to 0°C. Stirring was 
continued for a further 0.5h before the addition of (192) (0.5g) and then continued for a further 
24h. The reaction was quenched with water (25ml) and extracted with dichloromethane 
(3x25ml); the organic layers were combined, washed with hydrochloric acid (2M, 15ml), 
sodium hydroxide (0.1m, 25ml) and water (3x25ml), and then dried over magnesium sulphate. 
The solvent was removed under reduced pressure to yield a clear oil product.
iH nmr analysis showed only a very small degree of tosylation to have occurred and on 
standing a crystalline product precipitated from the oil which upon removal was found to be tosyl 
chloride. Further nmr analysis pointed to the isolated product being a mixture of the starting 
materials.
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The previous (199, p i33) procedure was repeated including the addition of a catalytic 
amount of 4-dimethylaminopyridine, but the material isolated was spectrally identical to that 
which was previously isolated.
1 -f3-Hvdroxvpropoxv)benzotriazole ( 196)
' 1-Hydroxybenzotriazole (5.0g) and potassium carbonate (5.5g) were stirred together in 
anhydrous DMF (50ml) with the exclusion of water (calcium chloride guard), a precipitate 
forming after 0.5h; 3-bromopropan-l-ol (5.4g) was then added, with stirring continued for 36h. 
The reaction mixture was poured into water (300ml) and extracted with dichloromethane 
(3x75ml); the organic layers were combined and washed with water (2x250ml) then dried over 
magnesium sulphate. The solvent was removed under reduced pressure and the product distilled 
under high vacuum to yield a colourless, viscous oil: yield 0.7Ig (10%), b.p.l40"C / 0.1 
mmHg, ÔH 1.96 (2H, quin., CH2-CH2-CH2), 3.71 (2H, q, CH2-OH), 4.66 (2H, t, CH2-ON), 
4.79 (IH, t, CH2-OH), 7.43 (IH, t, H-6), 7.60 (IH, t, H-5), 7.78 (IH, d, H-4), 8.03 (IH, d, 
H-7), JcH 3,CH2= 6 .2 , JcH 2,OH=4 .6, J4,6=8.4, 14,5= 1.0 , 15,6=6 .8 , 5 c  31.1 (CH2-ÇH2-CH2),
56.9 (CH2-OH), 98.4 (CH2-ON), 109.4 (C-4), 119.9 (C-7), 125.1 (C-6), 127.2 (C-5), 128.6 
(C-3a), 143.0 (C-7a).
Upon standing in the atmosphere the clear oil product darkened in colour over several 
days. The product was analysed by ^H and ^^C nmr but no change appeared to have occurred 
and the product was redistilled to remove the discolouration.
2.4.5-Trichloro-1-nitrobenzene (128)
1,2,4-Trichlorobenzene (198) (14.5g) was slowly added to fuming nitric acid (150ml) 
with continuous stirring at 0°C. Upon complete addition, the reaction mixture was poured into 
ice and water (500ml) whereupon a precipitate formed and was collected by filtration, dried in the 
vacuum oven and recrystallised from ethanol: yield 15.5g (76%), m.p.55-57"C (lit.H? 56“C), 
6h 7.68 and 8.04 (2H, 2s, H-3 and H-6), ôc 126.6 (C-2), 127.4 (C-6), 132.5 (C-5), 133.3 (C- 
3), 138.3 (C-4), 146.3 (C-1).
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5.6-Dichloro-l-hvdroxybenzotriazole ( 199)
2,4,5-Trichloro-l-nitrobenzene (128) (2.4g) was dissolved in hot ethanol (40ml), 
producing a yellow solution; hydrazine hydrate (100%, 0.7g) was then added and the reaction 
heated under reflux for 5h then allowed to cool. The orange precipitate which formed upon 
cooling was collected, dissolved in hot water (ca. 150ml) and precipitated with concentrated 
hydrochloric acid (pH=l). The precipitate was filtered and recrystallised from aqueous ethanol: 
yield 0.55g (25%), m.p.200“C (violent decomp.; lit.H6 210"C), Ôh 8.18 and 8.44 (2H, 2s, H-4 
and H-7), ôc 1119 (C-7), 121.2 (C-4), 127.5 (C-5), 128.1 (C-7a), 131.3 (C-6), 141.4 (C-4a).
5.6-Dichloro-l-(3-hydroxypropoxy)benzotriazole (200)
5.6-Dichloro-1 -hydroxybenzotriazole (199) (0.5g) and potassium carbonate (0.4g) were 
dissolved in anhydrous DMF (15ml) with the exclusion of water (CaCE guard) and stirred for 
0.5h after which time a precipitate had formed. 3-Bromopropan-l-ol (0.4g) was then added and 
stirring maintained for a further 18 h; the reaction mixtme was then poured into water (50ml) and 
extracted with dichloromethane (3x50ml); the organic layers were combined, washed with water 
(2x150ml) and dried over magnesium sulphate. The dichloromethane was removed in vacuo and 
the oil obtained crystallised on standing. The product was recrystallised from diethyl ether: yield
0.2g (31%), m.p.71-73“C. (Found: C, 41.6; H, 3.5; N, 16.2. C9H9CI2N3O2 requires C, 41.2; 
H, 3.5; N, 16.0%). ôy 1.93 (2H, quin., CH2-CH2-CH2), 3.65 (2H, q, CH2-OH), 4.65 (2H, t, 
CH2-ON), 4.75 (IH, t, CH2-OH), 8.28 and 8.43 (2H, 2s, H-4 and H-7), JcH3,CH2=6.2, 
Jc H2,OH=4.6, ÔC 31.0 (CH2-CH2-CH2), 56.9 (CH2-OH), 79.8 (CH2-ON), 111.3 (C-4), 121.2 
(C-7), 126.4 (C-5), 128.3 (C-6), 132.0 (C-3a), 141.8 (C-7a).
Attempted synthesis of 4.5.6.7-tetrachloro-l-hvdroxyhenzotriazole (202)
Pentachloronitrobenzene (201) (5.0g) and hydrazine hydrate (100%, 4.5g) were heated 
under reflux for 2h in ethanol (50ml) and toluene (50ml). After cooling the solvent was removed 
and the resultant solid stirred in potassium hydroxide (5%, 100ml). The mixture was filtered and 
the filtrate acidified with concentrated hydrochloric acid: the precipitate was collected but was
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found not to be the correct product. The precipitate was insoluble in all the solvents tried and 
could not be recrystallised. The solid did not melt and was presumed to be a salt.
Despite several attempts at this reaction, none of the desired product was isolated and no 
expalantion can be offered for its failure.
Attempted reaction of benzofiirazan AT-oxide with nitromethane
i) Benzofurazan jV-oxide (209) (2.0g) was dissolved in chloroform (30ml) and 
triethylamine (2.0g) and nitromethane (1.2g) added. The reaction was heated under reflux for 
24h. After cooling the solvent was removed in vacuo and the resultant solid recrystallised from 
methanol. Analysis of the solid showed it to be a mixture of the starting material and other 
unknown components rather than the desired product.
The above procedure was repeated a further two times after the distillation of both the 
nitromethane and triethylamine and the drying of the chloroform but in each case the reaction was 
unsuccessful.
A slightly different procedure was then attempted for the above reaction:
ii) Benzofurazan jV-oxide (209) (2.0g) was dissolved in ethanol (50ml) and the solution 
saturated with ammonia gas over 2h. Nitromethane (1.2g) was then added prompting a change in 
the solution colour from yellow to red, and stirring was then continued for a further 3h. The 
solvent was removed in vacuo and the resultant solid recrystallised from methanol to yield a 
yellow product. nmr and mass spectral analysis of the solid showed it to be unreacted starting 
material.
3.4-Dichloroacetanilide (212)
3.4-Dichloroaniline (211) (15.0g), pyridine (12.0ml), acetic anhydride (18.8g) and 
toluene (500ml) were heated under reflux for 2h then allowed to cool. The solvents were 
removed in vacuo. The crude solid obtained was dissolved in hot aqueous ethanol and allowed to 
cool; the product was collected by filtration and dried. Yield 9.8g (52%), m .p.l20-12rc (lit.H7 
12rC ), ÔH 2.07 (3H, s, CH3), 7.49 (IH, dd, H-6), 7.52 (IH, d, H-5), 8.00 (IH, d, H-2), 
10.13 (IH, s, NH), 35,6=7 .2 , 32,6=2 .4 . A D2O shake collapses the signal at Ô 10.13. Ôc 23.9
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(CHs), 118.9 (C;6), 120.2 (C-2), 124.4 (C-4), 130.4 (C-5), 130.9 (C-3), 139.3 (C-1), 168.7 
(C=0), m/z =203 / 205 / 207 (M+ ).
4.5-Dichloro-2-nitroacetanilidc (213)
To 3,4-dichloroacetanilide (212) (26.0g), was added glacial acetic acid (17.5ml) followed 
by concentiated sulphuric acid (34.3g) and the solution stirred and cooled to 0"C. A cooled 
solution of concentrated nitric acid (d 1.40, 10.6g) and concentrated sulphuric acid (8 .6g) was 
then added over 0.5h, stirring then being continued for a further 2h. The reaction mixture was 
poured on to ice (250ml) yielding a yellow precipitate which was collected by filtration and 
washed with water until the washings were neutral. The product was purified by column 
chromatography and recrystallised from ethanol to yield a yellow crystalline solid: yield 10.1 g 
(32%), m.p.l23-124"C (lit.H? 123-124"C), Ôh 2.11 (3H, s, CHg), 7.98 (IH, s, H-6), 8.25 
(IH, s, H-3), 10.41 (IH, s, NH). A D2O shake collapses the signal at Ô 10.41. ôc 23.5 (CH3),
125.6 (C-6), 126.4 (C-4), 126.5 (C-3), 131.5 (C-1), 136.5 (C-5), 140.1 (C-2), 168.8 (C=0).
4.5-Dichloro-2-nitroaniline (214)
4.5-Dichloro-2-nitroacetanilide (213) (0.50g) was heated under reflux in 70% sulphuric 
acid (3ml) for 0.75h. The reaction mixture was poured into cold water (17ml) and yielded a 
yellow precipitate; the mixture was basified to pH 10 with concentrated ammonia solution and the 
precipitate collected and washed with water (20ml) then recystallised from ethanol and water to 
yield orange needles: yield 0.30g (72%), m.p. 181-183"C (lit.l32 175“C), ôy 7.26 (IH, s, H-6), 
7.65 (2H, s, NH2), 8.10 (IH, s, H-3). A D2O shake collapses the signal at ô 7.65. Ôc 116.4 
(C-4), 119.8 (C-6), 126.4 (C-3), 129.3 (C-2), 138.2 (C-5), 145.1 (C-1).
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Chapter 5 
Experimental
5.1 Procedure
Each of the compounds to be tested was fully characterised using l^C and nmr 
spectroscopy and C/H/N analysis, and those samples which were found not to be completely 
pure were not tested. In the event of activity being found, any impurities in the samples used 
could be held responsible for the said activity; each impurity present is effectively a further 
compound being tested for activity against the virus used in the assay. The compounds to be 
tested were made up as solutions in DMSO at a concentration of ca. 20 mM, and immediately 
prior to the assay these solutions were diluted with cell medium to a maximum concentration of 
200pM.
5.2 Cells and Viruses
Vero cells were grown in Glasgow-modified Eagle's medium (G-MEM) (Gibco) with 
10% new-born calf serum (CS). High-titre HSVl was prepared from infected vero cells by the 
extraction of freeze fractured cells; the virus was stored in 50% glycerol solution at -70°C.
5.3 End-point titration
An end-point titration of the virus stock was carried out to find the concentration at which 
the virus infected the entire monolayer over a 48h period (see overleaf).
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For the titration, a stock of vero cells was removed from a stock bottle using trypsin / 
EDTA solution, and diluted to 40 ml with GS-MEM 710% CS. The cells were then divided and 
incubated at 37°C in a 96-well microtitre plate for two days, to allow a confluent monolayer to 
grow. The first well of the microtitre plate was infected with thawed, concentrated cell-released 
virus stock, and two-fold serial dilutions made across the plate. The plate was once again 
incubated over 48h, with checking after 24h, to establish that the cytopathic effects of the virus 
were not progressing too fast. After 48h an end-point was found (a point after which the 
monolayer remained intact; the virus had been diluted to such a level that no plaque-forming units 
remained, hence the intact monolayer indicated healthy cells), and so a dilution at which the 
monolayer was completely infected after 48 hours; 1 : 100 000 (10^).
2-Fold serial dilutions
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end-point
monolayer 
of cells 
broken, 
intact 
monolayer 
at end-point
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5.3 Fixing and staining
After analysis of the monolayer of infected cells for adequate cytopathic effect (cpe), 
through the progression of viral cycles, the cells were fixed and stained. The cell medium was 
removed and replaced with a solution of formalin (2% aqueous formaldehyde) for a period of ca. 
10 minutes. The formalin was removed and replaced by the stain, crystal violet, for a further 
period of 10 minutes. The stain was gently washed out with water and the cells analysed more 
closely for cpe or an absence due to compound activity. The second plate was analysed for 
evidence of toxicity shown by the cells. The fixing and staining procedure was repeated for the 
titration and all assays completed.
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